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Abstract 
 
Background: The Community Intravenous Therapy (CIVT) service gives 
patients the benefit of receiving IV therapies (including blood transfusion) in 
their own home, avoiding hospital admission. It is important to ensure this 
service can be offered to as many patients as possible. If red cell transfusion 
could be safely performed over a shorter duration (accelerated transfusion), 
this could theoretically increase the capacity of the service without additional 
resource. Red cell transfusions are usually administered over a minimum of 
90 minutes to a maximum of four hours per unit. It was proposed that one 
unit could be given in 60 minutes (up to a maximum of 2 units per transfusion 
episode) to medically selected patients who do not have heart failure or other 
risk factors for circulatory overload. 
Methods: Physiological tolerability and safety of accelerated transfusion was 
evaluated by clinically assessing patients for symptoms and signs of 
transfusion-associated circulatory overload (TACO) after standard and 
accelerated rate transfusions. The impact on service capacity and staff 
resource was evaluated by auditing home transfusion workload data to 
determine the number of patients who were eligible for accelerated rate 
transfusion and the potential impact this had on treatment delivery time. 
Patient and practitioner experiences of accelerated transfusion were 
evaluated by conducting thematic analysis on semi-structured interviews to 
assess the acceptability and desirability of service change. 
x 
 
Results: When accelerated red cell transfusion was performed on medically 
selected patients who had been screened for risk factors for circulatory 
overload, accelerated transfusion appeared to be safe. None of the patients 
in the study (n=25) developed transfusion associated circulatory overload 
across 269 accelerated transfusions performed. The mean arterial pressure 
appeared to statistically significantly increase up to 24 hours after blood 
transfusion regardless of whether it was infused at a standard or accelerated 
rate, with the group mean remaining within the normal range (standard rate 
transfusion: p = 0.0441; accelerated rate average across three transfusions: 
p = 0.009). There was no statistically significant difference between pre and 
post-transfusion mean arterial pressure measurements when standard and 
accelerated rate transfusions were compared (average across three 
accelerated rate transfusions: p = 0.473), showing that accelerated 
transfusion itself did not cause an increase in mean arterial pressure above 
that of standard rate transfusion. A significant proportion of haematology 
patients (57%, 26/46) were medically eligible for accelerated transfusion, and 
49% of total transfusion episodes (224/459) were performed as such. 
Performing accelerated transfusion on eligible patients could potentially save 
105 nursing hours, allowing an additional 35 three hour visits or 26 four hour 
visits per year. Accelerated transfusion was well received by patients. 
Positive themes from the data included less time receiving healthcare 
allowing freedom and time to do other things, improvements in comfort and 
altruism from knowledge that other patients and the service was benefitting. 
CIVT practitioners were highly motivated and positive about accelerated 
transfusion. Themes included satisfaction in seeing positive benefits in 
xi 
 
quality of life and social aspects of patient’s lives; improved continuity of 
care, better work scheduling; increased service capacity, job satisfaction; 
better working conditions and professional autonomy in clinical decision-
making. 
Conclusion: Accelerated red cell transfusion appears to be safe in medically 
selected patients. It can potentially increase service capacity through efficient 
use of staff resource whilst maintaining a safe and high quality service. 
Understanding of patient and practitioner experience suggested that 
changing the service to offer accelerated transfusion would be both 
acceptable and desirable. 
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Chapter One: 
Introduction 
This research study is based upon a service development project at a 
National Health Service (NHS) Foundation Trust, incorporating the 
Community Intravenous Therapy Team (CIVT), the Clinical Haematology 
service, and the Blood Transfusion service within the Laboratory Medicine 
Department. The first chapter introduces the purpose of the research, the 
research questions and hypotheses generated, and how these meet the 
aims and objectives of the research. The chapter concludes with a rationale 
framework for the research, providing a conceptual synopsis of the 
introductory chapter. 
Problem Statement 
The CIVT Team requires increased capacity to be able to offer intravenous 
(IV) therapies (including blood transfusion) to more patients at home without 
impacting on current resources. 
In terms of developing the current home transfusion service, two general 
questions are therefore raised: whilst maintaining or improving the benefits of 
the service, whether this service may be delivered more efficiently and if so, 
the options for increasing the efficiency and capacity of the service. 
Statement of Purpose and Research Questions 
If red cell transfusion could be safely performed over a shorter duration, this 
could theoretically increase the capacity of the service without additional 
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resource. More patients could potentially be treated at home, and the patient 
would have less intrusion from medical interventions with a shorter home 
visit, which may also have a positive impact upon patient and practitioner 
experience. Red cell transfusions are usually administered over a minimum 
of 90 minutes to a maximum of four hours per unit (BCSH, 2009). It is 
proposed that one unit can be given in 60 minutes (up to a maximum of 2 
units per transfusion episode) to medically selected patients who do not have 
heart failure or other risk factors for circulatory overload. 
The general  research question was developed from the literature review in 
the following chapters and can be defined by asking: whether transfusing two 
units of red cells over 60 minutes per unit (accelerated transfusion) is safe 
and could potentially increase CIVT service capacity, while gaining 
understanding of the patient’s and practitioner’s experience. 
The question can therefore be viewed through the two lenses of 
physiological tolerability and experiential and organisational 
acceptability/benefit. This forms the foundation of the multi-methods 
approach which is discussed further in the Methods chapters. 
Hypotheses 
Based upon the background and impetus for the research supported by 
existing evidence, the following hypotheses can be developed for the 
quantitative aspects of the research question: 
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 H1: Two units of red cells transfused over 60 minutes each can be 
physiologically tolerated in selected patients (H0 there is no difference 
in the incidence of Transfusion Associated Circulatory Overload 
(TACO) between standard and accelerated rate transfusions) 
 H1: Implementation of accelerated transfusion could potentially 
increase CIVT service capacity (H0 Implementation of accelerated 
transfusion would not potentially increase CIVT service capacity) 
The qualitative strand of the study is value-adding and seeks to inductively 
gain understanding of patient and practitioner experience without a priori 
theories and therefore hypotheses are not appropriate. 
Aims and Objectives of the Research 
The aim of the research was to determine the physiological tolerability of 60 
minute per unit red cell [accelerated] transfusions in selected patients. The 
research also aims to understand the experiential effect of accelerated 
transfusion on patients and practitioners, and whether there is improvement 
of service capacity.  
The primary objective of the research was to develop and implement this 
aspect of transfusion practice locally, if the alternative (H1) hypotheses are 
accepted, and provide evidence for other healthcare organisations to do 
similar. The secondary objective was to develop and progress existing 
evidence relating to the recommended rate of transfusion in selected 
patients, adding to the literature regarding the selection of transfusion rate 
appropriate to the patient’s condition. The study will also contribute to the 
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literature in the currently under-researched areas of patient and practitioner 
experience of blood transfusion, and add to the currently small number of 
qualitative studies in transfusion. 
Rationale and Justification for the Research, and Contribution to 
Current Knowledge: 
The home transfusion service in the participating NHS Trust is an exemplar 
of national policy for care delivered closer to home and has received national 
recognition (Audit Commission, 1999). It is popular both with patients using 
the service and CIVT practitioners delivering it. The service is well 
established and has an excellent safety and governance record. Although 
complex to quantify, there is some evidence this model of service provision is 
more cost effective than equivalent hospital care (Koepke et al 1988; DH, 
2009). The exact cost of a blood transfusion for each service model is to 
some extent academic as each will have different indirect costs for which 
there will be interdependencies with other unrelated procedures delivered by 
each of them. There are clear non-economic advantages to the service that 
persuades the case for continued provision and indeed expansion of home 
transfusion.  This was first endorsed by Rabiner and Telfer (1970) and 
continues to be important for patients with physical, clinical and social issues 
to whom hospital day care visits are problematic. Therefore, the alternative 
perspective to improve the efficiency of the service is to improve capacity, 
rather than compete on the cost of an individual care episode. 
The proposal to improve service capacity by reducing treatment time is 
constrained by currently limited evidence for safe infusion rates for blood 
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transfusion, due to a lack of experimentally designed studies in this area of 
clinical practice. This lack of clarity is further complicated by the paucity of 
prospective studies of Transfusion Associated Circulatory Overload (TACO) 
in elective red cell transfusion in stable patients who are not receiving 
concomitant intravenous (IV) fluids. Previous studies of TACO have been 
retrospective, sometimes focussed on other types of blood components, non-
blood concomitant IV fluids were also sometimes confounding factors, and 
also involved patients in acute care settings where acute illness could have 
pre-disposed the patient to fluid overload. It is also difficult to establish the 
overall incidence of TACO where red cells were independently responsible, 
due to poor reporting on fluid balance and concomitant fluids in 
haemovigilance reporting to the UK Haemovigilance Organisation: Serious 
Hazards of Transfusion (SHOT). This research will generate prospective 
data on this specific patient group. 
The co-morbidity and risk factor themes that have emerged from the SHOT-
reported cases of TACO allow for the development of strategies to identify 
patients who are at risk of circulatory overload. This can be used to inform 
the development of medical selection criteria to create a framework for the 
rate and volume of transfusion. This research could potentially contribute 
new knowledge and evidence for a more refined understanding of safe red 
cell dosing and infusion-rates and establish a mandate for patient-tailored 
therapy. 
The limited research that exists on patient experience of receiving blood 
transfusions reports negative responses in terms of the long duration of 
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treatment. This finding concurs with the anecdotal observations of patients 
using the service, and staff delivering the service locally, and advocates 
further research into this area of enquiry.  There are no studies on 
practitioner experience of administering blood transfusions to patients. 
Research based on qualitative methodology is under-represented in the body 
of research in transfusion medicine. This study may generate more interest 
in this approach within this area of practice and demonstrate the benefits of 
mixed methods research to bring patient-focus to practice change. 
The research also respects the external drivers of related national policy: 
cost-effectiveness and responsible use of resources; patient-centred care 
and experience; delivery of care closer to home; and national guidance on 
the co-designing of services with patients. This is further developed in the 
contextual framework in the following chapter and also justifies the research 
study. 
Thesis Structure  
The following preparatory chapter forms the contextual framework from 
which the conceptual framework develops, informing and justifying the 
methodological approaches. To ensure a clear relationship with the research 
questions, the methods are presented as three separate chapters which 
represent the physiological (safety) enquiry, resource and service capacity 
enquiry, and the patient and practitioner experience enquiry. A similar 
structure follows with the analytical chapters. The findings from each of the 
three strands of enquiry then conflate in the concluding chapter to answer 
the research questions and debate the findings in the light of the limitations 
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of current evidence on which the research was designed. The discussion 
also addresses further strengths and limitations of the study and the impact 
of the research on the future delivery of home transfusion and other IV 
therapies in the Trust. The influence of the research on the international 
definition/surveillance diagnosis of TACO and other aspects of transfusion 
practice, including opportunities for further study are also discussed. 
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Chapter Two:  
Literature Review 
 
Literature Review Strategy 
The purpose of the literature review is to identify, appraise, synthesise and 
analyse published evidence to produce a contextual framework in chapter 
three, providing background and critique on the current status of research. 
The thesis is developed in the conceptual framework in chapter four where 
the literature review supports the development of the arguments formed in 
the contextual framework chapter. 
The type of literature review was determined by considering its aim in the 
context of the methodological approach. Grant and Booth (2009) proposed a 
typology of literature reviews which provide a useful tool in determining an 
appropriate literature review type. The aim of the literature review was 
determined a priori. It was required to pragmatically demonstrate a robust 
and methodical search process where the quality of the literature identified 
was appraised for significance, representativeness, reliability, contribution 
and contemporaneousness. The literature subsequently identified was then 
used to support arguments for the development of the thesis, emphasising 
the generation of hypotheses and innovation through critical evaluation. 
Grant and Booth (2009) characterised review types by assessing them 
against a Search, AppraisaL, Synthesis and Analysis (SALSA) framework. 
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The aims of the literature review accord most closely with the SALSA 
characteristics of The Critical Review and Systematised Review. This was 
cross-checked with the author’s descriptor for both types of review to 
demonstrate appropriate attribution of review typology. This is summarised in 
table 2.1 below. 
Table 2.1: Literature Review Typology Evaluation 
Review 
Type 
Description 
key words 
Search Appraisal Synthesis Analysis 
Review type 
for this study 
Pragmatic, 
methodical, 
significance, 
robust, critical 
evaluation, 
theses 
development, 
hypotheses, 
innovation 
Identify most 
significant 
(pragmatic- may 
not be 
comprehensive) 
Based on significance, 
representativeness, 
contribution,  reliability, 
contemporaneousness  
Narrative, 
conceptual, 
chronological 
What is 
known, 
limitations, 
uncertainty, 
conceptual, 
derivative, 
new theory 
Critical 
Review 
Extensive, 
quality, critical 
evaluation, 
analysis, 
conceptual 
innovation, 
hypothesis, 
model 
Identify most 
significant 
According to 
contribution 
Narrative, 
conceptual, 
chronological 
Conceptual, 
derivative, 
new theory 
Systematised 
Review 
Stops short of 
systematic 
review, 
comprehensive, 
critical 
+/- 
comprehensive 
+/- quality assessment Narrative/ 
tabular 
What is 
known, 
limitations, 
uncertainty 
Adapted from Grant and Booth (2009) 
 
The literature review process for this study aspires to the same aims as the 
Critical Review in that the output of extensive researching and critical 
evaluation of quality on the value of published work manifests in the 
synthesis new ideas and hypotheses. However, the limitation of the Critical 
Review is lack of systematisation as the search and appraisal process. The 
Systematised Review provides an attempt at systemisation but 
acknowledges insufficiencies in meeting the criteria for a Systematic Review 
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such as multiple reviewers and access to all databases and published works. 
The degree of systemisation may also be limited to parts of the review 
methodology such as the literature searching method alone. The literature 
review strategy for this research study combines elements of both Critical 
and Systematised Review typologies to demonstrate fulfilment of the 
literature review aims. This is intended to demonstrate a robust approach 
using methodical and systematic search and appraisal methods in order to 
produce output that can present the current status of research while 
providing critique on limitations and uncertainties, and developing a thesis for 
the new concept of accelerated transfusion, and its associated hypotheses. 
The methods applied to this strategy follow below. 
Literature Review Methods 
Sources 
The literature search was performed using the National Institute of Health 
and Care Excellence (NICE) Healthcare Databases Advanced Search 
(HDAS) using Open Athens account access to allow access to all its 
available databases. A broad range of databases were required as the 
research study involved medicine, clinical science, health and social care, 
psychology, health management and health economics. Of the available 
databases the following were judged as relevant to the research study, but 
was accepted as possibly not exhaustive: British Nursing Index (BNI, 1992 to 
present); Cumulative Index to Nursing and Allied Health Literature (CINAHL, 
1981 to present); Excerpta Medica Database (EMBASE, 1974 to present); 
Health Business Elite (HBE, 1922 to present); Health Management 
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Information Consortium (HMIC, 1979 to present); Medline (1946 to present); 
PsycINFO (1806 to present); and PubMed.  
It was recognised that relevant sources may not be captured by databases 
for published works in journals, this included websites, reports, guidelines 
and comment produced by various organisations. An additional grey 
literature search was conducted using GoogleTM and Google ScholarTM 
search engines. There was also a requirement to hand-search a limited 
number of sources to address specific complex questions. 
 
Search Terms and Search Limits  
Search terms were determined by each aspect of the research study title and 
research questions, and modified according to a trial search in HDAS and 
GoogleTM after judging the broad relevance and quantity of the search output 
and removing duplications. The thesauri of each database were utilised to 
finesse search key-words. Search terms were limited to the abstract and/or 
title depending on the number of records returned, and searched in HDAS 
without date restrictions. The records returned were limited to English 
language publications and relating to human research studies. The first 
literature search was first conducted when designing the research study in 
December 2013 and was repeated in April 2017 when writing the thesis. 
Table 2.2 below summarises the literature search terms used. 
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Table 2.2: Literature Search Terms 
Aspect of title and  
research question 
Sources Search terms applied 
Blood transfusion practice BNI, CINAHL, EMBASE, 
Medline, PubMed 
("blood transfusion").ti,ab AND ("history of 
medicine").ti,ab 
(transfusion).ti,ab AND (guideline).ti,ab 
("intravenous therapy").ti,ab AND (standards OR 
guideline).ti,ab 
 ("cost of blood transfusion").ti,ab 
Google, Google Scholar “history of blood transfusion” 
“transfusion guidelines” 
“administration of blood” 
“standards for infusion therapy” 
“intravenous therapy practice” 
Local blood transfusion 
policy 
Hand-search 
Rate of blood transfusion  
Volume/dose of red cells 
BNI, CINAHL, EMBASE, 
Medline, PubMed 
("blood component").ti,ab AND ("infusion rate").ti,ab 
("transfusion").ti,ab AND ("body weight").ti,ab) AND 
("red cells").ti,ab  
Home transfusion BNI, CINAHL, EMBASE, 
Medline, PubMed, HBE, 
HMIC 
("home transfusion").ti,ab 
 
Local audits and reports 
 
Hand-search 
Safety of blood transfusion BNI, CINAHL, EMBASE, 
Medline, PubMed 
("blood transfusion").ti,ab AND (governance).ti,ab 
(("blood transfusion" AND safety) AND UK).ti 
Google, Google Scholar “transfusion safety UK” 
“transfusion regulation” 
“transfusion governance” 
Serious Hazards Of 
Transfusion reports 
 
Hand-search 
Transfusion-associated 
circulatory overload and 
iatrogenic fluid overload 
BNI, CINAHL, EMBASE, 
Medline, PubMed 
("pulmonary complications").ti,ab AND 
("transfusion").ti,ab 
("transfusion associated circulatory overload").ti 
(iatrogenic AND "fluid overload").ti,ab 
("fluid balance").ti,ab AND ("fluid overload").ti 
Clinical medicine text-
books 
Hand-search 
Patient-centred care, co-
designing of services in the 
context of policy and 
regulation 
BNI, CINAHL, EMBASE, 
Medline, PubMed, HBE, 
HMIC 
("healthcare at home").ti,ab 
(co-designing).ti,ab 
Google, Google Scholar “patient centred care policy” 
“co-design of healthcare services” 
Patient and practitioner 
experience 
BNI, CINAHL, EMBASE, 
Medline, PubMed, HBE, 
HMIC 
(transfusion).ti,ab AND ("patient experience").ti,ab 
(transfusion).ti,ab AND ("lived experience").ti,ab 
((transfusion AND nurse) AND experience).ti,ab 
((transfusion AND nurse) AND attitude).ti,ab 
Google, Google Scholar “patient’s experience of blood transfusion” 
“nurse experience of blood transfusion” 
 
Appraisal Method 
Each title and abstract returned by the HDAS search was evaluated for 
significance, representativeness, contribution, reliability, and 
contemporaneousness. The inclusion and exclusion criteria were based on 
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column 1 of table 2.2 above, favouring recent original articles from high 
impact journals. Titles and abstracts meeting these criteria were considered 
eligible and saved outputted into a Microsoft ExcelTM file. Records from other 
sources were evaluated on-screen. This was not a formal systematic review 
but a degree of rigour was required in the appraisal of the quality of the 
literature identified from the search. This is represented diagrammatically in 
figure 2.1 below. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Literature Search Results 
 
Records returned by 
database searches = 
3356 
Records retained after 
eligibility appraisal = 
334 
Remaining eligible 
records = 166 
Database records 
included = 41 
Duplicate records = 
178 
Records from grey 
searches = 34 
Total records included 
in literature review = 
75 
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Synthesis and Analysis 
The remaining literature was then used to produce a narrative which critically 
evaluated the background and current status of research in this area of 
transfusion medicine and clinical practice, highlighting gaps in current 
knowledge, limitations and uncertainty, and providing a contextual framework 
for the research study in chapter three. The synthesis of the published 
literature collectively provided added value in building arguments to 
challenge and progress current practice, by supporting the development of 
new theses and testing of hypotheses presented as a conceptual framework 
in chapter four. 
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Chapter Three: 
Contextual Framework 
 
This chapter is a review of the literature using the strategy described in 
chapter two. The chapter comprehensively introduces the elements of the 
thesis title describing the history, safety and clinical practice of blood 
transfusion, including the development and delivery of home transfusion. The 
current status of research in this area and the influence of wider healthcare 
policy are also considered, leading to the development of a contextual 
framework for the study (figure 3.1, page 41). 
 
Blood Transfusion in Clinical Practice 
This introductory section considers the station of blood transfusion in wider 
clinical practice and its importance in the provision of elective and 
emergency healthcare. The regulation and governance of blood transfusion 
provide practice standards and a means of evaluating the safety of blood 
transfusion as evidenced by haemovigilance reporting data. The practical 
aspects of performing blood transfusion and care of patients receiving blood 
transfusion are also considered in the context of current clinical guidelines. 
The wider context, safety and practical aspects discussed here provide a 
descriptive and critical platform from which the contextual framework of the 
thesis later develops. 
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Historic Development of Blood Transfusion 
The history of blood transfusion is polarised by momentous achievements 
and catastrophic failures, on a background of intrigue, rivalry and 
accusations of murder (Tucker, 2011). The maverick experimenters of the 
17th century laid the foundations for modern transfusion medicine. The 
collateral damage of experimental failures also stalled it for 150 years 
through hastening the demise of animals and humans alike. This resulted in 
the practice being outlawed despite being cited in the 1666 Philosophical 
Transactions of the Royal Society (Royal Society, 1666). By the early 19th 
century, James Blundell [1791-1878], a medical practitioner, revisited the 
concept of blood transfusion after witnessing a woman dying from a post-
partum haemorrhage (Sturgis, 1942). However, progress in establishing the 
technique was impeded due to technical difficulties in administering blood, 
preventing the blood from clotting, and not least, understanding donor-
recipient compatibility. The latter problem was solved by Karl Landsteiner’s 
[1868-1943] work on discovery of the ABO human blood group system in 
1901 for which he received a Nobel prize in 1930 (Landsteiner, 1930). The 
20th century observed an exponential increase in discovery and knowledge in 
transfusion science and medicine, making transfusion safer for those who 
needed it. The first UK blood bank was opened in Ipswich in 1937. 
Organised altruistic blood donation began in a number of regional centres in 
the United Kingdom (UK), which became critically important in treating 
casualties of war when the Second World War began a few years later. The 
National Blood Service was established in 1946. Now known as UK Blood 
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and Transplant (part of the National Health Service), the organisation collects 
around 2.1 million blood donations per year (NHSBT, 2014).  Transfusion of 
red cells, plasma and platelets saves, and improves the quality of life for 
hundreds of thousands of patients in the UK every year. Transfusion of red 
cells is given for haemorrhage (including trauma), bone marrow failure and 
other causes of severe anaemia. Major surgery and myelosuppressive 
chemotherapy would not be an option for patients if red cell transfusion were 
not possible, and many patients would quickly die from bone marrow failure 
diseases without regular transfusion support.  
Laboratory and clinical practice in blood transfusion is now highly regulated. 
Modern research and development has yielded solutions to the fundamental 
barriers based upon experience by the early experimenters such as 
optimising the storage and administration of blood, compatibility-testing, and 
screening/testing to improve blood safety. Blood transfusion is a mainstay of 
current medical and surgical practice, and continuous research and 
development in every aspect of transfusion practice is essential to refine and 
finesse knowledge and understanding of this field to improve the safety and 
utility of this vital therapy. 
The Safety of Blood Transfusion in the UK 
Blood Transfusion is subject to a high level of regulation and governance, to 
ensure high safety and quality standards. The transfusion clinical process is 
not directly regulated. The governance of blood transfusion was, until 
recently, covered by a specific criterion of the NHS Litigation Authority 
(NHSLA) Standards (NHSLA, 2013), and is now indirectly governed and 
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regulated by the Care Quality Commission (CQC) and cross-cuts several 
aspects of the Standards (CQC, 2010). Transfusion Laboratory activities are 
regulated by the Medicines and Healthcare products Regulatory Agency 
(MHRA), who inspect facilities under the Blood Safety and Quality 
Regulations (BSQR, 2005). The MHRA inspect activities relating to the 
testing, processing, storage and distribution of blood in hospitals. The MHRA 
also jointly administrate a haemovigilance system, Serious Adverse Blood 
Reactions and Events (SABRE) with Serious Hazards of Transfusion 
(SHOT), and hospitals are legally obliged to report to SABRE under the 
auspices of the regulations. The SABRE gateway allows simultaneous 
reporting to SHOT and SABRE. Reporting to SHOT is not legally mandated, 
but the majority of organisations do report to SHOT as this is good 
governance practice. 
In 2016, 100% of NHS organisations participated in SHOT reporting (Bolton-
Maggs et al, 2017). SHOT has compiled data on transfusion errors, adverse 
events and reactions since 1996, and publish an annual report with 
recommendations to improve the safety of transfusion practice. The risks of 
transfusion can be broadly considered to be procedural errors, pathological 
reactions and pulmonary complications. The pathological reactions and 
pulmonary complications may be idiosyncratic and therefore unavoidable, 
although some may be prevented by improved clinical practice, and were 
regarded by SHOT as possibly preventable. However, the risks caused by 
procedural error are considered preventable. There were 26 deaths reported 
in the 2016 report, 8 of which were regarded as probably and 15 possibly 
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related to transfusion, and three definite. One was in a category regarded as 
not preventable (acute transfusion reaction), 15 were in categories that are 
regarded as possibly preventable with improved practice (haemolytic 
transfusion reaction and transfusion associated circulatory overload), and 10 
were in categories that are regarded as preventable (delayed transfusion, 
and avoidable transfusion). There were a further 122 cases of major 
morbidity. In context, the risk of death from transfusion is 1.05 per 100,000 
blood components issued in 2016, and 4.91 for major morbidity (Bolton-
Maggs et al, 2017). Blood Transfusion can be considered a low risk for 
serious harm or death and compares favourably with other medical 
interventions. For example, the 90 day mortality for a total hip replacement 
was estimated to be 0.65% (650 in 100,000) (Berstock et al, 2014) which is 
approximately 650 times more than the mortality risk for blood transfusion. 
Intravenous Administration of Blood  
Blood components (including red cells) can be administered by two methods, 
either gravity infusion or an infusion device. Gravity infusion is a manual 
technique using an IV administration set specifically for use with blood. The 
administration set incorporates a 170-200 micron screen filter designed to 
remove any particulate material present in stored blood. The set is attached 
to the blood unit via a sterile port. The chamber is filled with blood, and the 
line is primed. The line is then attached to a cannula sited in a suitable vein 
in the dorsal aspect of the patient’s hand, or in the arm. An indwelling 
catheter may be used if the patient has had one inserted for other regular 
intravenous treatments such as chemotherapy.  The volume and rate of the 
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infusion is prescribed by the medical officer, and the ‘drip-rate’ is calculated 
by the practitioner administering the transfusion, using the volume stated on 
the blood unit label. The volume (ml) to be infused is multiplied by the 
number or drops in 1ml (typically this is 15 for blood and more for crystalloid 
fluids which are less viscous than blood, but the manufacturer’s instructions 
should be followed). This value is divided by the number of minutes over 
which the infusion is to be delivered. This gives the number of drops falling 
into the drip chamber per minute (Dougherty, 1999). The practitioner adjusts 
the drip rate accordingly and monitors the infusion to ensure the rate is 
maintained throughout the transfusion. Alternatively, blood may be 
administered using an infusion pump that is validated for use with blood 
components. A specific blood IV administration set must be used that is also 
compatible with the infusion pump equipment. The pump is programmed to 
deliver a specified volume (as stated on the blood unit label) over a specified 
duration, as set by the practitioner in accordance with the prescription. The 
technique is otherwise identical to gravity infusion in terms of attaching the 
administration set to the unit, priming and connecting to a cannula in the 
patient. Infusion pumps have the additional benefit of minimising calculation 
errors, and will alarm if the flow rate is interrupted. The residual volume of 
blood remaining in the administration set (and therefore not reaching the 
patient) is approximately 15ml. 
Volume and Infusion Rate Relationship in Red Cell Transfusion 
The volume of red cell transfusion in the normovolaemic patient is an 
important consideration in achieving an appropriate haemoglobin increment 
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in the patient to resolve the symptoms of anaemia. The recommended 
volume or dose of red cell transfusion in adults is empirical. The NICE 
guideline for blood transfusion promotes single unit transfusion in non-
bleeding patients with review of the patient’s symptoms and haemoglobin 
level after each unit, including recommendations for target post-transfusion 
haemoglobin level (NICE, 2015). The guideline acknowledges that 
transfusion-dependent patients require individualised transfusion regimes 
which may not reflect the standard single unit approach. This relates to the 
cause of anaemia. Patients with acute and/or reversible anaemia require a 
single dose of red cells to resolve their symptoms of anaemia and this acts 
as a buffer until their bone marrow can respond and sustain a physiologically 
normal haemoglobin level. In contrast to this, patients with bone marrow 
failure or suppression are transfusion-dependent as the bone marrow cannot 
contribute to red cell production and therefore repeated transfusions are 
required to maintain a haemoglobin level that mitigates the symptoms of 
anaemia.  The majority of transfusion-dependent patients receiving regular 
transfusion receive two units of red cells and have their haemoglobin level 
checked periodically to inform the frequency of transfusion. All current 
transfusion guidelines fail to recognise the impact of the compound effect of 
the size of the adult patient and the variability in the volume of blood units, 
and how this may affect effective red cell dosing in order to achieve a target 
haemoglobin level. A dose of 4ml/Kg has been reported to raise the 
haemoglobin level by 10g/L, but this guidance may only be reliable in a 70Kg 
adult (Norfolk, 2013). More recently, a red cell dosage calculator was 
developed showing that a dosage recommendation based on 4ml/Kg 
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achieved a target haemoglobin level in around 90% of cases. It also 
demonstrated that the use of actual or estimated body weight in the dose 
calculation had no effect on predicting achievement of the target 
haemoglobin level (as a group effect) but may be important to individual 
patients with extremes of body weight, especially patients with low body 
weight who may be at risk of circulatory overload (Grey et al, 2016). 
The current UK guideline recommendation for the duration of red cell 
transfusion is 90 min to 4 hours per unit (BCSH, 2009). This is based upon 
opinion from experience in practice (equivalent to grade C, level IV 
evidence/expert opinion), rather than evidence derived from experimentally 
designed studies. The American Association of Blood Banks Technical 
Manual (Roback et al, 2008) recommends 150-300ml per hour, while the 
Australian and New Zealand Society for Blood Transfusion guidelines (2011) 
recommend the rate of transfusion as 60-180 minutes per unit, unless the 
patient has heart failure or is at risk of fluid overload. Based upon the 
shortest recommended infusion time, this is 30 minutes per unit of red cells 
faster than the current UK guideline recommendation (BCSH, 2009). Aside 
from general guiding medical principles relating to patients who may not 
tolerate excessive infusion rates due to co-morbid conditions, there is 
currently no evidence-based recommendation for a definitive red cell infusion 
rate for either general application or specific patient groups. General opinion 
that ‘fast transfusion’ may contribute to circulatory overload is a well-
established belief but the evidence for this is lacking (Popovsky, 2009). One 
study demonstrated a statistically significant relationship between the 
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duration of transfusion (121 minutes versus 83 minutes average duration) 
and the development of transfusion-associated circulatory overload in 
patients receiving a transfusion episode over the shorter period 
(Andrzejewski, 2012). The significance of this is difficult to evaluate as the 
data were not analysed as infusion rate in the context of volume transfused.  
The patient’s body weight not only affects the required dose of red cells to 
reach a target haemoglobin, but additional variable of variation in individual 
unit volume which may significantly impact upon the infusion flow rate and 
overall transfused volume. This may be clinically important particularly in the 
smaller patient. It has been proposed that by changing practice from a 
standard ‘unit over time’ approach to rate of transfusion, in the context of red 
cell volume/dose and body weight over time (ml/Kg/hr), may finesse the 
approach to transfusion infusion rates, thereby individualising treatment and 
improving safety for the smaller adult patient (Grey, 2015). Weight-adjusted 
infusion rate for red cell transfusion in the context of safe and effective 
transfusion is under-researched but its importance suggested some time ago 
(Popovsky, 2009), and could also standardise data for future research. 
Clinical Monitoring of Patients during Blood Transfusion and the 
Detection of Adverse Events and Reactions 
The British Committee for Standards in Haematology guideline sets out the 
minimum standards for the administration of blood transfusions, to support 
the development of standardised local guidelines and practice (BCSH, 2009). 
The scope of the guideline covers pre-transfusion samples, prescription, 
collection, and administration of blood components. In common with others, 
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our NHS Foundation Trust Clinical Transfusion Process policies are based 
upon this guideline (Bolton NHSFT, 2014). The rationale for the standards 
relating to administration procedures is the early detection of a pathological 
reaction, which allows for action to be taken at the earliest opportunity.  
The monitoring procedure involves the general observation of the patient to 
detect any new signs or symptoms such as skin rashes/flushing, pain, 
discomfort, gastrointestinal upset and specific measurement and recording of 
vital signs. Acute transfusion reactions are usually easily detected in a 
conscious adult with appropriate monitoring. They may be less obvious in an 
unconscious or anaesthetised patient and their detection therefore relies on 
an appropriate level of clinical monitoring, observation, and care whatever 
the clinical condition of the patient. The patient’s vital signs: temperature, 
blood pressure, heart rate and respiratory rate are measured and recorded 
for every blood unit transfused. The respiratory rate is measured by 
observing and counting the patient’s chest movements for one minute (the 
normal range is 12-20 per minute). Blood pressure and heart rate can be 
measured automatically using an electronic device. Alternatively, blood 
pressure can be measured using a manual sphygmomanometer and 
stethoscope to auscultate the brachial artery (normal blood pressure is 
between 90/60mmHg and 140/90mmHg) .However, 40% of adults have a 
blood pressure measuring greater than 140/90, with the proportion 
increasing with age (NICE, 2011). This complicates the use of blood 
pressure as a parameter to detect adverse events in blood transfusion. A 
scale change in blood pressure may be more informative but there is no 
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specific guidance on this. The heart rate can be measured manually by 
palpating and counting the radial pulse for one minute (normal is 60-90 beats 
per minute). Temperature is measured using an infrared tympanum (ear) 
thermometer in a healthcare setting, as they minimise infection control and 
prevention risks (normal temperature is around 37oC). The BCSH 2009 
guideline does not make a recommendation for the routine monitoring of 
oxygen saturation, however the updated 2018 guideline now recommends 
monitoring oxygen saturation in patients at risk of TACO (Robinson et al, 
2018). This may serve as an early warning of respiratory compromise if 
respiratory rate fails to provide warning. 
The first set of measurements is taken prior to the transfusion starting (no 
more than 60 minutes before the transfusion starts). This is a baseline 
measurement. The next set of observations is taken 15 minutes after the 
start of the transfusion. The respiratory rate may not be recorded after the 
first measurement if there are no signs of reaction. The rationale for the 
measurement at 15 minutes is to detect severe reactions. Many (but not all) 
severe reactions such as an ABO incompatible haemolytic transfusion 
reaction, anaphylaxis and those associated with bacterially contaminated 
blood usually begin within the first 15 minutes. Another set of observations is 
performed and recorded when the blood unit is completed. Some patients 
have abnormal vital sign observation values prior to transfusion which relate 
to their underlying health condition. Indeed, some patients requiring blood 
transfusion for severe anaemia may have tachycardia, increased respiratory 
rate, and hypotension detected by their pre-transfusion measurements, as 
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this is a physiological response to anaemia. The rationale for serial vital sign 
measurements is the early detection of a reaction which may manifest as 
outright abnormal measurements, or may become apparent less abruptly as 
a trend. The National Early Warning Score (NEWS) (RCP, 2012) produces 
an aggregated score for vital sign observations that identify patients for 
escalation of care and is therefore also useful for patients receiving blood 
transfusion in acute care settings and also includes measurement of oxygen 
saturation. 
Complications arising from transfusion and pathological reactions may occur 
sometime after the transfusion episode has ended. The most common type 
of late onset acute reaction is fever (febrile transfusion reaction). However, 
pulmonary, infective and immune type reactions can also occur in the hours 
following a blood transfusion. Patients should be made aware of this and 
informed about how to recognise them. Hospital inpatients continue to be 
observed as part of their ongoing medical care, but patients receiving 
transfusion as a day case or at home require special consideration. It is good 
practice to provide information and contact details for patients in case they 
become unwell after they have left the care of the healthcare practitioner 
following their transfusion and, where possible, the patient should have a 
responsible adult with them for at least 2 hours (Green et al, 2013). Patients 
receiving day case or home transfusions in the participating Trust are 
provided with an information and contact booklet entitled ‘Advice for patients 
receiving blood transfusion as a day case’, which explains transfusion 
reaction symptoms and signs, and provides 24 hour contact advice. 
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If a patient develops signs of a reaction, the symptoms and signs are 
evaluated to determine whether they are related to the patient’s underlying 
condition. If the underlying condition is excluded as a likely cause, and a 
transfusion reaction is suspected, an assessment is conducted to ascertain 
whether the reaction is mild, or moderate/severe. Mild reactions are defined 
as: a fever of less than 390C (or no more than 20C above the baseline 
measurement, if the baseline was less than 370C) with no other symptoms 
(i.e. isolated fever); or a mild allergic reaction where there is a rash but no 
symptoms suggestive of anaphylaxis (such as hypotension, dyspnoea, 
wheeze or angio-oedema). This type of reaction is treated with the 
appropriate medication to relieve symptoms such as an anti-pyretic or anti-
histamine. There is usually no requirement to stop the transfusion and/or 
perform diagnostic tests, or report to SHOT/SABRE (MHRA), although the 
patient will require more frequent vital sign observations performing to 
ensure the reaction is not worsening. 
Moderate/severe reactions may manifest as a high fever greater than 390C, 
or 20C above the baseline measurement (with or without rigors/chills), 
significant changes in blood pressure, respiratory rate and heart rate, rash 
(with additional symptoms), pain, haemoglobin in the urine, or reduced urine 
output, uncontrolled oozing/bleeding, nausea/vomiting or diarrhoea. These 
symptoms and signs may occur in isolation or in combination. As with mild 
reactions, moderate/severe reactions should be evaluated for significance in 
the context of the patient’s underlying condition. A clinical assessment and a 
range of diagnostic testing is undertaken to ascertain the nature of the 
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reaction. These reactions must be reported to SHOT and SABRE/MHRA 
(MHRA, 2010; BCSH, 2012; SHOT, 2014; Bolton NHS FT, 2014). These 
guidelines and regulatory requirements for detecting adverse events have a 
post hoc focus and there has more recently been interest in pre-emptive 
approaches to avoid or mitigate adverse reactions. NEWS can facilitate the 
early response to a deteriorating patient but beyond this, others have sought 
to identify patients at risk of reaction and this has been particularly evident 
for pulmonary complications of transfusion. Risk assessment check-lists 
have been developed (Tseng, 2016; Bolton-Maggs et al, 2016) and active 
electronic surveillance of health records (Clifford et al, 2013) to identify 
patients at risk.  
Review of the literature shows that through continuous development, blood 
transfusion is a safe and effective treatment and a mainstay of wider medical 
and surgical practice when practised in accordance with its regulation and 
governance. National transfusion procedural guidelines are well established 
for the care and monitoring of patients receiving transfusion, but do not 
account for the problematic nature of blood pressure as parameter for 
monitoring due to the prevalence of chronic hypertension in the general 
population. The more personal and anticipatory approach of risk assessment 
and active surveillance prior to transfusion may further strengthen the clinical 
guidelines. The literature review highlighted the unsatisfactory status of 
research on safe infusion rates for red cell transfusion, including the varying 
guidelines stated globally, and lack of standardisation for what is understood 
by ‘rate’ transfusion. The lack of evidence for this aspect of the transfusion 
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process invites a challenge of the perception that ‘faster’ transfusion 
contributes to circulatory overload. 
Blood Transfusion Service Provision 
This section considers the delivery of blood transfusion services to patients, 
and specifically evaluates the benefits of home transfusion by considering 
local experience and the wider literature. Issues with current home 
transfusion provision present a case for change. As an exemplar of patient-
centred care, potential changes to home transfusion services are considered 
in the wider context of national regulation and policy. 
The Location of Blood Transfusion and Out of Hospital Transfusion 
Blood transfusions usually take place in a hospital setting. Urgent and 
emergency transfusions are performed on hospital inpatients in acute care 
environments such as hospital wards, theatre or specialised units. 
Additionally, routine transfusions also take place in elective care settings 
such as day-case units within hospitals. Some hospitals have developed out-
of-hospital transfusion services with healthcare facilities outside their 
organisation, such as Hospices and intermediate care. Provision of 
transfusion outside a healthcare facility is less common, although has a long 
history.  
Home transfusions were first described in haemophilia patients over 40 years 
ago by Rabiner and Telfer (1970) who reported significant social benefits and 
safe outcomes from transfusion of plasma components in the patient’s home. 
Koepke et al (1988) later reported the economic value of home transfusion 
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as a cost effective alternative to hospital admission for selected patients. 
Benson et al (1998) acknowledged the paucity of information regarding home 
transfusion practices and surveyed US healthcare providers to gain insight. 
They found that only 16% of respondents [surveyed in 1994] were involved 
with the provision of home transfusion services.  Whilst the precedent for 
home transfusion has origins outside the UK, there are very little data in the 
literature regarding the prevalence or experience of home transfusion 
practice within the UK. The professional experience of the author of this 
study perceives the majority of healthcare Trusts across the UK do not 
provide home transfusion services. More research is required to understand 
the reasons for this, given that NHS England, the Department of Health and 
Monitor have endorsed the transformation of services to enable medical care 
to be delivered closer to home (NHS England, 2014; DH, 2009; Monitor, 
2015). 
These suggest that both economic and patient experience issues may have 
a bearing on development of these services. There have been a small 
number of studies on the financial cost of blood transfusion and where 
published, these are difficult to interpret and compare due to differences in 
scope and methodological approaches. Abraham and Sun (2012) published 
a systematic review which attempted to standardise the results of previous 
studies in order to estimate the cost of a two-unit red cell transfusion. The 
cost of a two-unit red cell transfusion was adjusted for historic exchange 
rates to produce a standardised value. The three UK studies included in the 
review were reported (in Euros at 2011 rates) as: €969 (Agrawal et al, 2006), 
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€972 (Varney and Guest, 2003) and €672 (Hadjianastassiou et al, 2002). 
There are no studies comparing the costs of hospital versus home 
transfusions, however the Department of Health produced a Best Practice 
Guideline in 2009 which cited a case study of home transfusions in South 
Staffordshire reported their hospital transfusion cost as £500, and that home 
transfusions were less than half this cost (DH, 2009). The article implies this 
cost is per transfusion episode however this was not made explicit and does 
not state the number of units per episode. The differential cost of home and 
day case transfusion in the participating Trust is difficult to assess. The direct 
costs are identical (blood products, laboratory compatibility testing and 
clinical consumables), but the indirect costs (overheads, workforce and pay 
related costs) are more complex to calculate. This largely depends on the 
overall indirect costs of each service model, which extends far beyond the 
provision of blood transfusion alone.  
The Home Transfusion Service 
The Rapid Response Team (now known as the Community IV Therapy 
(CIVT) Team was formed in 1995 as an extension of district nursing services 
provided by our Community Healthcare NHS Trust. The team’s role was to 
provide a direct alternative to acute hospital admission, by treating patients in 
their own home. The types of patients treated by the team included those 
with acute illnesses, social support issues, physical disabilities, and those 
with palliative care needs. The service expanded in 1997 to support medical 
patients with acute care needs, and the delivery of IV (intravenous) therapies 
including antibiotics, chemotherapy and blood transfusion (Audit 
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Commission, 1999). The CIVT service is now part of the local NHS 
Foundation Trust: an integrated care organisation that delivers both 
community and hospital services to the area. 
The origins of the home transfusion service developed from a nurse’s 
concern about the risks and difficulties of transferring a sick patient to 
hospital from their home for a blood transfusion. The consultant 
haematologist responsible for the patient’s care considered home transfusion 
as a possible option to improve the patient’s experience. The procedure in 
the home setting had not yet been undertaken by the organisation at that 
time (1997), but it was acknowledged that such a service could potentially 
bring benefit to patient care. Recognising both economic and non-economic 
advantages, a key partnership was set up including the CIVT Team, the 
Clinical Haematology Team, the Blood Transfusion Laboratory, and patients 
and their care providers. 
The participating Trust was probably one of the first organisations to develop 
a home transfusion service in the UK, and has been providing home 
transfusions since the CIVT Team expanded in 1997. The service allows the 
patient to be treated in their own home, avoiding admission to hospital, which 
is associated with organisational costs, puts pressure on inpatient bed 
availability and increases the risk of infection (as a significant number of 
these patients are immuno-compromised). Elderly, chronically transfused 
haematology and medical patients are the main users of this service, many 
of whom have physical and social difficulties accessing hospital-based 
services. The blood is provided by the Blood Transfusion Laboratory at the 
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Hospital and the transfusions are administered and monitored by specialist 
CIVT Team nurses. The service was highly commended in the 1999 Nursing 
Times National Nursing Awards, and published as a ‘good practice’ case 
study by the Audit Commission in 1999 (Audit Commission, 1999). Home 
transfusion procedures are as rigorous as hospital-based transfusion 
services.  
An audit (unpublished) was performed by the participating NHS Foundation 
Trust’s Haematology Department in 2002, based on 1997-2002 home 
transfusion data, to evaluate the implementation of the service. The audit 
reported several advantages stated by staff involved in the service: patients 
particularly liked the continuity and one-to-one care they received; 
maintained dignity, comfort and convenience for the patient, but also for their 
carers who also may have had their own health and mobility issues. There 
were also organisational advantages reported such as reduction of pressure 
on inpatient beds and the associated costs of inpatient care, and perceived 
reduced risk of healthcare-associated infection. Hospital-acquired infection 
was reported in 6.4% of inpatients in acute care hospitals in 2011(Public 
Health England, 2016) making avoidance of inpatient admission an important 
factor for potentially immune-compromised haematology patients who may 
be vulnerable to infection. Practitioners themselves liked the extended role 
and the relationships that developed with their regular patients. They 
generally felt the benefits of working on a single task, which reduced stress 
and the potential for procedural errors.  A number of disadvantages were 
also reported by staff in this audit, such as working in unsafe environments 
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where personal safety was an issue, or where standards of hygiene was 
below acceptable standards. However, checks and safeguards were in place 
to identify, avoid or minimise such risks. At the time of the audit (2002), the 
CIVT Team were administering 130 home transfusions per year. The rate in 
2015 was 222 per year which represents a 41% increase in 13 years. 
Currently, patients are triaged to receive home transfusion because demand 
for the service outstrips capacity. Fewer priority cases are admitted as day 
cases either on the Oncology unit or as a day case admission to a medical 
ward.  
Although this has been reported to be an excellent and, anecdotally, popular 
service to the patient, it requires lengthy one-to-one treatment time, typically 
four hours for a two unit red cell transfusion (three hours infusion time and 
one hour for other tasks). In this respect it is a less efficient use of nursing 
resource than a transfusion delivered as an inpatient, or hospital day case. 
This prolonged patient contact reduces the overall capacity of the service to 
deliver transfusions and other IV treatments to other patients requiring the 
service. The service is currently under pressure to increase its scope and 
capacity due to policy drivers for out-of-hospital care (NHS England, 2014; 
DH, 2009; Monitor, 2015), and increasing additional clinical demands. Blood 
transfusion is only one aspect of the IV services they deliver.  
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Patient-Centred Care, Patient Experience and the Co-Designing of 
Services in the Context of National Policy and Regulation 
The Department of Health and the NHS have established a mandate for 
patient-centred care and valuing patient experience as a central ideology that 
penetrates all aspects of their activities, and its foundation is established in 
various UK legislation and national policies. The formative research in this 
area was commissioned in 2010 by the Department of Health and NHS 
Institute for Innovation and Improvement who engaged King’s College 
London and the King’s Fund to undertake research on “What matters to 
patients” (Robert and Cornwell, 2011), with the purpose of developing an 
evidence base for measuring and improving patient experience. The authors 
argue a case for methods to improve services and patient experience of 
healthcare, and strengthening the voice of patients. In February 2012, the 
NHS National Quality Board (NQB, 2012) defined the NHS Patient 
Experience Framework, which is based on the Picker Institute framework for 
patient experience. This framework was identified as a potential framework 
for defining good patient experience by research funded by the King’s Fund 
and King’s College London. The framework outlines evidence-based key 
elements which are fundamental to patients’ experience of NHS Services, 
and recommends using them to inform service improvement (DH, 2012a). 
The principles of patient-centred care and patient experience were evident in 
the ‘The Health and Social Care Act’ when published later the same year 
(DH, 2012b). The act legislates for “a greater voice for patients”, and 
although this primarily focuses on the collective voice of patients for 
36 
 
application at a commissioning level, it resonates with the philosophies of 
patient-centred care and patient experience. The NHS Constitution (DH, 
2013a) also establishes core values that relate to patient-centred care and 
patient experience by pledging that patients will be “at the heart of everything 
the NHS does”, the patient’s right to be involved in changes to services and 
encourages patients to provide feedback about their experiences. There is 
also a commitment to best value for tax-payers money and recognising the 
obligation to effective and sustainable use of finite resources.  The NHS 
Constitution also states the responsibilities of its staff to sustainably improve 
services by working in partnership with patients, and view services from the 
standpoint of patients. This is similarly reflected in the ‘Putting Patients First’ 
NHS England Business Plan for 2013/14-2015/16 (NHS England, 2013b) 
which sets a patient-centred mandate for the securing of value for money 
with respect to the NHS England commissioning budget. It aspires to best 
outcomes for patients and taxpayers through “innovative approaches to 
service delivery”, “deliver better at lower cost” and “driving quality 
improvements” (NHS England, 2013b, p. 39). The Department of Health also 
published best practice guidance for effective clinical and financial 
engagement in the NHS (DH, 2013b) which correspondingly recognises the 
need to bring synergy to clinical outcomes and optimum management of 
financial resources. The guidance was operationalised by the Healthcare 
Financial Management Association (HMFA) in association with Monitor under 
the auspices of ‘value-based healthcare’, where ‘value’ is defined as a 
product of patient-defined outcomes, clinical or experience, and ‘resource’ as 
opposed to ‘price’. This demonstrates a high level of policy level mandate for 
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patient-centred healthcare which is a laudable manifesto however it is 
distanced from actual practice.  Although patient-centred care is now widely 
acknowledged as a fundamental tenet of healthcare provision, it has also 
been criticised as rhetoric. The 2011/12 Care Quality Commission report on 
the State of Healthcare in which they reported previous successive reports 
repeatedly finding fault regarding the lack of patient-centred care, 
demonstrating the disparity between well-intentioned policy and its 
translation into actual patient care and experience. The report stated that too 
much emphasis was placed on task-based rather than patient-centred care, 
and lack of involvement and planning in how care is delivered. This lack of 
finesse regarding individual needs was evidenced by the finding that “in too 
many cases care was not person-centred, people were fitted into services 
rather than the service being designed and delivered around them” (CQC, 
2012, p.72). Bate and Robert (2006) also criticised the rhetoric and gap 
between ‘patient-centred’ ideology and actual practice. They went further to 
develop the patient-centred care philosophy, to propose the role of the 
patient in the co-designing of services to redress the disconnection between 
policy and practice. They described this as “experience-based design” (Bate 
and Robert, 2006, p. 308) utilising patient storytelling as an approach to 
providing evidence for changing and designing health services around the 
patient/user, an antidote for the unaccomplished rhetoric of ‘patient-
centeredness’ of service provision and design, and to close the gap between 
policy and practice. Their approach distinguishes between ‘experience’ and 
‘attitudes’, the former lending itself to qualitative approaches that can be 
utilised to design good experiences rather than focusing entirely on good 
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(task-based) processes which may potentially subtract the value of human 
experience, and therefore the overall effectiveness and user acceptability of 
the process or service.  
Drawing together the principles of patient-centred care, patient experience 
and the concept of co-design of services described earlier (Bate and Robert, 
2006), the King’s Fund launched a toolkit for ‘evidence-based co-design’ 
(EBCD), facilitating the operationalisation of research and high level policy. 
The toolkit emerged from the King’s Fund Patient-Centred Care Project in 
2011 (King’s Fund, 2011) which reports on an EBCD project in which 
patients using cancer services worked with staff to develop service 
improvements. Experiences were gathered from patients and staff and ‘touch 
points’ (Bate and Robert, 2006 p. 308) or emotionally significant points were 
identified, that could be used to develop changes that offered patients a 
better experience of care and the service they used. The approach was 
inductive and is not based on a priori assumptions.  
There is now an emerging culture and clear case for harnessing patient 
insight and feedback, which is a common thread through later policy. In 
2013, NHS England published ‘Transforming participation in health and care’ 
(NHS England, 2013a), which describes the use of both quantitative and 
qualitative techniques to accomplish the vision of participatory endeavour in 
co-designing systems and services. 
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Patient and Practitioner Experience of Blood Transfusion 
A literature search did not reveal any research on practitioner experiences of 
the administration of blood transfusions. To a lesser extent, there is also a 
paucity of published research on patient experience of the administration of 
blood transfusion: a literature search revealed only two papers: Fitzgerald et 
al (1999) and Adams and Tolich (2011), highlighting this as an under-
researched area of practice. Fitzgerald et al (1999) reported on the 
experience of information-giving regarding blood transfusion and what the 
patient understood by it. Adams and Tolich (2011) reported on a qualitative 
study in which every patient responded negatively regarding the duration of 
the procedure, describing it as “slow”, “tedious” and “lengthy”. This finding 
concurs with the anecdotal observations of patients and staff using, or 
delivering, the service locally in our Trust. Qualitative research in transfusion 
medicine is still unusual despite its advocates (Whittaker, 2006; Arnold and 
Lane, 2011).  
Although home transfusion is not widely implemented, a small number of 
studies have shown to provide multiple benefits both to the patient and 
organisations. The desire to provide care closer to home and increasing 
workload challenges service capacity. Review of national legislation and 
policy suggests this should influence how change to systems and services 
are decided and delivered. Specifically this requires a recognition of ‘value 
for money’ and responsible use of NHS resources, and a participatory 
approach with patients. The literature review revealed a paucity of studies on 
patient experience of blood transfusion, suggesting that patients were not 
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necessarily involved in the way this service is delivered for them. Patients 
also expressed dissatisfaction with the time taken to receive a transfusion 
which concurs with local anecdotal experience.  
The Contextual Framework Model 
Blood transfusion is safe and highly regulated, and has allowed important 
advances in medicine and surgery. The delivery of blood transfusion at home 
has been shown to have significant economic and social benefits, and is a 
key IV service delivered by the CIVT Team. The CIVT service is highly 
valued and has been providing IV services in the patient’s home long before 
DH policy and mandates for care closer to home were established. 
Unfortunately, demand is now difficult to balance with available capacity. 
Identifying ways to improve the efficiency and capacity of the service is vital 
so that it may be offered to more patients, avoiding in-patient admissions.  
Achieving this within current resources requires considering the feasibility of 
shortening treatment time for blood transfusion. The literature review 
demonstrates the empirical nature of current clinical practice concerning the 
rate, volume and duration of transfusion in the unexplored context of variable 
blood unit volume, and weight of adult patients. Consequently, there is 
currently no available evidence to safely make this change and would require 
challenging the widely-held view that ‘faster’ rates of transfusion may 
contribute to circulatory overload. 
Service development changes should continue to respect the patient-centred 
care philosophy of the CIVT service and of national policy and regulation 
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through a participatory approach based upon understanding the patient’s 
experience. Current though limited, evidence suggests that patients are 
frustrated with lengthy infusion times. 
The contextual framework model shown below in figure 3.1 illustrates the 
current benefits of the CIVT service and need for service delivery change in 
the face of increased demand. It identifies potential efficiencies in increasing 
capacity by reducing the treatment delivery time, in the context of external 
forces affecting service development, and the limitations of current available 
evidence to allow safe change of practice.  
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Figure 3.1: Contextual Framework Model 
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Precis of Thesis Development 
 Home transfusion has a long history and has been shown to offer 
significant economic and social benefits to both organisations and to 
patients. The Community Intravenous Therapy (CIVT) Service at the 
local NHS Trust established a service providing blood transfusions at 
home many years ago. 
 Over the years, the additional pressure of national policy for out-of-
hospital care, new and diverse intravenous treatments, and the 
increased demand for home transfusion outstripped service capacity 
for this relatively small and highly skilled team. 
 Achieving increased capacity within current staff resources relied on 
finding new and efficient ways of delivering the service, so that it may 
continue to benefit patients and avoid in-patient admissions. 
 One of the variables in the current service model is treatment delivery 
time per home visit. One of the most time-consuming treatments 
delivered by the CIVT service is blood transfusion, and there is some 
evidence in the current literature that patients are frustrated with the 
length of this treatment. 
 This posed the question as to whether the infusion time of a red cell 
transfusion could be safely reduced in order to gain service capacity 
and improve patient experience. 
 The literature review demonstrated the unstandardized and empirical 
nature of current clinical practice concerning the rate, volume and 
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duration of transfusion in the unexplored context of variable blood unit 
volume, and weight of adult patients. 
 Current guidelines on the duration of transfusion is based upon low-
level evidence established from experience and expert opinion rather 
than experimentally designed studies, with global variation in practice 
 Weight-adjusted safe rates of transfusion are under-researched but 
were identified as important some time ago 
 There is currently no available evidence to safely make this change 
and would also challenge the widely-held view that ‘faster’ rates of 
transfusion may contribute to circulatory overload. 
 The primacy of creating efficiencies that focussed on the task and 
quality of experience as opposed to the number of staff delivering it, 
respects national policy drivers for service development and change 
concerning cost-effectiveness, responsible use of resources, and 
value-based healthcare. 
 There is a paucity of research on patient experience of blood 
transfusion and no research studies on practitioner experience of 
blood transfusion 
 The patient-centred philosophy of the CIVT service and evidence that 
patients may be dissatisfied with the length of treatment provided a 
potential mandate to co-design service change with patients and 
practitioners who use the service. 
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 This chapter provides the foundation of a conceptual framework that is 
further developed in the following chapter, where the concept of 
‘accelerated-transfusion’ is explored. 
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Chapter Four:  
Conceptual Framework 
 
Purpose and Development of the Conceptual Framework 
The conceptual framework model below (figure 4.1) is an evolution of the 
contextual framework model (figure 3.1) in chapter three, where the concept 
of accelerated transfusion was proposed as a means to improve CIVT 
service capacity, while observing the principles of patient-centred care. This 
chapter forms an argument for the proposal, positioning it within the wider 
field of research in this area. The chapter also explains the relationship of the 
conceptual framework to the development of the research question, the 
research design and methodological approach to answering the research 
question, and testing of the hypotheses. 
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Figure 4.1: Conceptual Framework Model 
 
Conceptual Framework: Addressing the ‘Rate’ of Transfusion 
The ability to safely prescribe red cells for infusion over 60 minutes per unit 
(instead of 90 minutes per unit) could significantly shorten treatment times. 
This requires new evidence to be generated for safe standardised infusion 
rates based upon volume and body weight (ml/Kg/hr). The issue of defining 
the ‘rate’ of transfusion was introduced in the previous chapter as current 
definitions do not take the variables of red cell unit volume and the patient’s 
body weight into account. Current guidance on the duration of transfusion in 
international standards provide various guidelines and is based upon low-
level evidence and is presented as ‘red cell unit’ over time (BCSH, 2009; 
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ANZBT, 2011) or as volume over time (AABB, Robeck, 2008). The 
problematic nature of this can be deconstructed using the following example 
(figure 4.2). Both patients are on a regular transfusion regime and receive 
two units of blood per transfusion episode. The frequency of transfusion 
depends upon the maintenance of their haemoglobin between transfusions. 
 
 
                  
        
Figure 4.2: effect of body weight on infusion rate 
 
Both patients ultimately receive the same volume of blood but the rate of fluid 
challenge is higher in the smaller patient. The other variable is the volume of 
the red cell unit. The volume of a UK (NHS Blood and Transplant) red cell 
unit is 220-340ml, with a mean of 280ml (NHSBT, 2012). The added variable 
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of patient body weight can produce a significant difference to the infusion 
rate (figure 4.3). 
 
               
              
Figure 4.3: effect of unit volume variability on infusion rate 
Red cell units are not allocated to patients based upon volume or body 
weight in current practice, and therefore shortening the infusion time to 60 
minutes per unit could significantly affect the consequent infusion rate. This 
may particularly clinically important in the smaller patient with a significantly 
lower circulating blood volume who may therefore have increased risk of 
circulatory overload. 
Determining a proposed safe rate of transfusion that would allow two 
red cell units to be transfused over 60 minutes each 
Notwithstanding the problematic nature of the definition of transfusion ‘rate’, 
there is a lack of evidence for a safe rate of transfusion as previously 
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discussed. There is however some evidence to support the proposition that 
red cell transfusions can be administered over a shorter duration than is 
currently endorsed by national UK transfusion guidelines to certain patient 
groups i.e. those without heart failure or otherwise at risk of fluid overload. 
The Australian and New Zealand Society for Blood Transfusion guidelines 
(ANZSBT, 2011) recommend the rate of transfusion as 60-180 minutes per 
unit (unless the patient has heart failure or is at risk of fluid overload). Based 
upon the shortest recommended infusion time this is 30 minutes per unit of 
red cells faster than the current UK guideline recommendation of 90-120 
minutes (Robinson et al, 2018). However, there is some variability in the 
volume range of UK and Australian red cell units. The typical volume of an 
Australian standard red cell unit is  236-282ml, mean 259ml (Australian Red 
Cross Blood Service, 2012), and the volume of a UK (NHS Blood and 
Transplant) unit is 220-340ml, mean 280ml (NHSBT, 2012). This must be 
evaluated in the context of body weight-based infusion rate for the smaller 
patient. 
• 259 ml = mean volume of Australian red cells 
Therefore, one unit per hour in a 50Kg adult at 259 ml / 50Kg = 5.2ml/Kg/hr 
• 280 ml = mean volume of UK red cells 
Therefore, one unit per hour in a 50Kg adult at 280 ml /50Kg = 5.6ml/Kg/hr 
This suggests that 5ml/Kg/hr would provide some margin and not exceed 
the ‘Australian’ maximum recommended rate of transfusion (60 minutes per 
unit) when transfusing UK manufactured red cell units. This is only relevant 
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up to a body weight of 67Kg. At this body weight, the calculated dose to not 
exceed 5ml/Kg/hr would be 685ml and the combined total of two UK red cell 
units could not exceed 680ml, which is the maximum possible for two units of 
UK red cells. Patients weighing greater than 67Kg would therefore not 
require volume-selected red cells as randomly selected red cell units would 
not exceed 5ml/Kg/hr in these patients. Conversely, patients weighing less 
than 67Kg would need to receive volume-selected red cell units to ensure the 
infusion rate did not exceed 5ml/Kg/hr. 
In summary, the definition for the ‘rate’ of transfusion was unsatisfactory and 
neglected to consider the impact of the variables of patient body weight and 
variation in red cell unit volume on the rate of infusion. Expressing the 
infusion rate as ml/Kg/hr provides standardisation and brings clarity when 
comparing recommended red cell infusion rates across international 
guidelines. When adjusting for the variation in red cell unit volume between 
the UK and Australia, 5ml/Kg/hr appears to be safe in the smaller (50Kg) 
patient according to the Australian experience of transfusing red cell units 
over a maximum of 60 minutes per unit. As UK blood units are on average 
larger than those manufactured in Australia, volume-selected units would be 
required for patients weighing less than 67Kg in order to receive a unit over 
60 minutes without exceeding an infusion rate of 5ml/Kg/hr. 
Challenging the Perception that ‘Faster’ Transfusion Contributes to 
Circulatory Overload 
In agreement with Popovsky (2009), no specific evidence was found in the 
literature to demonstrate a clear link between the speed of transfusion and 
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the development of circulatory overload. Although a relationship had later 
been suggested and investigated (Andrzejewski et al, 2012 and 2013) the 
results of this study were difficult to interpret as the data did not make 
reference to volumes transfused, referring only to the overall differential 
duration between each group in the study. There were no studies which 
compared study groups using standardisation (e.g. ml/Kg/hr) in adults. There 
have been a small number of studies in paediatric patients with severe 
chronic anaemia where infusion rates of >1.5ml/Kg/hr (Agrawal et al, 2012), 
2ml/Kg/hr (Jayabose et al, 1993), and 3ml/kg/hr (Olgun et al, 2009) were 
shown to be safe. The physiological differences between paediatric and adult 
patients may not allow generalisability between these populations, requiring 
new evidence for safe red cell infusion rates in adults. The other variable to 
consider when challenging this assertion is the nature of TACO, which is 
explored in the following sections. 
Defining and Recognising Transfusion-Associated Circulatory 
Overload (TACO)  
If TACO is suspected to be an adverse consequence of higher rates of 
transfusion, among other aetiologies, then characterising and defining it is 
important in giving credence to this proposition, but this has not been without 
challenges. TACO is one of a triad of pulmonary complications recognised 
and defined by SHOT, which also includes Transfusion-Related Acute Lung 
Injury (TRALI) and Transfusion-Associated Dyspnoea (TAD). A universally 
accepted definition for TACO does not currently exist, but has been broadly 
regarded by the blood transfusion expert community as an adverse outcome 
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of transfusion characterised by respiratory distress as a result of pulmonary 
oedema following infusion of blood components, due to excessive volume 
and/or infusion rate, and/or when pre-disposing co-morbidities are present 
(Andrzejewski et al, 2013). This can be represented diagrammatically as 
shown in figure 4.4. 
 
                                                  
 
 
 
 
Figure 4.4: Factors believed to contribute to the development of TACO 
 
The International Society of Blood Transfusion (ISBT) draft definition 
(diagnostic assessment criteria) suggests that TACO cases should include at 
least two primary criteria within 6 hours of transfusion (sometimes up to 12 
hours), and acute or worsening respiratory distress must be present. Primary 
Excessive 
volume of 
blood and/or 
non-blood 
fluids 
Excessive rate 
of transfusion 
Comorbidities 
and risk 
factors that 
pre-dispose 
fluid overload 
Pulmonary 
Oedema 
54 
 
criteria include acute or worsening pulmonary oedema with bilateral 
infiltrates, cardiomegaly on imaging and evidence of fluid overload such as 
positive fluid balance or clinical improvement with diuretics. Alternatively, one 
primary and two supporting criteria may be present. Supporting criteria may 
be raised brain natriuretic peptide (BNP) or NT-Pro BNP where the level is 
greater than 1.5 times the pre-transfusion value, an increase in mean arterial 
pressure or pulmonary wedge pressure (often with widened pulse pressure), 
or hypotension in the case of acute cardiac collapse (ISBT, 2014). SHOT 
assess reported cases for TACO based upon the presence of key clinical 
features of the condition: acute respiratory distress (in the absence of other 
specific cause), acute or worsening pulmonary oedema on imaging, 
evidence of positive fluid balance, evidence of volume intolerance (response 
to treatment for circulatory overload or evidence of pulmonary oedema on 
clinical examination). SHOT encourages the reporting of suspected cases 
even if available information does not meet all of the criteria for TACO, and in 
suspected cases that have occurred between 6 and 24 hours where there is 
respiratory distress that improves with treatment for circulatory overload (e.g. 
diuretics, nitrites and morphine) (Bolton-Maggs et al, 2016). Issues with 
defining and clinically assessing TACO were highlighted in the SHOT report 
(Bolton-Maggs et al, 2016) which drew out a number of problematic areas. 
Broadly, these included the effect of inter-(expert) assessor variability, lack of 
inclusivity of some diagnostic approaches, due to lack of routinely available 
diagnostics or those which may be more suited to a high-care environment, 
and the presence of confounding clinical factors which may influence the 
strength of diagnostic certainty. A logic-based application was developed to 
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calculate the likelihood of TACO based on the presence of weighted 
symptoms and signs across four diagnostic categories to produce an 
aggregated score (Bolton-Maggs et al, 2016). The application requires 
further development but may be a useful tool in the future to facilitate 
reproducible and standardised TACO surveillance diagnosis assessments. 
International collaboration continues to make incremental steps toward 
definitional surveillance assessment criteria. 
Pathogenesis and Differential Diagnosis of the Pulmonary 
Complications of Transfusion 
The characterisation of TACO is further frustrated by the complexities of the 
differential diagnosis of the other pulmonary complications of transfusion, 
Transfusion-Related Acute Lung Injury (TRALI) and Transfusion-Associated 
Dyspnoea (TAD), and the proposition that they may not be distinct entities. 
New theories on the patho-biology of TACO add a further layer of complexity. 
 TRALI is defined as acute dyspnoea, with hypoxia and bilateral pulmonary 
infiltrates, during or within 6 hours of transfusion, not due to circulatory 
overload or other likely causes. TAD brings together a heterogeneous group 
of cases of acute respiratory distress that do not otherwise match the TRALI 
or TACO diagnostic criteria, and therefore TAD is a diagnosis of exclusion 
(SHOT, 2014). The exact pathogenesis of TRALI is not fully understood, but 
there are thought to be immune and non-immune causes. A two-event model 
was proposed which requires an initial trigger such as infection, trauma or 
surgery, followed by a second event where anti-leucocyte antibodies 
(immune TRALI) or bio-active substances (non-immune TRALI) present in 
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the blood product are transfused to the patient. This activates neutrophils in 
the lungs which induce endothelial cell damage and capillary leakage, 
causing non-cardiogenic pulmonary oedema. More recent studies have 
demonstrated the formation of neutrophil extracellular DNA traps in response 
to activation which are injurious to the alveolar tissue of the lung (Thomas et 
al, 2012). This contrasts with the pathogenesis of TACO, in which 
cardiogenic pulmonary oedema is caused by iatrogenic fluid overload (where 
the fluid is a blood component).  
Fluid overload can be precipitated as a result of any intravenous fluid 
infusion, and is therefore not limited to blood transfusion.  Volume overload 
(hypervolaemia) has no precise definition but there have been attempts to 
quantify fluid accumulation and correlate this to clinical outcomes. The 
percentage of fluid accumulation can be expressed by dividing the 
cumulative fluid balance (litres) by the patient’s baseline body weight (Kg) 
and multiplying by 100% (Malbrain et al, 2014). Fluid overload was identified 
as greater than 10% increase in fluid accumulation and this was associated 
with worse outcomes in patients receiving critical care with acute kidney 
injury (Macedo et al, 2010). There are limited data on volume tolerance in 
humans in non-acute settings, but studies on euvolaemic volunteers (i.e. 
normal blood volume) suggest that the infusion of 2-3L of isotonic saline will 
precipitate mild symptoms and signs of fluid overload (Collins et al, 1973; 
Holte et al, 2003). However, it is difficult to relate this to red cells to predict 
tolerance to blood transfusion because red cells are not a crystalloid 
substance that can be removed by the kidney when present in excess. 
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Hypervolaemia causes pulmonary oedema due to increased haemodynamic 
pressure resulting in the over-distension of the left ventricle of the heart, 
causing increased pulmonary capillary pressure. The increased filtration of 
fluid out of the capillaries into the interstitial space results in interstitial 
oedema. Further accumulation of fluid causes cellular disruption and 
accumulation of fluid in the alveolar spaces (alveolar oedema). The clinical 
features of pulmonary oedema are dyspnoea, wheeze and crackles (heard 
by chest auscultation with a stethoscope), and cough (usually productive of 
blood-tinged frothy sputum), tachycardia, and cyanosis caused by peripheral 
circulatory shutdown, and raised venous pressure. The chest X-ray shows 
diffuse haziness due to the accumulation of alveolar fluid. Many of the clinical 
criteria of TACO relate to the symptoms and signs of pulmonary oedema. 
Hilton et al (2008) suggest that complications of fluid overload usually arise 
in the context of co-morbidities that affect the cardio-respiratory system 
and/or where there is severe inter-current illness. Consequently, patients with 
pre-existing heart failure are at greater risk of TACO when volume-
challenged. However, individuals without co-morbid conditions can also 
develop pulmonary oedema caused by large volume and/or rapid infusion. 
The volume and rate of infusion is therefore an important safety 
consideration for all patients receiving blood transfusions, and particularly 
significant for those patients with certain co-morbidities or risk factors. 
Some authors believe there may be some overlap in the pathogenesis of the 
pulmonary complications of transfusion. Andrzejewski et al (2013), put 
forward a theory that some cases of TACO may have pro-inflammatory 
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(immune-based) aspects and may share pathophysiology with non-immune 
TRALI. They proposed the concept of “barotrauma” (Andrzejewski et al, 
2013, p.3045) where damage to the vascular endothelium as a result of 
increased vascular pressure may be the first step in a process leading to pro-
inflammatory state and increased vascular permeability. 
This challenges the notion that TACO is simply an iatrogenic adverse event 
singularly relating to pulmonary oedema caused by excessive 
haemodynamic forces. Indeed, this ambiguity acknowledges the significance 
and importance of the TAD categorisation. It emphasises the current lack of 
depth of understanding of the pulmonary complications of transfusion, 
suggesting a multi-factorial basis in some cases, and the benefit of a flexible 
reporting criteria to capture cases. 
Given the considerable number of similarities of symptoms and signs 
between TACO, TRALI and TAD, plus the additional theory that the 
pathogenesis of each may overlap, there may be difficulties in establishing 
an accurate differential diagnosis. However, this is clinically important from 
the perspective of medically managing the patient, and for ensuring accurate 
reporting to SHOT and SABRE/MHRA. Failure to differentiate between 
TRALI and TACO could lead to the inappropriate use of diuretics in a TRALI 
case that would increase morbidity/mortality if the patient is already volume 
depleted. Dyspnoea is common to all pulmonary complications of 
transfusion, and may also occur in anaphylaxis and otherwise unexplained 
(uncategorised) complications of transfusion. In the absence of shock, 
TRALI, TACO and TAD are the likely diagnoses. Stridor and wheeze suggest 
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an allergic reaction however these signs have been occasionally reported in 
TACO, which, again, may support the theory for the complex pathogenesis of 
pulmonary complications. Pulmonary oedema and basal crackles are 
suggestive of TACO or TRALI, and helps exclude allergy. The differential 
diagnosis of TRALI and TACO in a patient with dyspnoea as the predominant 
symptom (where low oxygen saturation and anaphylaxis are excluded), can 
be evaluated by assessing certain clinical parameters. Some of the criteria 
relate to the changes in haemodynamics in patients with TACO due to fluid 
overload. Blood pressure, jugular venous pressure, pulmonary wedge 
pressure, pulse pressure and mean arterial pressure are often raised in 
TACO, with abnormal echo-cardiography and cardiomegaly. In contrast, 
blood pressure is often reduced in TRALI, and jugular venous 
pressure/pulmonary wedge pressure are normal, with normal echo-
cardiography and heart size. Pulmonary oedema can be present in both 
TRALI and TACO and chest imaging does not always provide clear 
differentiation. As would be intuitively expected, TACO worsens with fluid 
load and improves with diuretics whereas the opposite is true for TRALI 
(Popovsky, 2008; Popovsky, 2010; Kopko and Holland, 1999). These 
pathophysiological and diagnostic uncertainties create difficulty in confidently 
attributing either circulatory overload or an idiosyncratic/non-preventable 
cause for respiratory compromise, which could have occurred independently 
of the rate of transfusion. 
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Epidemiology of TACO 
Uncertainty regarding the definition and diagnostic criteria for TACO also 
impacts upon confidence in quantifying its incidence. A total of 96 cases of 
TACO were reported to SHOT in 2013. Ninety two cases involved red cell 
transfusions (Bolton-Maggs et al, 2014). Fifty four of these cases were 
transfusions given in the absence of haemorrhage, and TACO was reported 
in 28 cases where 2 or fewer units of red cells had been administered. 
Where data were available, the median duration of the transfusion of the red 
cell unit was 2.5 (range 1.5-5.0) hours. For all cases of TACO where data 
were available (n = 93), the onset of symptoms for 51.6% (48/93) was 
between 0-2 hours, 33.3% (31/93) between 2-6 hours, and between 6-24 
hours in 15.1% (14/93) patients. In context, the overall risk of mortality from 
TACO is 0.56, and risk of major morbidity is 0.72 per 100,000 blood 
components issued in the UK in 2016 (overall major morbidity for blood 
transfusion being 4.91 and mortality 1.05) (Bolton-Maggs et al, 2017). 
Based on SHOT data, TACO is therefore the leading cause of transfusion-
related morbidity and mortality, with some authors believing it to be under-
reported (Popovsky, 2008; Bolton-Maggs et al, 2014). This theme is recited 
in a number of papers on TACO, but there are few prospective studies that 
allow for objective quantification of this proposition. Raval et al (2013), 
suggest that passive reporting of TACO underestimates its true incidence, 
and conducted a prospective study. The retrospective analysis revealed an 
incidence of 1:5997, but when analysed prospectively, the incidence was 
much greater at 1:167 platelet units transfused. Li et al (2011) demonstrated 
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a 6% incidence rate in a prospective study of intensive care unit (ICU) 
patients receiving fresh frozen plasma (FFP), which exceeds the overall 
incidence reported by SHOT. Narick et al (2012) also conducted a 
prospective study on patients in an acute care or resuscitation setting. An 
incidence rate of 6.4 per 10,000 units of FFP transfused was observed with 
prospective analysis, and 147 per 10,000 when analysed retrospectively, 
was reported. Although these studies support the assertion that TACO is 
under-reported, these studies were limited to specific patient populations and 
types of blood component, where concomitant fluids were administered that 
may have contributed to positive fluid balance. For this reason, the findings 
are not generalizable and may not be representative of patients receiving 
elective transfusions of red cells in non-acute settings. There are no specific 
data on the incidence of TACO in patients receiving red cell transfusion in 
home or day-care settings. 
Co-Morbidities and Risk Factors for TACO 
Patients with comorbidities and risk factors pre-disposing fluid overload have 
increased risk of TACO independent of the rate of transfusion. In particular, 
patients with heart failure are predisposed to pulmonary oedema even before 
a fluid-challenge is administered. Cardiac failure occurs when the heart is 
unable to maintain sufficient cardiac output to meet the demands of the body. 
A number of physiological haemodynamic and neurohormonal mechanisms 
adapt and compensate, such as vasoconstriction to increase the venous 
pressure. This leads to sodium and water retention causing raised pulmonary 
capillary pressure, leading to the leakage of fluid into the alveolar spaces, 
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resulting in pulmonary oedema. The pathophysiology of fluid overload in 
heart failure is not fully understood but it is acknowledged that it may be 
more than a mechanical disorder: Cotter et al (2008) proposed that fluid 
overload in heart failure is caused by the redistribution rather than uniform 
accumulation of fluid. The cause of this is thought to be linked to vascular 
constriction in the lung, neurohormonal and inflammatory activation, renal 
dysfunction and possibly the unwanted effect of some medications. The 
overall effect of this is the accumulation of redistributed fluid in the body and 
importantly in the lungs resulting in the development of cardiogenic 
pulmonary oedema. The pathological processes in existing cardiac failure 
are exacerbated by further fluid loading from IV fluid administration.  
Patients with renal failure are also predisposed to fluid overload. Renal 
failure is associated with a decreased glomerular filtration rate (GFR) which 
reduces the capacity of the kidney to excrete sodium. Sodium accumulation 
causes water retention which leads to expansion of the extracellular volume 
and oedema. This significantly reduces the patient’s capacity to tolerate 
further fluid loading if administered intravenously, and would considerably 
increase the risk of pulmonary oedema developing. 
Patients develop hypoalbuminaemia for a number of reasons, broadly 
relating to synthesis or loss of albumin. Conditions associated with 
hypoalbuminaemia include renal disease with albuminuria, burns, 
haemorrhage, gastrointestinal losses, liver disease, malnutrition, sepsis, 
heart failure, inflammatory diseases and haemodilution caused by the 
administration of intravenous fluids. Albumin has a key role in maintaining 
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plasma oncotic pressure, and when this is deceases in hypoalbuminaemia, 
water is lost from the vascular space to the interstitial space. The circulatory 
volume is then reduced with a fall in cardiac output. The compensatory 
physiological mechanisms are similar to those seen in heart failure. The 
extracellular volume then expands and venous pressure increases causing 
the development of oedema. The increased extracellular volume then 
predisposes the patient to fluid overload (Kumar and Clark, 1999). 
Low body weight has also been associated with the risk of TACO (Bolton-
Maggs et al, 2014) which is to be expected as smaller individuals have a 
lower blood volume and therefore require a relatively lower volume of IV fluid 
to achieve the required level of treatment. Even without co-morbidities, 
patients with low body weight can only be expected to tolerate excess 
volume up to a point, beyond which pathological consequences (pulmonary 
oedema) would ensue. 
The presence of one or more co-morbidities that are considered to increase 
the risk of TACO were reported to SHOT in 58.3% (56/96) of cases, and not 
reported in 16 cases (Bolton-Maggs et al, 2014) . Where body weight data 
were collected, 5/25 cases had a body weight of 50Kg or less. There is also 
an association with age and the development of TACO with 63.5% (61/96) 
being 70 years or over (Bolton-Maggs et al, 2014). This may be related to the 
prevalence of co-morbidities in this group rather than it being an independent 
risk factor. Unfortunately, fluid balance data were only reported in 28.1% 
(27/96) of cases, which makes it difficult to determine the proportion of 
patients who developed TACO from the infusion of blood components alone, 
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or understand the scale to which blood components (or other fluids) may 
have contributed to the development of pulmonary oedema. This is a 
possible source of ambiguity and without more detailed data it is not possible 
to define the reported incidence of TACO, in terms of blood components 
being independently responsible for pulmonary complications caused by 
pulmonary oedema resulting from fluid overload.   
Cumulative SHOT data have provided an important insight into risk factors 
for TACO, which include cardiac failure, renal impairment, 
hypoalbuminaemia, pre-existing fluid overload, aged more than 70 years and 
low body weight (Bolton-Maggs et al, 2014). Thematic analysis of the 
‘definite and highly likely’ TACO cases reported to SHOT in 2015 revealed 
that infusion of concomitant fluid during or in the 24 hours prior to 
transfusion, followed by pre-existing fluid overload and pre-existing cardiac 
dysfunction were the most significant themes in patients who developed 
TACO. Other significant but less frequent, themes relating to fluid intolerance 
were pre-existing pulmonary oedema, low body weight and pre-existing 
peripheral oedema (Bolton-Maggs et al, 2016). All but the fluid management 
issues are relevant to patients receiving blood transfusions in the non-acute 
setting (as concomitant fluids are not administered to these patients). The 
themes emerging from haemovigilance data have provided a useful basis for 
developing a risk-assessment for patients at risk of TACO (Grey, 2015; 
Bolton-Maggs et al, 2016). This provides a useful tool to exclude patients 
from accelerated transfusion where the impact of the rate of transfusion on 
the development of TACO is uncertain. The prevalence of risk factors for 
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circulatory overload in this population would affect the number of patients 
eligible for accelerated transfusion, and therefore would need to be 
evaluated as part of the study. 
 
Summary 
The study does not seek to demonstrate whether ‘faster’ rates of infusion 
contribute to the development of TACO. Having established the lack of 
evidence for safe rates of transfusion it is prudent to exclude patients who 
have recognised risks for TACO, where uncertainty remains about whether 
‘faster’ transfusion contributes or not. The debate in this chapter also raises 
the question of how ‘faster rates of transfusion’ are meaningfully defined. It is 
not possible to state what constitutes ‘faster transfusion’ and evaluate 
outcomes, without first establishing a standardised method and rate of 
transfusion that is shown to be as safe as current custom and practice. The 
rate of 5ml/Kg/hr is only ‘accelerated’ relative to current practice. This rate of 
transfusion could in future be regarded as a ‘standard’ rate of transfusion. It 
is not possible to determine whether this rate of transfusion is safe in patients 
with risk factors for TACO without an experimentally designed study. 
Revisiting Andrzejewski et al (2013) broad definition of TACO in the context 
of this study, figure 4.5 illustrates the uncertainties and mitigations. 
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Figure 4.5: Factors believed to contribute to TACO in the context of 
‘accelerated transfusion’ 
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Conceptual Framework: Development of the Research Question and 
Hypotheses 
The contextual framework described in chapter three (and illustrated in figure 
3.1) proposed the concept of accelerated transfusion. The conceptual 
framework (figure 4.1) is the output of the synthesis of the literature which 
supports this proposition and from which the following research question and 
the hypotheses were generated. The original benefits of the CIVT service are 
patient-focussed care provided at home for those who require it, while 
protecting inpatient care where it is medically appropriate. These 
cornerstones remain embedded within the conceptual framework ensuring 
the research output continues to deliver the intended service philosophy and 
objectives, with the anticipated benefit of service improvement based on new 
evidence for practice. The research question can be framed as: 
General Research Question 
Whether transfusing two units of red cells over 60 minutes per unit 
(accelerated transfusion) is safe and could potentially increase CIVT service 
capacity, while gaining understanding of the patient’s and practitioner’s 
experience. 
The question can therefore be viewed through the two lenses of 
physiological tolerability and experiential and organisational 
acceptability/benefit. This forms the foundation of the multi-methods 
approach which is discussed further in the Methods chapter. 
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Hypotheses 
Based upon the background and impetus for the research supported by 
existing evidence, a number of hypotheses can be developed for the 
quantitative aspects of the research question: 
H1: Two units of red cells transfused over 60 minutes each can be 
physiologically tolerated in selected patients (H0 there is no difference in the 
incidence of Transfusion Associated Circulatory Overload (TACO) between 
standard and accelerated rate transfusions). 
H1: Implementation of accelerated transfusion could potentially increase 
CIVT service capacity (H0 Implementation of accelerated transfusion would 
not potentially increase CIVT service capacity). 
The qualitative strand of the study is value-adding and seeks to inductively 
gain understanding of patient and practitioner experience without a priori 
theories and therefore hypotheses are not appropriate. 
 
Contextual Tenets of the Conceptual Framework: Influence on 
Research Design and Methodological Approach 
The conceptual framework model conflates the cornerstones of the existing 
home transfusion service with the contextual tenets of external (national) 
policy drivers, patient-centred factors, organisational objectives, and the 
philosophy of continuous service improvement that rely on the generation of 
new evidence for practice. The approach and choice of methodology and 
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underpinning philosophy of each strand of enquiry is also imbued within the 
framework. 
The contextual tenets of the conceptual framework (colour-coded below) 
inform the methodological approach by establishing three strands of enquiry 
which require different methodological approaches. Each respective segment 
can be broadly regarded as: practitioner/service-facing; patient-facing; 
finance/resource-facing; and organisation-facing (figure 4.5). 
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Figure 4.5: Contextual tenets of the conceptual framework informing 
methodological approach 
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Having defined the research question, developed hypotheses from the 
conceptual framework, it is evident that both quantitative (physiological 
tolerability/safety, service capacity), and qualitative (patient and practitioner 
experience) elements are embedded within it, and from which the two 
methodological approaches eventuate. This provides the structure and 
design of the research and informs the choice of method for each strand of 
enquiry.  
The research design can be identified as a multi-methods design as each 
‘strand’ can be regarded as an independent enquiry.  The quantitative and 
qualitative phases can potentially be reported separately and do not 
necessarily relate to each other, or confirm the findings of the other (as 
would be required to satisfy the definition of a mixed methods approach). 
Morse (2003) proposed three principles for characterising multi-methods 
research. The first principle defines the theoretical drive (inductive or 
deductive), the second principle defines the dominance of each method, and 
the third principle defines the design type (simultaneous or sequential, 
depending on the temporality of how the methods are conducted). According 
to Morse’s nomenclature, the design of this study can be characterised as a 
sequential QUANTITATIVE → qualitative study, which indicates a 
quantitative driven project that is followed by a second qualitative project. 
The theoretical drive for this research study is predominantly deductive and 
is experimentally designed to establish the physiological tolerability and 
resource economics of accelerated transfusion using quantitative 
methodology. This is followed by a further, self-contained inductive study 
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designed to provide understanding of patient and practitioner experience 
using qualitative methods. 
Figure 4.6 introduces and summarises the study design and the 
underpinning philosophy which is described in detail in the following methods 
chapters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Research Design and Underpinning Philosophy 
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Precis of Thesis Development 
 Red cell transfusions are infused over a maximum of 90 minutes per 
unit in current practice. The total treatment time for a two unit red cell 
transfusion was around four hours. The proposal was to reduce this to 
60 minutes per unit (accelerated transfusion), in order to reduce the 
overall treatment time for a two unit red cell transfusion by one hour. 
In theory this would release time and increase the capacity of the 
service while reducing the burden of long treatment times for the 
patient. 
 The evidence for current practice is based upon expert opinion and 
experience as opposed to experimentally designed studies. 
Unpacking the notion of ‘duration’ of transfusion raises questions 
about how this is satisfactorily and meaningfully described. 
 The combined variables of patient body weight and red cell unit 
volume are not taken into account in current practice where it is usual 
to prescribe a ‘unit’ over a period of time in adult patients. This results 
in variations in the determination of the actual infusion rate and may 
disregard the influence of the individual patient’s size. 
 The rate of transfusion is not adequately defined in current practice 
but could be standardised by expressing as ml/Kg/hr 
 Derivation of Australia and New Zealand transfusion guidelines 
support the proposition that 5ml/Kg/hr may be safe which would allow 
a unit of standard UK red cells to be transfused over 60 minutes per 
unit. Volume-selected red cells would be required when the patient’s 
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body weight is less than 67Kg to avoid an infusion rate exceeding the 
proposed value. 
 Excessive rate of transfusion is believed to be a cause of Transfusion-
Associated Circulatory Overload (TACO) but there is no specific 
evidence for this, in part due to lack of standardisation of the rate of 
transfusion and how this has been represented in published studies. 
 TACO has aetiologies beyond the rate and volume of transfusion 
which complicates the contribution of rate of transfusion to the 
development of TACO, and poses difficulties in its differential 
diagnosis and epidemiology 
 Comorbidities associated with volume intolerance are shown to 
predispose the development of TACO and may be more important 
than the rate of transfusion. 
 The research question and hypotheses were generated from the 
conceptual framework 
 The contextual tenets of the conceptual framework (patient, 
practitioner, finance and organisation) inform the methodological 
approach forming three strands of enquiry requiring both quantitative 
and qualitative methods described in the following chapters 
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Chapter Five:  
Research Ethics, Clinical Governance and  
Risk Management 
 
This chapter examines the ethical, clinical governance and risk management 
issues common to all aspects of the study methodology, and forms a 
foundation for the following methods chapters. 
 
Ethical approval  
Ethical approval for this research was obtained from the National Research 
Ethics Service (NRES): (REC application reference 14/NW/0229), 
Manchester Metropolitan University (MMU) research ethics committee and 
the author’s NHS Foundation Trust’s Research and Development 
department. The recruitment did not commence until full approval was 
obtained from all parties. 
 
Specific Ethical Considerations 
Table 5.1 describes key ethical issues that were identified in the 
development of the project proposal and explains how they were addressed. 
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Table 5.1: Addressing identified ethical issues 
Issue 
Identified 
Action 
Avoiding 
coercion to 
participate 
The patient and practitioner received a letter of invitation, information 
and a response-form which they could read privately and ask for 
further information if required. The letter explained their right to refuse 
without consequence or compromising their treatment. The documents 
were developed in accordance with the “information sheets and 
consent forms: guidance for researchers and reviewers, NPSA 
Research Ethics Service (2009). 
Respecting 
autonomy and 
choice 
As above. Additionally, the participant was required to consent before 
each procedure (or interview) with the option to decline at any stage 
without consequence or compromising their treatment. The document 
was developed in accordance with the “information sheets and 
consent forms: guidance for researchers and reviewers, NPSA 
Research Ethics Service (2009). 
Ensuring 
participants are 
not 
inconvenienced 
No patient was expected to attend a clinic or receive treatment at a 
time (or frequency) than they otherwise would have done. Patient and 
practitioner interviews were conducted at a time and place convenient 
to the participant. 
 
Patient safety The research hypothesis was based upon existing evidence that 
suggests the proposed intervention is safe for patients who meet the 
inclusion criteria. The inclusion/exclusion criteria were approved by a 
consultant cardiologist and consultant haematologist. A pre-
transfusion clinical assessment was performed before every 
transfusion. The transfusions were monitored by a trained and 
experienced nurse at all times. The patient was provided with post-
transfusion contact/care information and also received a visit from a 
trained healthcare practitioner (24 hours after the transfusion) to 
perform a post transfusion clinical assessment. In the event of adverse 
event, a medical officer was to be contacted and there was facility to 
transfer the patient to hospital. 
Practitioner 
Safety 
Existing domiciliary and lone-worker organisational policies applied to 
patient home visits as part of the study. 
Potential for 
compromising 
practitioner 
professional 
scope of 
practice 
The research protocol inevitably had some aspects of transfusion 
practice that did not match current organisational transfusion policy. 
All practitioners involved in any aspect of the research study were 
trained to the protocol and this was registered on a training log, 
ensuring professional standards are respected and appropriate 
governance applied. 
Data protection All participant-identifiable hard copy data generated in the study was 
kept in a locked filing cabinet in an office that was locked when not in 
use. All participant-identifiable electronic data was kept on a password 
protected NHS personal computer. The data was not stored on the 
hard drive (it was stored on a remote server). Any electronic data that 
was required to be put on a USB drive was only put on an encrypted 
device. 
Confidentiality Participant data was kept confidential by using a code that could only 
identify the individual from a single master linkage document that was 
kept secure. 
Anonymity No person-identifiable data will appear in print however participants 
were made aware that quotations from their interviews may appear in 
print. This was made clear in participant information and consent 
document for the interview. 
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Choice of 
participant 
It is not feasible to answer the research question without home 
transfusion and CIVT practitioners as participants (no other patient or 
practitioner group could be used as an alternative). Haematology 
patients attending the oncology unit for day case transfusion were also 
invited to participate in order to ensure sufficient participant for the 
physiological enquiry strand of the research (these patient would 
normally be eligible for a home transfusion except that their postcode 
is beyond the scope of the CIVT service geographical reach). These 
patients were otherwise physiologically similar to the home transfusion 
patients however they were not be invited for interview (as they had 
not experienced transfusion at home). There were fewer potential 
practitioner participants as they are a small clinical team. Established 
team members were favoured for their greater experience of both 
types of transfusion. 
Numbers of 
participants 
required 
The sample size and power calculation suggested 39 patients were 
required for the physiological tolerability part of the study (albeit with 
some limitations). This was not to be exceeded if this number was 
reached before the expected end of the study. The number of 
participants for the patient and practitioner part of the study could not 
be pre-defined and was dependent upon participant willingness to be 
interviewed. This was nominally set at 10 participants per group for 
ethics application purposes. 
 
Permissions and Liability 
All required permissions were obtained as detailed above prior to the start of 
the study and recruitment of participants. Legal liability of the sponsor (the 
author’s NHS Foundation Trust) for the management, design and conduct of 
the research was covered by the NHS indemnity scheme, and this was 
approved under the auspices of the research ethics and research and 
development approval process. 
Serious Adverse Events (SAE) and Serious Adverse Reactions (SAR) 
In the event of a SAE or SAR, procedures were in place to investigate and 
report these appropriately to satisfy both organisational governance and 
statutory reporting obligations. No additional procedures were required for 
the purposes of the research study beyond those already in place for blood 
transfusion SAE and SAR reporting to SHOT and SABRE/MHRA (Serious 
Adverse Blood Reactions and Events/Medicines and Healthcare products 
78 
 
Regulatory Authority). However, an additional form was generated to record 
SAEs and SARs specifically in research participants in order to maintain a 
separate record where required (appendix A). 
Risk Management 
A risk assessment (table 5.2 below) using a ‘5 x 5’ model (NPSA, 2008) was 
performed on the research protocol. All risks identified were classified as 3 
(low risk/green) except for the risk of development of TACO which scored as 
4 (moderate risk/yellow). This was based on low likelihood (score 1) but high 
severity (score 4). However, this was judged as having adequate controls 
and precautions in place in terms of exclusion criteria, patient monitoring, 
patient support and follow-up. The protocol was medically reviewed and 
approved by three consultant haematologists and a cardiologist.  
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Table 5.2: Accelerated Transfusion Protocol Risk Assessment 
 
Hazard Identified 
 
Persons at Risk 
 
How they might be 
harmed 
 
Existing Controls/Precautions 
 
Likelihood 
 
Severity 
 
Risk 
Rating 
Decision to participate 
later felt to be wrong 
decision 
Patient 
Practitioner 
Feeling of regret or coercion, 
stress 
Letter of invitation can be read and responded 
to without pressure or specific time limit. 
Consent has to be given prior to transfusion or 
interview with an option to decline without 
consequences. 
3 1 3 
 
Development of TACO 
 
 
Patient 
 
TACO (pulmonary complication of 
fluid overload) 
 
Medical exclusion criteria approved by 
consultant medical staff. 
Pre and post transfusion clinical assessment 
Patient has contact details and information if 
unwell and require help 
1 4 4 
Not all healthcare 
providers aware of 
patient’s participation in 
study 
Patient 
 
Patient may not be appropriately 
clinically managed if attending 
hospital for treatment or if 
develops a complication of 
transfusion 
Patient’s GP will receive a letter informing 
them of their patient’s wish to participate and a 
copy will be placed in the patient’s medical 
notes. 
1 3 3 
Not all healthcare 
practitioners in the team 
aware of study related 
procedures 
Patient 
 
Practitioner 
Patient may not be appropriately 
clinically managed 
May affect the member of staff’s 
professional registration if 
performing variations on 
procedures with no formal training 
All staff involved in the study will be trained in 
the aspects they are involved in (see training 
log and contents page of protocol) 
1 3 3 
Data protection and 
confidentiality 
Patient 
Practitioner 
Organisation 
Breach of confidentiality Forms will be identified using a participant 
number and the linkage document will be held 
securely. Completed forms will be stored 
securely. Electronic files will be on a password 
protected Trust PC with no hard drive (data on 
a server). USB sticks are encrypted. 
1 3 3 
Personal safety when 
visiting a patient’s home 
Chief Investigator 
BCIVT practitioners 
Assault, other breaches of 
personal safety and security 
The CI will leave details of home visits and 
expected return times with a colleague. They 
will have a mobile phone at all times. 
1 3 3 
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Research Protocol Training and Responsibilities 
The Chief Investigator and research team were trained in Good Clinical 
Practice by the NHS Institute for Health Research on ethical and scientific 
quality standards in clinical research, a mandatory requirement for 
researchers who take consent and/or are responsible for managing and 
reporting SAEs or SARs. This is in accordance with the Research 
Governance Framework for Health and Social Care (DH, 2005). All were 
committed to two-yearly retraining whilst engaged in research. 
All personnel (chief investigator, the clinical haematology team, CIVT staff 
and transfusion laboratory scientific staff) were trained to the relevant parts 
of the research protocol according to their role in the study and tasks they 
were expected to perform, and this was updated with protocol version 
changes. A delegation of duties log was maintained that described the tasks 
each individual undertook in the study. Both training and delegation of duties 
log were updated for staff leaving or joining the organisation during the study 
period. These records were stored securely in the research site file by the 
Chief Investigator. 
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Chapter Six: 
Strand 1 Methods 
Physiological/Safety Enquiry 
 
This chapter discusses the methods used for the physiological/safety strand 
of the study which is designed to address whether accelerated transfusion 
(60 minutes per unit, not exceeding 5ml/Kg/Hr) is associated with a higher 
incidence of transfusion-associated circulatory overload (TACO) than 
standard rate transfusion (90 minutes per unit). 
General Research Question 
Whether transfusing two units of red cells over 60 minutes per unit 
(accelerated transfusion) is safe and could improve CIVT service capacity, 
while gaining understanding of the patient’s and practitioner’s experience. 
Hypothesis 
H1: Two units of red cells transfused over 60 minutes each can be 
physiologically tolerated in selected patients (H0 there is no difference in the 
incidence of Transfusion Associated Circulatory Overload (TACO) between 
standard and accelerated rate transfusions). 
Method Aim 
The selected method aims to demonstrate the accelerated transfusion 
procedure is no worse (in terms of patients developing signs of TACO) than 
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the current standard rate transfusion procedure. The end point was whether 
or not the patient developed TACO within 24 hours of the transfusion. This 
was evaluated using a simple post-transfusion observational assessment of 
the patient’s vital signs. Further analysis of the vital sign observations aimed 
to demonstrate any statistically significant differences between standard rate 
and accelerated rate transfusion, in the absence of clinically overt TACO. 
This was to demonstrate measurable differences physiological response 
between standard and accelerated rate transfusion. 
Method Design: Rationale and Philosophical Foundations 
An analytical experimental design was considered the most appropriate 
approach to testing the hypotheses and research question regarding 
physiological tolerability of accelerated transfusion. A quantitative 
methodology is appropriate for the objective evaluation of the observed, 
measurable phenomenon of TACO, and this underpins the philosophical 
basis of this approach. The positivist/post-positivist paradigm accords with 
the general tradition and empirical nature of biomedical research as it is 
based upon objective and measurable phenomena, and concurs with the 
approach taken to identify and measure TACO in this study. From an 
ontological perspective, the realist  believes that a physiological “reality” 
exists that is driven by natural laws, but this is tempered by the critical 
realist’s position that one cannot possibly fully understand or capture its 
behaviour when fundamentally reality can only be incompletely understood 
(Guba, 1990). This ontological standpoint acknowledges that the current 
understanding of TACO and patients at risk is therefore incomplete. 
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Epistemologically, the modified objectivist’s approach taken to identifying and 
measuring it can only aspire to an approximation based upon previous 
research that attempts to define the clinical criteria for TACO, and therefore 
patients who are at risk of developing it. The methodological approach to this 
study is philosophically defensible, but acknowledges the limitations of 
knowledge derived from previous research and observations, and of 
knowledge per se. 
The design is a prospective cohort crossover study, where the patient acts 
as their own control. All patients who receive regular two unit red cell 
transfusions either at home or as a day case on the oncology unit were 
considered for inclusion. Patients with risk factors for fluid overload were 
excluded from participating based upon medically assessed exclusion criteria 
(appendix B). Consenting patients meeting the medical inclusion criteria 
initially received a standard rate (90 minute per unit) transfusion for their next 
scheduled transfusion. If this was physiologically tolerated (no signs of 
TACO), they then proceeded to an accelerated (60 minute per unit) 
transfusion when they would next normally receive a transfusion, typically 
two to six weeks later for most patients. Accelerated transfusion was 
subsequently offered for future transfusions if there had been no signs of 
TACO and the patient remained medically eligible. This was intended to 
strengthen the data regarding tolerability of accelerated transfusion, and 
allow for patient choice.  
The rationale for the choice of study design primarily relates to logistic 
reasons and the physiological nature of the intervention under investigation. 
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A randomised controlled trial (RCT) would require two groups of patients 
randomised to either a standard rate or accelerated rate transfusion arm. 
This would have the advantage of reducing random error relating to 
physiological variation of individual patients, but would require a relatively 
large number of participants. As there are a relatively limited number of 
patients eligible for this study in the time available, the cohort crossover 
study has the advantage of requiring fewer participants as the patient will act 
as their own control. However, it is acknowledged that what is gained in 
convenience may be off-set by the potential for bias to be introduced by 
studying a smaller group which may not be as representative of the 
physiological variation in this patient population. Additionally, a two-arm 
design is usually chosen when the intervention has a potentially permanent 
effect or requires a significant ‘wash out’ period. One of the main criticisms of 
this type of study when reviewed by Mills et al (2009) was the distorting 
effect of carry-over which may affect the outcomes subsequent treatments or 
interventions. This is not the case with a red cell transfusion, as opposed to 
drugs, as there are no permanent physiological effects that could bias a 
subsequent transfusion intervention. A cohort crossover design is therefore 
scientifically and clinically justifiable and reduces the sample size required. 
Sample Size, Power Calculation and Sampling Strategy 
The aim of the study is effectively to accept the null hypothesis (Blackwelder, 
1982): demonstrating the accelerated transfusion procedure is no worse, in 
terms of patients developing signs of TACO, than the current standard rate 
transfusion procedure. The study can therefore be defined as a binary 
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outcome non-inferiority study. There are two possible outcomes (TACO, or 
no TACO) which are intended to demonstrate that accelerated transfusion is 
no worse than standard rate transfusions in terms of patients developing 
signs of TACO. 
The sample size and power calculation was determined using a calculator for 
this type of study provided by Sealed Envelope TM, who offer randomisation 
services and online databases for clinical trials. Figure 6.1 (page 88) 
summarises the data used to derive the sample size and power. 
Evidence and Justification for the Sample Size and Power Calculation 
Calculation of the sample size required for the study requires knowledge of 
the incidence of TACO. The incidence of TACO in the literature focuses on 
particular patient groups such as ICU patients (Li et al, 2011; Rana et al, 
2006), orthopaedic patients (Popovsky et al, 1996), or elderly inpatients in 
the United states (Menis et al, 2012) and the blood components are not 
limited to red cells (Narick et al, 2012). Other studies report wide variation in 
the incidence of TACO (Murphy et al, 2010; Piccin et al, 2009; Popovsky, 
2006). Therefore this creates a generalisability issue when using data to 
justify the power/sample size calculation. 
The data used in this section were the most contemporaneous data on the 
reported incidence of TACO, blood issues, and wastage at the time of 
performing this calculation for the research ethics application. The SHOT 
2012 report, relating to 2011 data, states there were 23 cases of Transfusion 
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Associated Circulatory Overload (TACO) nationally, where up to two units of 
red cells were implicated (Bolton-Maggs et al, 2013, p. 163).  
To understand the (SHOT reported) incidence of TACO, denominator data 
regarding number of units transfused was required from approximately the 
same period of time. The number of units transfused nationally can be 
estimated using the Blood Stocks Management Scheme (BSMS) 2011/12 
annual report (MacRate (Ed.) and Taylor, 2012). Although less than 100% of 
hospitals fully participate with providing data, the majority do participate and 
will provide a realistic estimate of red cell wastage (which will allow a 
calculation of units actually transfused). This is shown in table 6.1 below. 
Table 6.1: Blood wastage in the UK and Ireland (2011/12) 
Blood Service Number of red 
cell units 
issued 
Wastage % Estimate of 
units 
transfused 
NHS Blood and 
Transplant 
1,835,000 2.1% 1,796,465 
Northern Ireland 
Blood Transfusion 
Service 
53,713 4.8% 51,135 
Welsh Blood Service 85,620 2.6% 83,394 
Scottish National 
Blood Transfusion 
Service 
188,361 0.86% (based upon 6 
participant with 270 units of 
wastage each on average) 
186,741 
Irish Blood 
Transfusion Service 
138,080 Not reported 138,080 
TOTAL units transfused 2011/12 (estimated) 2,255,825 
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The incidence of TACO can therefore be estimated as: 
23a                  
--------------   = 0.0010195% (incidence of reported TACO)  
2,255,815b  
a cases of TACO reported to SHOT in 2011 involving 2 or fewer red cell units 
b estimated red cell units transfused in UK and Ireland 
Or inversely expressed as: 
 ‘Successful’ transfusions (no TACO reported) = 99.9989805% 
 The number of home (2 unit) transfusions in 2 years prescribed by 
haematology consultants is (01.08.11 to 31.08.13) = 569 (n) 
 Number of TACO reports locally in that period = 0 
 Local incidence of TACO in home transfusion or day-case patients in 
2 years = 0% 
 1/n x 100% = non-inferiority limit (d) = 0.18% 
i.e. the estimated period of the data collection phase of the study will be 2 
years. One patient developing TACO in that period (increased from zero) 
would be clinically unacceptable. 
A sample size and power calculator provided by Sealed Envelope TM 
(www.sealedenvelope.com/power/binary-noninferior) specifically designed 
for binary outcome non-inferiority studies was used (Sealed Envelope Ltd, 
2012). 
The results of the sample size calculation (after the significance level, power, 
and percentage ‘success’ in the control and experimental group data had 
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been inputted based upon the calculations above). The calculation shows the 
sample size required for 80% power (39 patients). This was considered more 
likely to be achievable than powering to 90% (figure 6.1 below and appendix 
C). 
The results of the ‘sample size required’ calculation (after the significance 
level, power, and percentage ‘success’ in the control and experimental group 
data had been inputted based upon the calculations above). The above 
calculation shows the sample size required for 90% power (54 patients). This 
was considered less likely to be achievable than powering to 80% (appendix 
C). 
These show some agreement with sample sizes calculated from more recent 
morbidity and mortality data published by SHOT (Bolton-Maggs et al, 2016), 
where the combined mortality and morbidity risk of TACO was stated to be 
1.47 per 100,000 blood components issued. This provides a % ‘success’ rate 
of 99.99853% and computes a sample size of 57 if powering to 80% or 78 if 
powering to 90%. However, the comparisons are not identical as the SHOT 
denominator data is based on all blood components issued, whereas the 
calculation for the study is based on an estimate of the total number of blood 
units actually transfused, and is limited to red cells only. 
Local data from the participating Trust from 2006/07 to 2015/16 showed an 
incidence of TACO as 1 per 33,831 red cell units transfused (2 cases in 
67,661 red cell units transfused). This provides a % ‘success’ rate of 
99.9970441% and computes a sample size of 113 if powering to 80%. This is 
based on significantly fewer data than national figures and is easily skewed 
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as TACO is a relatively rare event, and in addition to this both cases were 
patients in acute care settings which do not represent the patient group being 
researched.  
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Determination and Justification of Sample Size and Power 
 
There were a number of important limitations with the data used for the 
sample size and power calculation, and these are discussed in the 
concluding chapter.  Despite the difficulties and limitations in determining 
sample size, it was important to address this as far as was practical with the 
Significance level (alpha): 5% 
Power level (1-beta): 80% 
% ‘success’ in control group:  
99.9989805% 
% ‘success’ in experimental group:  
99.9989805%  
 
Non-inferiority limit (d): 0.18% 
Sample size required per group: 39    (total number of patients in study) 
Each patient receiving one standard rate transfusion  
and a minimum of one accelerated rate transfusion 
Accepted level for biomedical investigations 
Lowest accepted level for biomedical 
investigations to yield accessible number of 
patients for the study 
Inverse of % of patients receiving two unit red 
cell transfusions reported to SHOT who 
developed TACO 
Identical % to control group as there is no 
evidence to suggest one is superior to the 
other 
It would be clinically unacceptable for 1 more 
patient to develop TACO (locally) than the 
current incidence of 0% based upon 2 year’s 
historic data 
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benefit of all available data and evidence, as this is was a requirement when 
applying for ethical approval. 
Sampling Strategy 
Consecutive non-probability sampling was judged as the most appropriate 
sampling strategy. The sampling was consecutive in that all consenting 
patients who fulfilled the medical inclusion criteria were included when they 
were referred to the Clinical Haematology Team for blood transfusion. This 
approach ensured the sample size and power were not compromised by 
excluding eligible patients from an already relatively small group of available 
patients. The sampling was not random and therefore the data are not 
generalizable to the general population, however the evidence generated 
from the study could potentially be applicable to the same population of 
patients, regardless of the location of transfusion, for example patients who 
have transfusion at home and/or as a hospital day-case. 
Method Protocol and Rationale 
The following sections describe the protocol and rationale for the 
physiological/safety enquiry methods and are designed to generate evidence 
for the safety of transfusing two units of red cells over 60 minutes each. 
Patient Selection 
Patients were identified from the Clinical Haematology ‘regularly transfused’ 
patient list, or identified by medical staff when they attended haematology 
clinic appointments.  
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Patients were invited to participate either at a usual clinic visit, or were 
contacted by telephone by Haematology medical/nursing staff if a clinic 
appointment was not scheduled for the near future. Patients meeting the 
basic inclusion criteria received a letter of invitation to participate in a) 
accelerated transfusion, and b) interview about their experience of 
accelerated transfusion (appendix D). The letter was accompanied by an 
information sheet (appendix E). Each patient was offered the opportunity to 
discuss the study further with a healthcare professional involved in the study 
if they wished. The patient was given instructions to contact the Clinical 
Haematology office to indicate that they wished to be included in the study. 
The patient was informed that arrangements would be made to take consent 
from them which would involve signing a form. Where and who took consent 
depended upon the patient’s usual delivery of care in order to minimise 
inconvenience to the patient. All healthcare professionals taking consent had 
Good Clinical Practice training. Consent could be taken by Haematology 
medical or nursing staff at a subsequent clinic appointment. If the patient did 
not have a scheduled clinic appointment, the Chief Investigator made 
arrangements to take consent at the patient’s home at a mutually convenient 
time. In either case, the patient was allowed a period of time to decide that 
was not less than 24 hours (appendix F). The completed consent forms were 
retained securely by the Chief Investigator and a copy was placed in the 
patient’s medical notes. 
The patients had a range of haematological diagnoses causing anaemia 
requiring transfusion such as bone marrow failure syndromes and/or on 
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myelosuppressive therapies. The patients received their transfusions at 
home or on the Oncology Day Care Unit. Some patients received 
transfusions in both locations or entirely in one or the other dependent upon 
their needs and whether their address was within the geographical reach of 
the CIVT service. All patients were included to maximise participant numbers 
for the physiological enquiry strand of the study as there was no reason to 
assume they were not physiologically identical. However, only home 
transfusion patients were invited for interview about their experience of 
accelerated transfusion. Patients who fulfilled the following basic inclusion 
criteria (in the professional opinion of Haematology medical staff) were 
considered for inclusion and invited to participate. The inclusion criteria are 
summarised in table 6.2. 
Table 6.2: Inclusion criteria 
 
Patients who elected to participate in the study were formally assessed by a 
medical officer from the Clinical Haematology Team against the exclusion 
criteria below in table 6.3. These criteria were designed to identify patients 
who may be at risk of fluid overload, based upon the SHOT (2012) report 
(Bolton-Maggs et al, 2013) recommendation, (BCSH guideline (2009) and 
Inclusion Criteria 
Expected to receive two or more transfusions over the course of their treatment 
Receive transfusions at home or on the Oncology Day Care Unit.  
Have no known co-morbidities that would pre-dispose the patient to fluid overload  
Judged to have full mental capacity to ensure they could give valid consent 
Could read and speak English 
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addendum (2012)). Patients with heart failure were excluded. This was 
verified by checking whether an echocardiogram has been performed 
previously with the Cardiology Department before accepting a patient into the 
study. All patients with chronic heart failure should have had 
echocardiography previously performed according to NICE guidelines (NICE, 
2010). 
The exclusion criteria (table 6.3) also ensured that baseline vital sign 
measurements did not exceed the criteria for assessing the presence of 
TACO on the 24 hour post-transfusion assessment. Stage 1 hypertension is 
defined as greater than 140/90mmHg, however 40% of adults in England 
have a blood pressure measuring greater than this and not all would 
necessarily require treatment (NICE, 2011). For this reason, modified stage 2 
hypertension criteria (with a slightly lower diastolic threshold) were chosen to 
define significant hypertension for the study. They were approved by the 
Haematology Consultant medical staff, and by a Consultant Cardiologist. The 
patient’s body weight was checked and recorded at a scheduled hospital 
appointment or home visit by the Chief Investigator. This was used for 
ensuring this aspect of the eligibility criteria was met and was also used for 
the dose calculation for the red cell prescription. 
 
 
 
 
 
 
94 
 
Table 6.3: Medical Exclusion Criteria for Accelerated Transfusion 
 
 
 
 
 
 
HISTORY 
Exclusion Criteria 
Patient has had echocardiography with reported chronic heart 
failure. Reported as moderate to severe left ventricular 
dysfunction (ejection fraction <35%).  
Severe aortic stenosis 
Hypoalbuminaemia (<35g/L) 
Low body weight (<50Kg) 
Significant renal failure (eGFR <30ml/min) 
Significant liver failure (bilirubin >30µmol/L) 
 
 
EXAMINATION* 
Oedema 
Cough, dyspnea and/or respiratory rate >20 breaths per minute 
Tachycardia (heart rate >100 beats per minutes) 
Un-treated or uncontrolled hypertension (diastolic >95 mmHg, 
systolic >160 mmHg) 
*checked on pre-transfusion assessment if examination not possible at the time of writing the 
prescription 
Patients who responded indicating they wished to participate in the study 
were prepared in the following way. The Chief Investigator sent a letter 
(appendix G) to the patient’s General Practitioner informing them of the 
patient’s wish to participate in the study. A copy was also placed in the 
patient’s medical notes.  
Each time a patient in the study had red cells prescribed a pre-transfusion 
checklist was completed to record that the patient still met the medical 
inclusion criteria (appendix B). The completed document was retained by the 
Chief Investigator for secure retention in the research site file. 
Requesting and Selecting Red Cell Units: Volume Calculation 
Red cells were requested following the existing procedure in the hospital 
Trust’s Transfusion Clinical Process Policy. Additionally, for the purposes of 
this study, the required red cell volume was specified on the request form. 
This was an instruction to the transfusion biomedical scientist in the 
laboratory to select and provide a specified volume for the patient based on 
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body weight. This ensured the transfusion rate did not exceed 5ml/Kg/hour. 
Where the calculation and request form was completed by Haematology 
nursing staff, it was checked by the prescribing medical officer when 
completing the prescription. 
The rationale for the dosage calculation was derived from the Australian and 
New Zealand Society for Blood Transfusion guidelines (2011) where the 
recommended rate of transfusion is stated as 60-180 minutes per unit, 
unless the patient has heart failure or is otherwise at risk of fluid overload. 
Based upon the shortest recommended infusion time, this is 30 minutes per 
unit of red cells faster than the current UK guideline recommendation of 90-
240 minutes (BCSH, 2009). However, there is some variability in the volume 
of UK and Australian red cell units (NHSBT, 2012; Australian Red Cross 
Blood Service, 2012); this was accounted for in design of the study protocol 
by standardising the prescribed dose of red cells to 5ml/Kg/hr. Variation 
between the volume of UK and Australian red cell units was important to 
consider, as this could introduce bias when developing a thesis based upon 
non-UK evidence, when the research was conducted using UK manufactured 
(NHSBT) red cell units. The typical volume of an Australian standard red cell 
unit is quoted as 236-282 ml (Australian Red Cross Blood Service, 2012). 
The volume of a UK (NHS Blood & Transplant) standard red cell unit is 220-
340 ml (NHSBT, 2012).  
In a small (50 Kg) adult this is equivalent to 5.2ml/Kg/hr based upon an 
average ‘Australian’ unit, and 5.6 ml/Kg/Hr based upon an average UK red 
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cell unit i.e. the smaller adult is most at risk of TACO with respect to low body 
weight as a risk factor. 
 259 ml = mean volume of Australian red cells 
Therefore, one unit per hour in a 50Kg adult at 259 ml / 50Kg = 5.2ml/Kg/hr 
 280 ml = mean volume of UK red cells 
Therefore, one unit per hour in a 50Kg adult at 280 ml /50Kg = 5.6ml/Kg/hr 
A 5ml/Kg/hr dose was chosen for ease of calculation and provides a margin 
that does not exceed the ‘Australian’ maximum rate of transfusion (60 
minutes per unit). This is only relevant up to a body weight of 67Kg. At this 
body weight, the calculated dose would be 685ml and the combined total of 
two units would not exceed 680ml, which is the maximum possible for two 
units of UK red cells. Patients weighing greater than 67Kg would therefore 
not require volume-selected red cells (table 6.4). 
The volume of red cells requested represented the total maximum volume 
(combined volume of two units) to be supplied by the laboratory, based upon 
the weight/dose (table 6.4). There was no requirement for the laboratory staff 
to match the calculated dose, only to ensure the dose was not exceeded. 
Table 6.4 describes the red cell volumes for a range of body weights to 
achieve a 5ml/Kg/hr dose of red cells. An additional amount (15ml) was 
included to allow for the residual loss in the blood component administration 
set. The residual volume was determined using saline by decanting and 
measuring the remaining volume of fluid. 
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Table 6.4: Red Cell Dose/Weight Chart 
Patient’s Body Weight 
(Kg) 
Total Volume to Request (ml) 
50 (lowest body weight for study inclusion) 515 
51 525 
52 535 
53 545 
54 555 
55 565 
56 575 
57 585 
58 595 
59 605 
60 615 
61 625 
62 635 
63 645 
64 655 
65 665 
66 675 
67 or more 685 
2 units will not exceed 680ml in total, which is 
the total combined maximum possible for 2 
units of UK red cells 
 
Table 6.4 shows whole kilograms for illustration. Actual calculations were 
accurate to one decimal place and calculated by the formula shown below. 
(Weight (Kg) x 10) + 15 = maximum volume (ml) of red cells to request from 
laboratory 
The transfusion biomedical scientists selecting blood for patients in the study 
were instructed and trained that the calculated volume requested by the 
medical officer did not need to be matched, but must not be exceeded. Two 
units of red cells were selected from the blood stock fridge. The transfusion 
biomedical scientist processing the request checked that the combined 
volume of both of the units as shown on the pack label did not exceed the 
volume the requester has stated on the transfusion request from. If the 
patient required selected blood as a special order from the Blood Centre 
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(e.g. required phenotyped blood, special requirements or required a 
crossmatch by the reference laboratory due to complex serological issues), 
the volume requirement was communicated when placing the order. A 
patient who has special transfusion requirements had their blood ordered 
following the Online Blood Ordering System (OBOS) laboratory standard 
operating procedure, ensuring there was an instruction in the ‘order notes’ in 
OBOS regarding the required volume to be supplied as calculated and 
instructed by the medical officer prescribing the blood e.g. “the 2 units must 
not exceed a total volume of 615ml”.  
If the blood was being crossmatched by the reference laboratory i.e. not the 
local laboratory, the transfusion biomedical scientist made the reference 
laboratory scientist aware of the specific volume requirement. Any queries or 
problems in selecting specified red cell volumes were referred to the Chief 
Investigator or senior member of staff in the Transfusion laboratory. The 
arrangements for ordering units of a specific volume was agreed with the 
Red Cell Immunohaematology Department at the supplying blood Centre, 
and the NHSBT customer service manager ahead of the study beginning. 
Prescribing Red Cells and Sequence of Transfusion 
The red cells were prescribed on the blood prescription as per usual 
procedure as stated in the hospital Trust’s Transfusion Clinical Process 
Policy. 
The patient’s first transfusion was a standard rate (90 minutes per unit). If the 
standard rate transfusion is tolerated with no signs of TACO, the patient’s 
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second transfusion was an accelerated rate (60 minutes per unit). If this was 
also tolerated without signs of TACO, subsequent transfusions during the 
study could also be at the accelerated rate. Figure 6.2 shows the sequence 
of standard rate and accelerated transfusion.
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Figure 6.2: Sequence of Red Cell Transfusion
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Pre-Transfusion Confirmation of Willingness to Continue in the Study 
The patient who has previously consented to participate in the study was 
required to confirm their willingness to continue before administering any 
transfusion given as part of the study. The patient had the right to withdraw 
at any time without giving a reason, or affecting their usual standard of care 
(DH, 2005). Continued willingness to continue with the study was 
ascertained verbally with the patient and recorded (appendix H). The form 
was returned to the Chief Investigator for secure retention in the research 
site file. 
Pre-Transfusion Clinical Assessment 
The purpose of this assessment was to screen the patient to indicate 
whether there may have been any changes to the medical exclusion criteria 
assessment made at the time the blood was prescribed. After checking 
whether the patient was still willing to participate in the study, the vital 
observations were performed and then recorded on the Pre-Transfusion 
Assessment form (appendix H). If any of the criteria were not met or the 
patient did not wish to continue in the study, the transfusion was 
administered over 90 minutes per unit. In this case the prescription was 
annotated accordingly by the nurse administering the transfusion. This was 
also explained to the patient. Any concerns about the patient’s condition 
were reported to a member of the Clinical Haematology medical staff and 
advice taken. The pre-transfusion assessment form was returned to the chief 
investigator for secure retention in the research site file. 
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Transfusion Procedure 
The transfusion was administered, monitored and documented as described 
in the hospital Trust’s Transfusion Clinical Process Policy for Home 
Transfusion (as per standard procedure). There were no variations to the 
standard procedure other than the duration of the transfusion (in the case of 
accelerated transfusion). The blood was administered by gravity infusion 
through a blood component administration set.  
In order to calculate the drip-rate, the volume (ml) to be infused was 
multiplied by the number of drops in 1ml (typically this is 15 for blood) 
however the manufacturer’s instructions for the drip-factor were observed. 
This value was divided by the number of minutes over which the infusion was 
to be delivered. This gives the number of drops falling into the drip chamber 
per minute (Dougherty, 1999). Close attention was paid to the progress of 
the transfusion to ensure it was administered over the prescribed time. 
 
 
To allow for practical difficulties (especially when using gravity infusion) in 
meeting the exact infusion durations prescribed (60 or 90 minutes per unit), a 
+/-10% margin was allowed for the overall duration of the transfusion 
episode. 
 
 
Example: volume stated on blood unit label (275ml) x 15 = 4125 
4125/60 min = 69 drops per minute 
i.e. Standard rate transfusion: 2 x 90 min = 180 min (162 min – 198 min) 
 Accelerated rate transfusion: 2 x 60 min = 120 min (108 min – 132 min) 
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The patient was given a post-transfusion contact booklet (as per standard 
procedure) to make them aware of signs of adverse reaction and advice on 
seeking medical help. The Blood Transfusion Clinical Record was returned to 
Clinical Haematology/Laboratory for validation and archiving as per usual 
procedure stated in the hospital Trust’s Transfusion Clinical Process Policy. 
Post Transfusion Clinical Assessment 
The purpose of the post-transfusion clinical assessment was to determine 
whether the patient had developed signs of TACO, the study end-point. The 
International Society of Blood Transfusion draft definition for TACO states 
that TACO develops within 6 hours of transfusion, but accepts that cases 
may be observed up to 12 hours after transfusion (ISBT, 2014). The Serious 
Hazards of Transfusion (Bolton-Maggs et al, 2013) criteria state that 
symptoms and signs usually occur within 6 hours of transfusion, but SHOT 
also accept suspected cases occurring up to 24 hours after transfusion.  
Given this considerable variability, the patient was visited at home to have an 
assessment performed at about 24 hours after the transfusion had ended to 
allow for this. Given the pressure on CIVT capacity and available nursing 
hours, this was undertaken by trained support staff and the Chief 
Investigator. The criteria for the end-point (signs of TACO) were based upon 
SHOT and some of the ISBT surveillance diagnosis criteria for TACO 
available at the time of designing the protocol and are summarised in table 
6.5. The ISBT draft criteria were updated after the protocol was submitted for 
ethical approval hence the criteria cited below are not the most recent 
version. 
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Table 6.5: Summary of SHOT and ISBT definition and surveillance 
diagnosis criteria for TACO 
SHOT (Bolton-Maggs et al, 
2013) 
ISBT draft definitions (ISBT, 2014) 
Any 4 of the following 
within 6 hours (or up to 24 
hours) of transfusion 
At least 2 primary criteria, or 1 primary and 2 
supporting criteria, within 6-12 hours of transfusion 
 Acute respiratory 
distress 
 Tachycardia 
 Hypertension 
 Acute or worsening 
pulmonary oedema 
 Evidence of 
positive fluid 
balance 
Acute or worsening respiratory distress must be 
present 
Primary Criteria 
 Acute or worsening pulmonary oedema with 
bilateral infiltrates 
 Cardiomegaly on imaging 
 Evidence of fluid overload (positive fluid 
balance, clinical improvement with diuretics) 
Supporting Criteria 
 Raised Brain Natriuretic Peptide (BNP) or NT-
Pro BNP greater than 1.5 times the pre-
transfusion level 
 Increase in mean arterial pressure or 
pulmonary wedge pressure (often with 
widened pulse pressure), or hypotension in 
cardiac collapse. 
 
The ISBT diagnostic criteria are best suited to the patient who has already 
been identified as acutely unwell with respiratory distress in a high care 
setting. The SHOT criteria more readily lend themselves to assessing 
patients in the home environment with simpler clinical measurements and 
observations. Of the five SHOT criteria, four must be present to suspect 
TACO although fewer would be accepted for further investigation and 
reporting purposes in strongly suspected cases. The vital sign 
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measurements would identify tachycardia, hypertension and tachypnoea. 
Acute or worsening pulmonary oedema (or overt heart failure) would be 
evident by the presence of tachypnoea, dyspnoea, cough and peripheral 
oedema (singularly or in combination). Therefore the 24 hour post-
transfusion check-list comprehensively covers the criteria for TACO 
according to the SHOT surveillance diagnosis. Although these criteria are 
intended for haemovigilance or surveillance diagnosis as opposed to clinical 
diagnosis for medical management, they are sufficiently sensitive to identify 
patients with acute respiratory distress caused by circulatory overload.  
The rationale for expected values for vital sign observations is based upon 
values used in the National Early Warning Score (NEWS) (Royal College of 
Physicians, 2012). NEWS was devised to promote the assessment of acute 
illness, the detection of clinical deterioration, and for the initiation of a timely 
and competent clinical response. NEWS is an aggregate of six physiological 
parameters (temperature, heart rate, systolic blood pressure, respiratory 
rate, oxygen saturation, and level of consciousness). A patient can score 
between 0 and 3 for each parameter (3 indicating higher risk), and the 
aggregated score triggers defined actions to ensure appropriate monitoring 
and escalation of care. Although NEWS is intended to be an aggregated 
score, in this study only some of the vital sign observations are undertaken 
for the purposes of identifying signs of TACO. A score between 0 – 1 was 
adopted as a low threshold trigger for each of the vital sign observations 
recorded. The NEWS score of 0 for systolic blood pressure is equivalent to 
111-219 mm Hg, and 12-20 breaths per minute for respiratory rate. 
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Therefore 219 mmHg was adopted as the upper limit expected for systolic 
blood pressure, and 20 breaths per minute for respiratory rate. A score of 1 
for heart rate is equivalent to 91-110 beats per minute, and a score of 0 is 
equivalent to 51-90 beats per minute. An upper limit of 100 beats per minute 
was adopted for the study to indicate tachycardia as 90 beats per minute 
may have been over-sensitive particularly as some patients have tachycardia 
due to the physiological effect of anaemia. 
The 24 hour post-transfusion clinical check-list below in table 6.6 (appendix I) 
was designed to detect the relevant symptoms and signs associated with 
TACO. This was based on the SHOT and ISBT definitions and surveillance 
diagnosis criteria for TACO shown in table 6.5 and lists the assessment 
criteria of the 24 hour post-transfusion clinical assessment. 
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Table 6.6: The 24 hour post-transfusion clinical assessment 
Clinical Parameter Expected Value Rationale 
Heart rate Less than 100 beats per 
minute 
To exclude tachycardia 
Systolic blood 
pressure 
Less than 219mm Hg To exclude significant hypertension 
(111-219 = NEWS* score 0) 
Diastolic blood 
pressure 
No value stated More useful for monitoring chronic 
hypertension than acute events* 
Respiratory rate Less than 20 breaths per 
minute 
To exclude respiratory distress 
(12-20 = NEWS* score 0) 
Presence of cough 
and/or dyspnoea 
Not present To exclude respiratory distress 
Presence of 
peripheral oedema 
Not present May indicate heart failure/fluid 
overload 
Any signs of acute 
illness or adverse 
event in past 24 hours 
Not present To allow comprehensive 
assessment of the patient’s post-
transfusion wellbeing 
*National Early Warning Score (RCP, 2012) 
 
If the patient had any abnormal vital signs or otherwise reported being 
unwell, the procedure was to report this to the Clinical Haematology medical 
staff and advice taken. If serious illness was suspected, arrangements would 
have been made for the patient to go to hospital as per usual procedure 
stated in our Trust’s Transfusion Clinical Process Policy for Home 
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Transfusion. If Transfusion Associated Circulatory Overload was diagnosed, 
the procedure required statutory external reporting to SHOT/SABRE (MHRA) 
as per existing departmental policy/procedures and regulatory requirements 
by the Chief Investigator. The patient was assessed for any Adverse Event 
(AE) having taken place between the transfusion and the post-transfusion 
assessment. This required documentation (appendix A) and reporting to 
Haematology consultant medical staff for causality assessment. 
Version 1 of the protocol required a 24 hour post-transfusion assessment 
after every accelerated transfusion. Some patients in the study found this 
onerous on their time, and with the benefit of having preliminary data 
supporting the safety of accelerated transfusion at that point, an application 
for ‘substantial amendment’ of the research protocol was made to the NRES 
committee, which was approved. 
After the patient had received three accelerated transfusions without signs of 
TACO or adverse event, version 2 of the protocol then allowed for the patient 
to continue to receive accelerated rate transfusions but invited to self-report 
any post-transfusion symptoms, without the need for a 24 hour post-
transfusion check-up. This was discussed with the patient and reference was 
made to the patient information and contact booklet that had been previously 
provided and explained. The procedure for patients reporting symptoms, was 
to contact the Clinical Haematology medical staff, GP out of hours service or 
the Emergency Department (depending on the time of day), as per guidance 
in the booklet. If the patient did not wish to self-report, then 24 hour post-
transfusion follow-up continued as previous procedure. The post-transfusion 
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assessment form was returned to the chief investigator for data collection 
and secure retention in the research site file.  
Data Collection Method 
The pre-prescription check-list (appendix B), the pre-transfusion check-list 
(appendix H), and the post-transfusion check-list (appendix I) returned to the 
Chief Investigator were used to obtain and record the required data. The 
following data set was compiled into a Microsoft ExcelTM spreadsheet for 
later analysis. 
All transfusion episodes 
 Participant identifier 
 Patient characteristics (age, weight, gender, and diagnosis) 
 Transfusion type (standard or accelerated) 
 Date of transfusion 
 Total duration of the transfusion for both units (minutes), and the 
reason for the transfusion duration not meeting the expected duration 
(if applicable).  
 Presence of symptoms and signs of TACO 
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Standard rate and first three accelerated rate transfusions 
 Pre and post-transfusion respiratory rate 
 Pre and post-transfusion heart rate 
 Pre and post-transfusion mean arterial pressure* based upon the 
systolic and diastolic blood pressure recorded. 
*MAP = [(2 x diastolic) + systolic] / 3 
Diastole counts twice as much as systole because 2/3 of the cardiac cycle is 
spent in diastole. Usual range:  70-110. 
Data Analysis Methods 
Basic descriptive statistics on the data collected are presented to provide an 
overview of the data. The analysis was performed using Microsoft ExcelTM. 
The method was required to demonstrate the relative risk of the ratio of the 
proportions of cases having a positive outcome (developing signs of TACO) 
in two groups (comparing standard versus accelerated transfusion) in order 
to accept or reject the null hypothesis (where the is no difference in the 
incidence of TACO between standard and accelerated rate transfusion). 
Although the Chi Squared test is designed to test independence by 
assessing whether paired observations on two variables (expressed in a 
contingency table), are independent of each other, the assumptions for Chi 
Squared test were likely to not be met in this study. This test relies on 
adequate cell counts and it was likely that all counts would be zero (i.e. 
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patients are not expected to develop signs of TACO).When defining 
equivalence Wellek (2005) recommends odds ratio (OR) and relative risk 
(RR) as suitable statistical methods for measuring dissimilarity for binomial 
two-sample problems, and goes on to state that the exact Fisher-type test for 
one-sided equivalence provides  a satisfactory approach for the analysis of 
non-inferiority study involving two independent samples of binary data. The 
data were analyzed using MedCalcTM (www.medcalc.org) simple descriptive 
statistics expressed as relative risk (RR), odds ratio (OR) with a confidence 
interval and p value. This statistical method has also been previously applied 
to non-inferiority studies (Connolly et al, 2009). 
Differences in physiological response between both types of transfusion 
were evaluated by performing paired t-tests as set out below.  
 
a) Is there a difference between the pre and post transfusion vital sign 
observations in standard rate transfusion (figure 6.3)? 
 
 
Fig 6.3: Comparison of pre and post-transfusion vital sign 
observations in standard rate transfusion 
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b) Is there a difference between the pre and post transfusion vital sign 
observations in accelerated transfusion, and is it consistent across 
three subsequent accelerated transfusions (figure 6.4)? 
 
 
Fig 6.4: Comparison of pre and post-transfusion vital sign 
observations in accelerated transfusions 
 
c) Is there a difference in the variance between pre and post transfusion 
vital sign observation values (pre value – post value), when standard 
and accelerated rate transfusion is compared (figure 6.5)?  
 
 
 
 
 
Fig 6.5: Difference in the variance between pre and post-transfusion 
vital sign observation values when standard and accelerated 
transfusion are compared 
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d) Is there a difference between pre and post transfusion vital sign 
observation actual values, when standard and accelerated rate 
transfusion is compared (figure 6.6)? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.6: Difference between pre and post transfusion vital sign 
observation actual values, when standard and accelerated rate 
transfusion is compared 
 
 
 
Standard 
Rate Pre-
Transfusion 
Value 
HR 
RR 
MAP 
‘v’ 
Accelerated 
Rate Pre-
Transfusion 
Value 
Accelerated 
1 
Accelerated 
2 
Accelerated 
3 
HR 
RR 
MAP 
Standard 
Rate Post-
Transfusion 
Value 
RR 
HR 
MAP 
‘v’ 
Accelerated 
Rate Post-
Transfusion 
Value 
Accelerated 
1 
Accelerated 
2 
Accelerated 
3 
HR 
RR 
MAP 
 
 
114 
 
 
Precis of Thesis Development 
 
 Quantitative methodology was considered appropriate as TACO (the 
study end-point) has objective and measurable features  
 The underpinning philosophy of the quantitative methodology was 
considered to be the positivist/post-positivist paradigm, realist 
ontology, and modified objectivist epistemology 
 A prospective cohort cross-over study design was chosen as this 
requires fewer participants who could act as their own control as there 
was no ‘wash-out’ period for blood transfusion. A randomised 
controlled trial would have reduced random error but required many 
more participants. The decision was pragmatic and based upon the 
balance of sample availability/convenience versus potential for bias 
 The study can be described as a binary outcome non-inferiority study 
i.e. TACO or no TACO, and accelerated transfusion is no worse than 
standard rate transfusion for the development of TACO 
 The actual incidence of TACO is debated in the literature and is 
important for determining sample size and power. The data used was 
based upon UK haemovigilance data and UK Blood Stocks 
Management data due to the limitations of individual research studies 
and of local incidence data 
 Patients were excluded from the study based upon risk-factors and 
comorbidities that predispose circulatory overload. Patients with 
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baseline examination features or vital sign measurements that would 
confound features of TACO were also excluded 
 Patients weighing <67Kg received volume-selected red cell units to 
ensure the rate of transfusion did not exceed 5ml/Kg/hr when 
receiving two units of red cells over 60 minutes each 
 Patients had a pre-transfusion clinical check performed to 
demonstrate continued study eligibility and to ensure there were no 
features that would pre-dispose or complicate the identification of 
TACO 
 Patients had a post-transfusion clinical check performed to identify the 
observable/measurable features of TACO (study end-point) that were 
based upon SHOT/ISBT haemovigilance surveillance diagnosis 
criteria for TACO 
 The data were analysed by calculating the odds ratio (OR) and 
relative risk (RR) to demonstrate differences between the paired 
observations for the incidence of TACO in standard and accelerated 
rate transfusion. Although the Chi squared test is also used for this 
purpose, it is not mathematically suitable when cell counts are small 
and values likely to be zero 
 Multiple comparisons of vital sign observations were designed to 
demonstrate differences in physiological response when comparing 
standard and accelerated rate transfusion using paired t-tests 
 The results for this strand of the study are presented in the next 
chapter 
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Chapter Seven:  
Strand 1 Results 
 Physiological/Safety Enquiry 
 
Summary of Patient Characteristics 
Twenty-eight research participants were recruited to the study, but three of 
these did not contribute data because either their transfusion requirements 
ceased or they died before a transfusion could take place. Although the 
majority of eligible patients accepted the invitation to participate in the study, 
the overall available number in this patient group within the time-frame of the 
study was inherently small, and fell short of the 39 participants determined by 
the sample size calculation. It has been argued that reliance on sample size 
can constrain innovative research (Bacchetti et al, 2011), and therefore 
results based on the sample size obtained in this study still make a useful 
contribution to knowledge.  
The issues presented previously regarding sample size determination are 
discussed in the concluding chapter. Table 7.1 below summarises the 
physical characteristics of the research participants. 
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Table 7.1: Summary of patient characteristics 
Patients Characteristics 
 
Gender 
 
Male: n=18, Female n=7 
Age (years) at first transfusion in study 
 
Range: 45 to 83 years 
(mean = 68.1 years) 
Body Weight (Kg) at time of consent 
 
Range: 59.0Kg to 98.0Kg  
(mean = 78.1Kg) 
Diagnoses 
 
Myelodysplastic syndrome (n=12) 
Primary myelofibrosis (n=3) 
Chronic lymphocytic leukaemia (n=5) 
Haemolytic anaemia (n=1) 
Acute myeloid leukaemia (n=3) 
Acute lymphoblastic leukaemia (n=1) 
 
Summary of Transfusion Episodes 
Table 7.2 below summarises the duration of transfusions performed in the 
study. The standard rate transfusion was two red cell units over 90 minutes 
each +/- 10% (162 to 198 minutes), and accelerated rate transfusion was two 
red cell units over 60 minutes each +/- 10% (108 to 132 minutes). 
Accelerated transfusions that were planned but not achieved due to 
excessive infusion time are also recorded. 
Table 7.2: Summary of transfusion episodes 
Transfusion Type Number 
 
Standard rate transfusions 
completed 
 
25 
Transfusion Type Number 
 
Duration 
Range (min) 
Duration 
Mean (min) 
Accelerated rate transfusions 
completed 
 
269 
 
97 to 132 minutes 
 
122.8 min 
Transfusion Type Number 
(Range) 
Number 
(median) 
Accelerated rate transfusions 
per patient 
 
1-39 
 
9 
Accelerated rate transfusions 
not achieved 
 
39/308 
(12.7%) 
Infusion-related: tissued cannula, positional 
problems, infusion pump programming, 
interruptions of flow (n=31) 
Patient-related: not performed because of the 
patient’s condition or patient declined because post-
transfusion follow-up was not convenient (n=8) 
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Summary of Transfusion Outcomes 
Transfusion outcomes are summarised in figure 7.1 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Figure 7.1: Summary of Transfusion Outcomes 
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The transfusion outcomes were analysed by computing the Relative Risk 
(RR) and Odds Ratio (OR). The RR is the number of times more or less 
likely TACO will occur in the accelerated transfusion group compared to the 
standard transfusion (control) group. It is the ratio of absolute risk (AR) for 
each group, where AR is the probability that and individual will experience 
TACO over a specified period of time.  
Interpretation of Relative Risk (RR) 
RR = <1.0: less risk of TACO with accelerated transfusion compared to 
standard rate transfusion 
RR = 1.0: identical risk of TACO when comparing accelerated and standard 
rate transfusion 
RR = >1.0: greater risk of TACO with accelerated transfusion compared to 
standard rate transfusion 
The OR is the odds of TACO occurring in the accelerated transfusion group 
expressed as a proportion of the odds of TACO occurring in the standard 
transfusion group. When an event is rare (as with TACO) the OR is 
analogous to the RR. 
Interpretation of Odds Ratio (OR) 
OR = <1.0: less chance of TACO with accelerated transfusion compared to 
standard rate transfusion 
OR = 1.0: identical chance of TACO when comparing accelerated and 
standard rate transfusion 
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OR = >1.0: greater chance of TACO with accelerated transfusion compared 
to standard rate transfusion 
The confidence interval (CI) quantifies random error and is an estimate of the 
range of where the ‘real’ value lies. If the CI crosses 1.0 then the RR or OR 
is not significant or informative, as ‘no difference’ (i.e. 1.0) is contained within 
the range. The p value informs whether the difference between the two 
groups is statistically significant which is taken as <0.05 (5%) by convention. 
As this study seeks to ‘prove’ the null hypothesis, this can be defined as x% 
chance of observing a difference as large as observed even if the two 
populations are identical (the null hypothesis is true). 
Table 7.3 below shows the statistical analysis of outcome by patienta and 
demonstrates there is no difference between standard and accelerated rate 
transfusion for the development of symptoms and signs of TACO (RR = 1.0, 
OR = 1.0, p =1.0000). Although the confidence intervals (CI) cross 1.0, 
indicating there is no difference between both groups in the study, the CI are 
wide meaning the true RR and OR could indicate increased or decreased 
risk of TACO by accelerated transfusion. However logically decreased risk is 
not a feasible outcome.  
Analysing the outcome data by transfusion episodesb reduced the RR and 
OR to <1.0 which indicates a reduced risk of TACO in the accelerated 
transfusion group, which again is not logically feasible. It also has the effect 
of narrowing the CI but this still crosses 1.0 indicating that the RR and OR 
analyses are not informative. 
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This type of analysis is difficult to reliably interpret with a small sample size 
and for rare events when the desired and expected positive/bad outcomes 
(TACO) for both interventions are expected to be zero.  
Table 7.3: Summary of relative risk (RR) and odds ratio (OR) by patients 
and transfusion episodes 
Group Outcome by Patienta Outcome by Episodesb 
Exposed 
group: 
Accelerated 
transfusion 
Positive/bad 
outcome 
(TACO) 
0 patients 
Negative/good 
outcome  
(no TACO) 
25 patients 
Positive/bad 
outcome 
(TACO) 
0 transfusion 
episodes 
Negative/good 
outcome  
(no TACO) 
269 transfusion 
episodes 
Control 
group: 
Standard 
transfusion 
Positive/bad 
outcome 
(TACO) 
0 patients 
Negative/good 
outcome  
(no TACO) 
25 patients 
Positive/bad 
outcome 
(TACO) 
0 transfusion 
episodes 
Negative/good 
outcome  
(no TACO) 
25 transfusion 
episodes 
Relative Risk 
(RR) 
1.0000 0.0963 
95% CI  0.0206 to 48.5272 0.0020 to 4.7539 
z statistic  0.000 1.176 
Significance 
level  
p = 1.0000 P = 0.2394 
Odds Ratio 
(OR)  
1.0000 0.0946 
95 % CI 0.0191 to 52.2205 0.0018 to 4.8700 
z statistic 0.000 1.173 
Significance 
level 
p = 1.0000 p = 0.2409 
 
This is an inherently difficult study to design with the objective of confidently 
demonstrating non-inferiority for accelerated rate transfusion due to the 
unknown true incidence of TACO in this population, and notwithstanding 
TACO is a relatively rare event. This is discussed further in the concluding 
chapter. 
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Comparison of Pre and Post-Transfusion Vital Sign Observations for 
Standard Rate and Accelerated Rate Transfusion 
a) Is there a difference between pre and post transfusion vital sign 
observations in standard rate transfusions? 
Table 7.4: Comparison of pre and post standard rate transfusion vital 
sign observations 
N = 24 Standard Rate Transfusion 
 
Heart  
Rate 
Respiratory  
Rate 
Mean Arterial 
Pressure 
 Pre Post Pre Post Pre Post 
mean 74.38 73.08 15.42 16.04 84.63 89.88 
SD 13.16 12.56 1.53 1.99 12.93 10.50 
p     0.2407    0.1091   0.0441 
CI   
 -0.93 to 
3.51    
 -1.40 
to 0.15   
 -10.35 
to -0.15 
 
There is no statistically significant difference between pre and post -
transfusion vital sign observations for heart rate and respiratory rate, but 
statistical significance is reached for mean arterial pressure due to a small 
increase in the mean for the group. The increase is well below the 
pathological range (reference range = 70-110 mmHg) which may be 
observed in circulatory overload, and therefore may reflect the physiological 
effects of treated anaemia. 
b) Is there a difference between the pre and post transfusion vital sign 
observations in accelerated transfusion, and is it consistent across 
subsequent accelerated transfusions?     
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Table 7.5: Comparison of pre and post accelerated rate transfusion 1 
vital sign observations 
n = 24 Accelerated Rate Transfusion 1 
 
Heart  
Rate 
Respiratory  
Rate 
Mean Arterial  
Pressure 
 Pre Post Pre Post Pre Post 
mean 74.25 70.83 15.38 15.38 85.63 93.00 
SD 11.91 12.94 1.95 2.24 12.50 12.61 
p    0.1116   1.0000   0.0036 
CI   
 -0.86 to 
7.69    
 -0.62 to 
0.62   
-12.08 to 
-2.67 
 
Table 7.6: Comparison of pre and post accelerated rate transfusion 2 
vital sign observations 
n = 20 Accelerated Rate Transfusion 2 
 
Heart  
Rate 
Respiratory  
Rate 
Mean Arterial  
Pressure 
 Pre Post Pre Post Pre Post 
mean 73.85 71.15 15.3 15.00 82.65 90.90 
SD 10.92 11.72 1.53 1.59 7.73 11.44 
p    0.0096   0.3793   0.0051 
CI   
0.74 to 
4.66    
-0.40 to 
1.00    
-13.71 to 
-2.79 
 
Table 7.7: Comparison of pre and post accelerated rate transfusion 3 
vital sign observations 
n = 16 Accelerated Rate Transfusion 3 
 
Heart  
Rate 
Respiratory  
Rate 
Mean Arterial  
Pressure 
 Pre Post Pre Post Pre Post 
mean 66.63 67.75 15.56 15.06 82.56 89.00 
SD 10.02 10.39 1.26 2.08 10.68 10.17 
p    0.5996   0.2281   0.0187 
CI   
 -5.60 to 
3.35    
-0.35 to 
1.35    
-11.64 to 
-1.23  
 
In common with the standard rate transfusion, all three consecutive 
accelerated transfusions show a consistent statistically significant increase in 
mean arterial pressure. The possible reasons for this are the same as 
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described in section (a) above. The second accelerated transfusion also 
shows a statistically significant decrease in heart rate, but this is not a 
consistent finding. It does not fall into the pathological range and is a 
directional change opposite to that expected for circulatory overload. 
c) Is there a difference between the variance between pre and post 
transfusion vital sign observation values (pre value - post value) when 
standard and accelerated transfusions are compared?    
Table 7.8: Comparison of variance between standard and accelerated 
rate transfusion 1 vital sign observations    
n = 24 
Heart Rate Variance 
(pre transfusion – 
post transfusion 
value) 
Respiratory Rate 
Variance 
(pre transfusion – 
post transfusion 
value) 
Mean Arterial 
Pressure 
Variance 
(pre transfusion – 
post transfusion 
value) 
 Std Rate 
Acc  
Rate 1 Std Rate 
Acc 
Rate 1 
Std  
Rate 
Acc 
 Rate 1 
mean -0.17 -3.50 0.63 0.04 5.25 8.13 
SD 6.03 10.06 1.84 1.52 12.08 11.3 
p    0.1743   0.1834   0.2449 
CI   
 -1.59 to 
8.25   
-0.30 to 
1.46   
-7.86 to 
2.11  
 
Table 7.9: Comparison of variance between standard and accelerated 
rate transfusion 2 vital sign observations 
n = 20 
Heart Rate 
Variance 
(pre transfusion – 
post transfusion 
value) 
Respiratory Rate 
Variance 
(pre transfusion – 
post transfusion 
value) 
Mean Arterial 
Pressure Variance 
(pre transfusion – 
post transfusion 
value) 
 
Std 
Rate 
Acc 
Rate 2 
Std  
Rate 
Acc Rate 
2 
Std 
Rate 
Acc 
 Rate2 
mean 0.45 -2.90 0.65 -0.30 5.05 8.25 
SD 6.08 3.78 1.76 1.49 10.75 11.66 
p    0.0827   0.0218   0.3557 
CI   
-0.48 to 
7.18    
0.15 to 
1.75    
-10.27 to 
3.87 
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Table 7.10: Comparison of variance between standard and accelerated 
rate transfusion 3 vital sign observations     
n = 16 
Heart Rate 
Variance 
(pre transfusion – 
post transfusion 
value) 
Respiratory Rate 
Variance 
(pre transfusion – 
post transfusion 
value) 
Mean Arterial 
Pressure Variance 
(pre transfusion – 
post transfusion 
value) 
 
Std 
Rate 
Acc 
 Rate 3 Std Rate 
Acc  
Rate 3 
Std  
Rate 
Acc  
Rate 3 
mean 1.56 1.13 0.56 -0.56 4.75 5.81 
SD 5.77 8.39 1.71 1.67 11.61 9.70 
p    0.8501   0.0668   0.8189 
CI   
 -4.41 to 
5.29   
 -0.09 to 
2.34   
-10.78 to 
8.66 
 
There are no statistically significant differences in the variance of pre and 
post-transfusion vital sign observations between standard rate and 
accelerated rate transfusions 1 and 3. The second accelerated transfusion 
also shows a statistically significant decrease in respiratory rate, but this is 
not a consistent finding. It does not fall into the pathological range and is a 
directional change opposite to that expected for circulatory overload. 
d) Is there a difference between pre and post transfusion vital sign 
observation actual values when standard and accelerated rate 
transfusion is compared? 
Table 7.11: Comparison of standard and accelerated rate pre-
transfusion 1 vital sign observations       
n = 24 
Pre-Transfusion  
Heart Rate 
Pre Transfusion  
Respiratory Rate 
Pre-Transfusion  
Mean Arterial 
Pressure 
 
Std 
Rate 
Acc  
Rate 1 
Std 
Rate 
Acc  
Rate 1 
Std  
Rate 
Acc 
Rate 1 
mean 74.38 74.25 15.42 15.38 84.63 85.63 
SD 13.16 11.91 1.53 1.95 12.93 12.50 
p    0.9569   0.9388   0.6255 
CI   
 -4.61 to 
4.86   
 -1.07 to 
1.15    
-5.18 to 
3.18 
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Table 7.12: Comparison of standard and accelerated rate pre-
transfusion 2 vital sign observations 
n = 20 
Pre-Transfusion  
Heart Rate 
Pre Transfusion  
Respiratory Rate 
Pre-Transfusion  
Mean Arterial 
Pressure 
 
Std 
Rate 
Acc 
Rate 2 
Std 
Rate 
Acc 
Rate 2 
Std 
Rate 
Acc 
Rate 2 
mean 74.60 73.85 15.15 15.30 84.90 82.65 
SD 13.71 10.92 1.27 1.53 12.99 7.73 
p    0.7384   0.7481   0.4916 
CI   
-3.88 to 
5.38   
-1.11 to 
0.81   
-4.47 to 
8.97  
 
Table 7.13: Comparison of standard and accelerated rate pre-
transfusion 3 vital sign observations 
n = 16 
Pre-Transfusion  
Heart Rate 
Pre Transfusion  
Respiratory Rate 
Pre-Transfusion  
Mean Arterial 
Pressure 
 
Std 
Rate 
Acc Rate 
3 
Std 
Rate 
Acc 
Rate 3 
Std 
Rate 
Acc 
Rate 3 
mean 72.50 66.63 15.06 15.56 84.19 82.56 
SD 11.82 10.02 1.18 1.26 11.35 10.68 
p    0.0036   0.1777   0.6553 
CI   
2.25 to 
9.50    
-1.25 to 
0.25   
-5.98 to 
9.23 
 
Table 7.14: Comparison of standard and accelerated rate post-
transfusion 1 vital sign observations 
n = 24 
Post-Transfusion  
Heart Rate 
Post-Transfusion  
Respiratory Rate 
Post-Transfusion  
Mean Arterial 
Pressure 
 
Std 
Rate 
Acc Rate 
1 
Std 
Rate 
Acc 
Rate 1 
Std 
Rate 
Acc 
Rate 1 
mean 73.08 70.83 16.04 15.38 89.88 93.00 
SD 12.56 12.94 1.99 2.24 10.50 12.61 
p    0.3398   0.2815   0.104 
CI   
-2.52 to 
7.02    
 -0.56 to 
1.90    
-6.94 to 
0.69  
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Table 7.15: Comparison of standard and accelerated rate post-
transfusion 2 vital sign observations 
n = 20 
Post-Transfusion  
Heart Rate 
Post-Transfusion  
Respiratory Rate 
Post-Transfusion  
Mean Arterial 
Pressure 
 
Std 
Rate 
Acc  
Rate 2 
Std 
Rate 
Acc 
Rate 2 
Std 
Rate 
Acc 
Rate 2 
mean 73.40 71.15 15.80 15.0 89.95 90.90 
SD 13.49 11.72 2.02 1.59 11.37 11.34 
p    0.2963   0.1189   0.5896 
CI   
 -1.89 to 
6.39    
-0.23 to 
1.83    
-4.57 to 
2.67  
 
Table 7.16: Comparison of standard and accelerated rate post-
transfusion 3 vital sign observations 
n = 16 
Post-Transfusion  
Heart Rate 
Post-Transfusion  
Respiratory Rate 
Post-Transfusion  
Mean Arterial 
Pressure 
 
Std 
Rate 
Acc 
 Rate 3 
Std 
Rate 
Acc 
Rate 3 
Std 
Rate 
Acc 
Rate 3 
mean 72.00 67.75 15.63 15.06 88.94 89.00 
SD 12.44 10.39 2.06 2.08 9.47 10.17 
p    0.0143   0.3925   0.9839 
CI   
0.98 to 
7.52    
-0.80 to 
1.92    
-6.54 to 
6.42  
 
There was no statistically significant difference between pre and post 
transfusion vital sign observation actual values when standard and 
accelerated rate transfusions 1 and 2 are compared. The third accelerated 
transfusion also showed a statistically significant decrease in heart rate, but 
this was not a consistent finding. It does not fall into the pathological range 
and is a directional change opposite to that expected for circulatory overload. 
In conclusion, the mean arterial pressure appears to increase up to 24 hours 
after blood transfusion regardless of whether it was infused at a standard or 
accelerated rate, with the group mean remaining within the normal range. 
There is no statistically significant difference between pre and post-
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transfusion mean arterial pressure measurements when standard and 
accelerated rate transfusions are compared, showing that accelerated 
transfusion itself does not cause an increase in mean arterial pressure above 
that of standard rate transfusion. 
 
Precis of New Knowledge 
 Accelerated transfusion (total infusion time for two units is 120 min +/- 
10% (108 to 132 minutes) was not always achieved. Accelerated 
transfusion was not achieved in 12.7% of episodes (39/308). This was 
due to flow interruptions and infusion pump programming issues in 
79.5% (31/39), and the patient declining accelerated rate transfusion 
in 20.5% (8/39) because they were unwilling to have a follow-up check 
the following day as part of the study 
 Twenty-five patients had standard rate transfusions with a total of 269 
accelerated rate transfusions completed in total. There were no cases 
of TACO detected 
 The OR and RR show no statistical difference between standard and 
accelerated rate transfusion by patient, however there is a wide 
confidence interval indicating the true risk of TACO from accelerated 
transfusion could be increased or decreased 
 Analysis by transfusion episodes shows no difference between 
standard and accelerated rate transfusion and produces a narrower 
confidence interval 
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 Choice of statistical method and subsequent analysis and 
interpretation was frustrated by small available sample size and rare 
events where the positive outcome (TACO) is expected to be zero for 
both interventions.  
 There was a statistically significant difference between pre and post-
transfusion mean arterial pressure (MAP) in standard rate transfusion. 
The increase was not within the pathological range and may reflect 
the physiological effect of treated anaemia 
 There was a statistically significant difference  between pre and post-
transfusion mean arterial pressure in accelerated rate transfusion 
which was consistent across all three accelerated rate transfusions 
 There was no consistent difference in variance of pre and post-
transfusion vital sign observations when standard and accelerated 
rate transfusion were compared 
 MAP appeared to increase within 24 hours of transfusion regardless 
of whether the transfusion was infused at a standard or accelerated 
rate, with the group mean remaining within the normal range 
 There was no statistically significant difference between pre and post-
transfusion MAP when standard and accelerated transfusion are 
compared, demonstrating that accelerated transfusion itself does not 
increase MAP above that of standard rate transfusion 
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Chapter Eight:  
Strand 2 Methods 
Service Capacity Enquiry 
 
This chapter discusses the method used for the service capacity strand of 
the study which is designed to address whether implementation of 
accelerated transfusion could potentially increase service capacity. 
General Research Question 
Whether transfusing two units of red cells over 60 minutes per unit 
(accelerated transfusion) is safe and could potentially increase CIVT service 
capacity, while gaining understanding of the patient’s and practitioner’s 
experience. 
Hypothesis 
H1: Implementation of accelerated transfusion could potentially increase 
CIVT service capacity (H0 Implementation of accelerated transfusion would 
not potentially increase CIVT service capacity) 
Method Aim 
The selected method aims to demonstrate whether introducing accelerated 
red cell transfusion for selected patients receiving transfusions at home could 
have a positive impact upon CIVT service capacity. 
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Method Design: Rationale and Philosophical Foundations 
A quantitative methodological approach was used to analyse capacity and 
costs associated with the provision of the CIVT home transfusion service. An 
analytical method based on workload audit was considered the most 
appropriate approach to test the hypotheses and research question 
regarding this aspect of the study. A quantitative methodology is appropriate 
for the objective evaluation of measurable parameters and this underpins the 
philosophical basis of this approach. The underpinning philosophy for this 
approach is described in chapter six regarding the physiological and safety 
enquiry and is therefore not duplicated in this chapter.  
A comparison was made between the current service model (where all 
transfusions are standard rate), and the developed/future state service model 
(where a proportion of transfusions are accelerated rate). Data on 
transfusions performed were collected from the CIVT workload records. 
Table 8.1 describes the comparison parameters of each service model. 
Table 8.1: Comparators for Resource Analysis 
Current Service Model 
(All Standard Rate Transfusions) 
Future Service Mode 
(Proportion Accelerated Rate Transfusions) 
Ratio of Standard Rate: Accelerated 
Rate 
(=1.0) 
Ratio of Standard Rate: Accelerated Rate 
(=1.?) 
Cost of standard rate transfusion 
(£ staff pay/annum) 
Cost of accelerated rate transfusion 
(£ staff pay/annum) 
Time delivering standard rate 
transfusions 
(hours/annum) 
Time delivering accelerated rate 
transfusions 
(hours/annum) 
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The rationale for this approach and choice of comparator was to generate 
data that demonstrates: (i) costs associated with each service model (staff 
pay is the only parameter required for analysis as all other direct and indirect 
costs remain the same); and (ii) treatment delivery time generates data 
regarding impact upon service capacity. The role of the cost comparator was 
to demonstrate the relative differences of each service model as opposed to 
generate an accurate cost. The role of the treatment delivery time 
comparator was to provide an indicative increase in available treatment time 
and how this may be used as additional treatment sessions. This provides a 
practical illustration of how any increase in service capacity may be utilised 
as well as placing a financial value on it. 
Data Collection Method  
Workload Audit Data Set 
Workload data were obtained from the CIVT administrator for each month of 
the study (July 2014 to November 2016) which detailed the home (red cell) 
transfusion workload of the team. This was recorded in a Microsoft Exel TM 
spreadsheet and data added with respect to the data set shown below in 
preparation for later analysis. 
 Month and year of transfusion 
 Patient identifier 
 Haematology patient or medical patient (only haematology patients were 
included in the study) 
 Whether the patient was recruited in the study 
 Reason for exclusion if the study inclusion criteria were not met 
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 Assessment of suitability for accelerated transfusion if not participating in the 
study 
 
Staffing Data 
To ensure standardisation, the calculation of staffing costs was based on the 
mid-point salary scale for a nurse at band 6 which is £30,357 per year, or 
£15.57 per hour in 2016 based on a 37.5 hour week without shift 
enhancements. This was the prevailing pay scale at the time of the data 
collection period (July 2014 to November 2016). This was to avoid bias 
caused by vacancies and staff incrementing up the pay scale during the 
duration of the study, and the effect of additional payments for unsocial hours 
as there were no data available to determine the number of transfusion 
performed during these shift periods. 
Data Analysis Method 
The data were based on the comparators defined in table 8.1 above. The 
ratio of standard to accelerated rate transfusions was obtained from the 
study data, which was dependent upon the final number of eligible patients. 
The time spent on administering each type of transfusion was calculated 
using knowledge of the actual time taken to deliver a standard rate 
transfusion (an average of four hours per visit, as confirmed by the CIVT 
service manager and nursing staff). An accelerated rate transfusion was 
determined as the standard rate (time) minus 60 minutes (i.e. 30 minutes x 2 
units of red cells). Therefore the average visit time is three hours for an 
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accelerated rate transfusion. The results were expressed as per annum 
values and were used to demonstrate any differences in staff resource 
utilisation. The calculations used to compare resource utilisation for each 
service model are shown below.  
Current Service Model –  
All standard rate transfusion 
 Predicted number of home transfusion episodes per year (based on audit 
data) multiplied by 4 hours (treatment delivery time for standard rate 
transfusion)  
= number of hours delivering standard rate home transfusions 
per year 
 Number of hours per year x £15.57 (standardised hourly rate) 
= staff costs of delivering standard rate transfusion per year 
Potential Future Service Model –  
Proportion of transfusions are at accelerated rate 
 Predicted number of home transfusion episodes per year (based on audit 
data) multiplied by proportion of accelerated rate transfusions (based on 
audit data) 
= number of predicted accelerated rate transfusions per year 
 Predicted number of home transfusion episodes per year (based on audit 
data) minus number of predicted accelerated rate transfusions per year 
= number of standard rate transfusions per year 
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 Number of predicted accelerated rate transfusion per year multiplied by 3 
hours (treatment delivery time for accelerated rate transfusion) 
= number of hours delivering accelerated rate home transfusions 
per year 
 Number of hours per year x £15.57 (standardised hourly rate) 
= staff costs of delivering accelerated rate transfusion per year 
 Number of predicted standard rate transfusion per year multiplied by 4 hours 
(treatment delivery time for standard rate transfusion) 
= number of hours delivering standard rate home transfusions 
per year 
 Number of hours per year x £15.57 (standardised hourly rate) 
= staff costs of delivering standard rate transfusion per year 
 Treatment delivery time of current service model minus treatment delivery 
time of potential future service model 
= number of nursing hours released per year by implementing 
accelerated transfusion 
 Number of nursing hours released per year by implementing accelerated 
transfusion divided by 3 or 4 
= potential number of additional 3 or 4 hour visits available if 
accelerated transfusion is implemented 
 Number of hours released per year multiplied by £15.57  
= value of released nursing hours 
 
 
136 
 
These calculations are fully documented in the following results chapter using actual 
data. 
Precis of Thesis Development 
 A quantitative methodological approach based upon audit was considered 
appropriate to objectively evaluate the effect of accelerated transfusion on 
CIVT service capacity 
 The method was designed to illustrate how any increase in service capacity 
could be utilised in terms of clinical hours generated and placing a financial 
value on it with respect to staff resource costs 
 A workload audit data set was developed, and staffing data was based upon 
standardised salary and hours 
 The current service model (all standard rate transfusions) was compared to 
the potential service model (where a proportion was accelerated rate 
transfusions depending on patient eligibility). The ratio was informed by the 
audit data and used to determine treatment delivery time and staff costs for 
each model 
 The results for this strand of the study are presented in the next chapter 
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Chapter Nine:  
Strand 2 Results 
 Service Capacity Enquiry  
 
Analysis of Patient Eligibility for Accelerated Transfusion 
Twenty nine months of home transfusion workload data were analysed (July 
2014 to November 2016). Seventy one individual patients (46 haematology 
patients and 25 medical patients) received home transfusions during that 
period. Their eligibility for accelerated transfusion in haematology patients is 
shown below in figure 9.1. 
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Figure 9.1: Patient Eligibility for Accelerated Transfusion 
 
The analysis above shows that 26/46 (57%) of haematology patients fulfilled 
the medical inclusion criteria for accelerated transfusion. Medical patients 
receiving home transfusion did not participate in the study but their medical 
eligibility for accelerated transfusion is theoretically similar, but their 
requirement for regular transfusion is less intensive.  
 
Patients Receiving Home Transfusion (Jul 14 to Nov 16) 
71 
Haematology Patients 
46 
Medical Patients  
(not invited  
into the study) 
25 
Medically 
Eligible 
26 
Eligible then later 
became medically 
excluded 
2 
Medically 
Excluded 
18 
Participated 
in the study 
15 
Not a suitable 
study 
participant but 
otherwise 
medically 
eligible 
11 
Care of dying 
pathway 
4 
Transfusion 
needs ending  
3 
 
Declined Study 
Participation 
2 
Unable to give 
consent for 
research study 
2 
Thalassaemia 
Major (3 units) 
2 
Low body 
weight 
2 
Unable to 
assess Doppler 
1 
Very elderly 
1 
Hypertension & 
oedema 
1 
Renal failure & 
low albumin 
5 
Renal Failure 
2 
Low albumin 
4 
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Analysis of Accelerated Transfusion Episodes 
Twenty nine months of home transfusion workload data were analysed (July 
2014 to November 2016). Five hundred and seventeen home red cell 
transfusions were performed during that period (459 haematology patients 
and 58 medical patients).  Eligibility for accelerated transfusion in 
haematology patients is shown below in figure 9.2. 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
  
   
 
  
Figure 9.2: Accelerated Transfusion Episodes 
Home Red Cell Transfusion Episodes (Jul 14 to Nov 16) 
517 
Haematology Patient Episodes 
459 
Medical Patient Episodes 
58 
Medically Eligible Episodes 
224 (49%) 
Medically Excluded Episodes 
235 (51%) 
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the study 
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study 
participant but 
otherwise 
medically 
eligible 
54 
Care of dying 
pathway 
15 
Transfusion 
needs ending  
3 
 
Declined Study 
Participation 
33 
Unable to give 
consent for 
research study 
3 
Thalassaemia 
Major (3 units) 
40 
Renal failure & 
low albumin 
43 
Low body 
weight 
12 
Low albumin 
27 
Unable to 
assess Doppler 
22 
Renal Failure 
2 
Very elderly 
5 
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oedema 
19 
Eligible then 
later became 
medically 
excluded 
65 
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The analysis above shows that 224/459 (49%) of haematology patient 
transfusion episodes fulfilled the medical inclusion criteria for accelerated 
transfusion. Medical patients receiving home transfusion did not participate in 
the study however their medical eligibility for accelerated transfusion is 
theoretically similar to haematology patients, but requirement for regular 
transfusion is less intensive. 
Analysis of the Impact of Accelerated Transfusion on CIVT Service 
Capacity 
Assumptions 
 215 red cell transfusion episodes are performed per year based upon 
the workload data (July 2014 to November 2016) 
 A standard rate transfusion episode requires a 4 hour home visit 
 An accelerated rate transfusion episode requires a 3 hour home visit 
 The pay-related cost of a home visit is nominally £15.57 per hour 
(salary mid-point for a band 6 nurse is £30,357 in 2016 based on a 
37.5 hour week without unsocial shift allowance) 
 
Current Service Model 
All transfusions are standard rate 
215 episodes per year x 4 hour visits = 860 nursing hours per year 
860 x £15.57 = £13,390 
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Proposed Future Service Model 
A proportion of transfusions (49%) are accelerated rate, based upon the data 
analysis. 
215 x 0.49 = 105 transfusions can be potentially performed as accelerated 
rate transfusions 
105 episodes per year x 3 hour visits = 315 hours (£4,905) 
110 episodes per year x 4 hour visits = 440 hours (£6,850) 
Totalling 755 nursing hours per year at a cost of (£11,755) 
The implementation of accelerated red cell transfusion could potentially save 
105 nursing hours per year (£1,635). This is equivalent to 35 extra three hour 
visits or 26 extra four hour visits, for example. 
Precis of New Knowledge 
 57% (26/46) of haematology patients fulfilled the medical inclusion 
criteria and were therefore eligible for accelerated transfusion 
 49% (224/459) of home transfusion episodes were eligible to be 
performed as accelerated rate transfusions.  
 If accelerated transfusion was implemented for both haematology and 
medical patients, service capacity could be increased by 105 nursing 
hours that could be utilised for additional patient visits whether for 
transfusion or other IV therapies 
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Chapter Ten:  
Strand 3 Methods 
Patient and Practitioner Experience 
Enquiry 
 
This chapter discusses the method used for the patient and practitioner 
experience strand of the study which is intended to add value to the overall 
study by exploring and gaining understanding of experience of accelerated 
transfusion. 
General Research Question 
Whether transfusing two units of red cells over 60 minutes per unit 
(accelerated transfusion) is safe and could potentially improve CIVT service 
capacity, while gaining understanding of the patient’s and practitioner’s 
experience. 
Method Aim 
The selected method aims to generate understanding of the experience of 
administering and receiving accelerated and standard rate transfusions, to 
address this aspect of the research question. The creation of understanding 
has implications for the acceptability and desirability of service development 
and change if accelerated transfusion is implemented into routine practice. 
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 Method Design: Rationale and Philosophical Foundations 
The patients and practitioners who use and deliver the service often develop 
close relationships with each other which are intensified by the context of the 
home environment, and often in the presence of life-limiting conditions. 
Proposed changes to their services must be approached with sensitivity, 
respecting the tenets of patient-centeredness, the value of understanding 
personal experience and the benefits of co-design to achieve improved 
experience of care. A generic qualitative approach was considered 
appropriate for generating understanding of the patient’s and practitioner’s 
experience of accelerated transfusion by exploring their thoughts and 
feelings. This approach is based upon the use of experience as knowledge, 
as explained by the individual. Cresswell states that talking directly with 
people without a priori assumptions allows exploration and detailed 
understanding (Cresswell, 2007). The subjective and individualistic nature of 
experience requires a philosophical approach based upon the constructivist 
paradigm, where relativist ontology acknowledges the person-dependent 
plurality of ‘reality’. If the reality of experience is a mental construction, then 
epistemologically the subjectivist must interact subjectively with the individual 
to unlock those constructions to ultimately generate knowledge (Guba, 
1990). Patient and practitioner research participants were invited to be 
interviewed (not exceeding 60 minutes as per ethical approval) about their 
experience of standard rate and accelerated transfusion. The interviews took 
place in the naturalistic setting of the patient’s home where the transfusion 
took place (or practitioner’s workplace) providing a holistic and contextual 
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setting. This allowed for an inductive/descriptive approach to answer the 
research question. The semi-structured interview was favoured as a 
structured interview may constrain dialogue. Structured, pre-determined 
questions could also make the interview more vulnerable to researcher bias 
through “asking the wrong questions” as a result of the interviewer’s 
assumptions or preconceptions (Charmaz, 2001: p.681). Other aspects of 
researcher bias cannot be completely eliminated but can be controlled 
through reflexive awareness. This should be balanced with the positive 
nature of reflexivity which has the potential to enrich the data. This is 
discussed further below in the context of rigour. 
Rigour in Method Choice and Data Analysis 
Guidelines have been produced in an attempt to provide a quality framework 
for qualitative researchers (Spencer et al., 2003). Whilst acknowledging the 
existence and influence of government endorsed guidance, the development 
of a positivistic procedural framework for conducting qualitative research is 
an epistemological contradiction. A prescriptive approach may not be 
appropriate to the diverse nature of qualitative research methods as this may 
in itself begin to define the design of the research (Mays & Pope, 2006), or 
become a “technical procedure” (Barbour, 2001, p. 1115).  
Reliable and valid research is seated in the practical choices, ethical conduct 
and self-awareness of the researcher. Trustworthiness (rigour) was 
described by Guba and Lincoln (1985) as having four criteria: credibility (truth 
value); dependability (neutrality); confirmability (consistency) and 
transferability (applicability). Applying Guba and Lincoln’s criteria to the 
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research provides a useful framework to evaluate rigour of the methods and 
the findings they produce. Ultimately, the reliability and validity of the 
research is attested by transparently demonstrating appropriate design, 
systematic data collection, assiduous data analysis, and skilful knowledge 
translation guided, but not bounded, by Guba and Lincoln’s criteria. 
Confirmability can be assured by observing the National Institute for Health 
Research principles of Good Clinical Practice (GCP) for research 
governance which covers both quantitative and qualitative research 
methods. The Chief Investigator is GCP trained and also experienced in 
quality management. This ensures high standards in maintaining a robust 
audit trail of all paper and electronic records generated throughout the data 
collection and analysis phases of the research process. This also provides a 
clear description of the rationale and analytical steps of the research-path, 
providing an auditable record of decision-making steps. 
The researcher’s station within the research and their potential to influence it 
is also important to address. This is especially relevant when conducting 
interviews with research participants where there is an existing relationship 
or some level of shared experience. Whilst reflexivity has been shown to 
enrich knowledge from interviews (Finch, 1993), it is also a potential source 
of bias and criticism regarding reliability and must be carefully managed. 
Finch’s paper is an interesting perspective on reflexive issues encountered in 
qualitative research. She has been influenced by Ann Oakley’s (1981) paper 
that argues that a researcher cannot subtract one’s own values, beliefs and 
opinions from the research process (i.e. in her case as a feminist). Whether 
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this is considered bias or enrichment is not easily defined and may be spared 
scrutiny depending on how it is framed and applied as a research tool. There 
is an assumption that bias and preconception are undesirable, but it can be 
argued this is seated in how the notion of ‘bias’ is constructed. It could be 
debated that objectivity is regarded as the ‘gold standard’ in the pursuit of 
rigorous research and in the absence of objectivity sits subjectivity, and 
therefore, bias.  But, subjectivity lends interpretation, perspective and 
ideology as part of the human condition, which can both enrich and 
jeopardise the rigour of qualitative research, and this is moderated by the 
researcher’s reflexive awareness. Objectivity may be incompatible with 
qualitative research depending on philosophical standpoint, but this is not to 
say that because qualitative research may be subjective, that ergo it is 
inherently biased. Malterud (2001) also argued a difference between 
‘preconception’ and ‘bias’, believing them to be different unless undeclared. 
Reflexive transparency positions the researcher with a unique perspective 
where rich and deep understanding may be achieved, as opposed to 
compromising reliability. Awareness and acknowledgement of subjectivity 
can therefore enhance the credibility of the research by confining bias, but if 
uncontrolled risks its detrimental effects on the rigour of research, as 
diagrammatically presented in figure 10.1. Reflexive transparency can 
therefore be viewed as a ‘check and balance’ for reliability. This alternative 
view may foster deeper understanding between interviewer and interviewee, 
as well as of the data itself, and bringing confidence to the rigour of the 
study. 
 
 
147 
 
 
 
 
 
 
 
 
 
Figure 10.1: Control of bias: relationship with objectivity and 
subjectivity 
 
Table 10.1 below summarises the researcher’s declaration of reflexive 
observations and preconceptions of the research participants. This served as 
a point of reflexive reference and calibration for conducting the interviews 
and data analysis, by serving to maintain self-awareness. 
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Non-measurable 
phenomena 
(Qualitative Research) 
Measurable phenomena 
(Qualitative Research) 
Philosophical platform 
Controlled by appropriate 
quantitative methodology 
Controlled by reflexive 
awareness and declaration 
Bias 
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Table 10.1: The Researcher’s declaration of reflexive observations and 
pre-conceptions of research participants. 
Researcher’s Reflexive Observations 
The interviewer is closely involved with the delivery and infrastructure of the blood 
transfusion aspects of the CIVT service. This has benefit of deep understanding of the 
service but could positively or negatively affect interpretation of what is being said by 
participants. 
The interviewer has a desire for the service to succeed and flourish for the benefit of patient 
care, and job satisfaction of staff and is therefore motivated for a positive outcome which 
must be moderated to avoid bias. 
The interviewer has a variable relationship history with the patient. There may have been 
several previous clinical contacts. The interviewer has professional relationships and regular 
contact with the CIVT. This may affect the interview dynamic positively or negatively 
depending upon how it is managed. 
Insider knowledge tempered with outsider distance may be a good balance to draw the sort 
of detail that may not be possible if the interviewer was completely neutral (and perhaps with 
no expertise or experience in blood transfusion).   
The interviewer’s ‘insider role’ may change the relationship between interviewer and 
interviewee. This relationship may be seen as a potential source of bi-lateral bias in the 
interview process, but may also enrich the process (see ‘credibility’ below). 
The interviewer is not a professional interviewer: interviewer’s perceived negative impact on 
data quality but this is balanced with the interviewer’s professional experience of asking 
questions and active listening in the medical consultation setting. 
Knowledge of the Chief Investigator analysing the interviews, and as a small team (even 
when formally anonymised) the CIVT practitioner’s comments would be unlikely to be 
completely disguised, remaining open to potential for perceived judgement by the researcher 
with whom they have a working relationship. 
Researcher’s Pre-Conceptions of Research Participants 
All CIVT practitioners are bound to have a more positive experience of accelerated 
transfusion compared to standard rate.  
Some patients may prefer the standard rate transfusions experience as they enjoy the social 
contact but may feel inhibited in articulating this as they feel compelled to endorse 
accelerated rate transfusions. 
CIVT practitioners may feel inhibited in articulating any criticisms of the experience of 
accelerated transfusion directly to the researcher. 
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Confidence in Credibility may be fostered by the concept of ‘prolonged 
engagement’. Although this perhaps traditionally has more relevance in 
ethnographic and field research, it also has utility in the context of this study. 
The Chief Investigator had many years of insight into the service before 
engaging in the research.  The degree of relationship with both patients and 
practitioner participants could be described as a peripheral member, 
assuming a marginal role, using membership typology suggested by Adler 
and Adler (1987).This provided orientation in the area of research through 
developing relationships and sharing experiences to achieve shared 
understanding and co-construction of meaning, at a distance that also allows 
impartiality. Personal insight not only allows accurate representation of the 
narrative, but allows reflexive awareness of pre-conceptions and subsequent 
distortions in the data that may need accounting for in the data analysis. 
From a participant perspective, relative distance from the researcher may 
also moderate inhibitions in expressing negative feelings and experiences of 
accelerated transfusion. 
The aim of data saturation was to increase the likelihood of obtaining 
comprehensive themes across the range of participants interviewed. Data 
saturation was [in this study] defined by failure to identify further 
codes/themes at the point at which the final data are analysed (based upon 
Guest et al, 2006). The emergence of strong themes provides confidence in 
the ‘truth’ of the findings, however this does not detract from the value of 
lesser occurring themes as significance is not based upon measurement or 
prevalence (Braun and Clarke 2006). 
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Identification of contradictory themes was also useful to disclose to 
demonstrate credibility and unbiased analysis. This can lead to the revision, 
broadening and confirming of emergent themes from the analysis, and was 
adopted in the approach to the thematic analysis (Patton, 1999). 
Dependability may be assured by ‘external audit’. Although formal external 
audit was not part of the method for data collection and analysis, the 
research was conducted under the supervision of an experienced researcher 
in qualitative methodology whose role was to provide feedback on drafts of 
the work relating to the participant interviews and thematic analysis. The 
effect of interviewer experience on data quality has been studied more 
frequently in structured or survey interviewing, Fowler and Mangione (1990) 
being among the first to report the positive effect of interviewer training on 
data quality. There is less in the literature regarding the effect of the 
interviewer on semi- or un-structured interviewing, however Fowler (2004) 
believes that the most difficult skills to acquire in semi-structured interviewing 
are careful construction of questions and nondirective probing, and that 
training in this area is profitable when pursuing good data quality. The 
interviewer had the benefit of professional experience of asking questions 
and active listening in the medical consultation setting. In agreement with 
Fowler’s guidance, an interview schedule was developed with general open 
questions and suggestions for probes and prompts (appendix J). It was 
piloted and modified prior to the actual interviews taking place. 
Transferability may be achieved by thick description. By describing detail, 
conclusions may be drawn regarding transferability of the research to other 
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contexts and scenarios (Lincoln and Guba, 1985). The purpose of the 
research was to generate experiential understanding to inform practice 
change in a specific area (home transfusion) and therefore the data were 
generated from this specific population without the primary intention of 
producing generalizable evidence. However patients receiving home 
transfusion also occasionally attend the oncology day unit for blood 
transfusion and therefore have experience of both settings. Accelerated 
transfusion could theoretically be offered in the future to patients receiving 
transfusion as a hospital day-case.  
Sample Size and Sampling Strategy 
The sample size of a qualitative method cannot be pre-determined. Hunter 
and Brewer (2006) assert that sample characteristics are more important 
than sample size in qualitative research as the aim is not statistical 
representativeness, but representativeness of participant experience relating 
to the research question. Breadth of knowledge is traded for depth, bringing 
richer data from fewer participants. For this reason purposive non-probability 
sampling was used, the participants were selected in a non-random fashion 
based upon their transfusion history. Patients who had been receiving long-
term blood transfusion had more experience of standard rate transfusions 
compared to new patients who may have only received one standard rate 
transfusion before being recruited into the study. For this reason, the 
participants who had a longer transfusion history were favoured for interview. 
This approach may be vulnerable to criticisms of bias if not stated, but 
returning to Charmaz’s point about “asking the wrong question” (Charmaz, 
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2001: p. 681), it can be argued that careful matching of research participant 
experience to the research question by asking the correct question in the 
correct way will avoid the creation of ‘false knowledge’ and ensure that only 
relevant knowledge is created. Difficulties with issues of bias also arise from 
the epistemological dichotomy of ‘sample number’ in qualitative research. A 
polarity exists between the positivistic view of numbers in probability 
sampling, and the constructivist view of richness in non-probability sampling. 
The aim was data saturation to ensure transferability of emergent themes 
from which participant numbers could not be predicted a priori. Ten 
participants were judged a reasonable nominal figure for this study in terms 
of stating participant numbers for the purposes of ethical approval. The final 
number of participants was also influenced by the availability of participants 
from inherently small groups, and the point at which data saturation was 
reached. This decision accords with Wibberley and Price (2012) who also 
performed a thematic analysis on ten, purposively selected participants for 
an exploratory-type study. Ultimately, data saturation was aspirational but 
acknowledged as potentially unachievable on a practical level. 
The sample number strategy for this aspect of the study contrasts with the 
quantitative strand where consecutive non-probability sampling was used. 
This was to ensure as many eligible patients as possible were recruited from 
the relatively small eligible population available to meet the calculated 
sample number. Sufficient quantity of participants was therefore more 
important to the quantitative aspect of the study than to the qualitative strand 
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of the study where participant characteristics, as opposed to number, were of 
greater importance. 
Interview Recruitment Process:  
Patient Invitation, Information and Response 
Patients who met the selection criteria for the study received a letter of 
invitation and a patient participant information sheet (PIS) (appendix D and 
E). The PIS stated that some patients may be asked to participate in an 
interview. Patients agreed to being potentially invited for an interview in their 
study participation consent form however it was made clear they did not have 
to participate in an interview if they only wished to participate in the 
accelerated transfusions. Patients who were later selected for interview were 
contacted by telephone or invited in person at their outpatient clinic visit. 
Patients were given an opportunity to consider the invitation for interview and 
reminded that they could decline if they did not wish to participate in this 
aspect of the study. 
Practitioner Invitation, Information and Response  
All members of CIVT nursing team were considered for invitation to 
participate in the interview regarding their personal experience of accelerated 
transfusion, providing they had administered both standard rate and 
accelerated transfusions. A letter of invitation to participate was sent to their 
workplace address (appendix K). The letter was accompanied by an 
information sheet (appendix L). The practitioner was offered an opportunity 
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to discuss the study further with the chief investigator if required. A response 
form and envelope was provided but a telephone response or email was also 
accepted. The returned consent/response forms were retained securely by 
the Chief Investigator in the research site file. 
Pre-Interview Preparation and Consent: Patient and Practitioner 
If the patient or practitioner responded indicating that they wished to 
participate in an interview, contact was made by telephone or in person to 
arrange a mutually convenient date for the interview to take place. The 
venue for the interview was the patient’s home (for patient interviews), or the 
practitioner’s workplace (for practitioner’s interviews). Steps were taken to 
ensure no inconvenience was incurred to the participant.  
Both patients and practitioners agreeing to participate in the interview gave 
valid consent prior to the interview taking place. The statement on the 
consent form was read to the patient/practitioner by the person taking 
consent to ensure understanding (appendix M). The patient/practitioner then 
signed and dated the consent form. The form was securely retained in the 
research site file by the Chief Investigator. 
Interview Procedure: Patient and Practitioner 
The interview took place only after the consent statement had been signed. 
The interview was a semi-structured following the schedule (Appendix J) and 
the duration, not to exceed 60 minutes. The interview was digitally recorded 
and saved as an audio file for the purpose of transcribing the narrative 
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verbatim by a professional transcribing service (www.fingertipstyping.co.uk). 
The transcripts were quality-checked by comparing the audio file content with 
the transcript document and auditable amendments made where required. 
Method Choice and Pre-Analytical Considerations 
Thematic analysis (TA) was chosen as a method to understand the patient 
and practitioner’s experience of standard rate and accelerated transfusion. 
The creation of understanding has implications for the acceptability and 
desirability of service development and change if accelerated transfusion is 
implemented into routine practice. 
TA is used to identify, analyse and report patterns (themes) in data and may 
go on to interpret the data. Boyatzis (1998) regarded TA as principal method 
within the wider field of qualitative analysis, whereas Braun and Clarke 
(2006) argued only lack of clarity and guidelines prevented it being 
considered a distinct method. TA was chosen as a method to analyse the 
data principally because of its flexibility and suitability for early qualitative 
researchers. Unlike most qualitative methods, TA is not bound by a single 
theoretical framework and can be applied across a range of approaches to 
provide detailed and complex insight into the data. The underpinning 
philosophy described earlier in this chapter places the study approach within 
the constructivist paradigm. Braun and Clarke (2006) suggest TA may also 
be considered essentialist, realist or contextualist. This represents another 
area for researcher reflexivity as it may influence analytical decision-making 
when seeking to reflect the ‘reality’ of the research participant’s experience. 
Themes do not ‘emerge’ from the data, rather they emerge from the 
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consciousness of the researcher analysing and reporting the data as an 
active process (Taylor and Ussher, 2001). Therefore the theoretical 
framework is based upon the researcher’s perspective and this must be 
made clear. Braun and Clarke (2006) argue that TA requires a number of 
choices, including that must be made explicit, and their account provides a 
useful framework and is explored in more detail in the following sections. 
Defining a theme 
A theme represents something important in the research question that can 
be identified as pattern in the data set. It is not bound by prevalence or the 
concept of ‘measurement’ in order to assign significance. Semantics used in 
some studies such as ‘many participants’ may indicate prevalence, but 
actually seek to persuade a case to justify the theme. This contrasts with 
content analysis which could have been considered as an alternative method 
for TA in this study, however this is a more deductive and quantitative 
approach and does not align with the underpinning philosophy embodied 
within the qualitative methodological approach discussed earlier. In this 
study, the ‘something important’ in the research question is the 
understanding of experience and therefore the initial coding of transcripts 
focused on participant accounts of feeling or meaning when talking about 
their experience of accelerated transfusion. 
Rich description versus detailed/limited account 
The study seeks to provide a rich and detailed thematic description of the 
whole data sets for both patient and practitioner interviews to ensure the 
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entire dataset for each group are accurately represented. Experience of 
blood transfusion is an under-researched area where a priori assumptions 
should not be made and therefore the research question is limited to gaining 
understanding only. A limited account may have been appropriate if there 
had been a specific research question based upon the finding of previous 
research studies, such as should patients have a choice over the infusion 
rate of their blood transfusion? 
Inductive versus theoretical TA 
As the analysis is not driven by a specific research question or theory, an 
inductive approach is appropriate. Themes are linked to the data themselves 
rather than constraining coding with a pre-developed coding framework 
based upon a priori assumptions or theories. An inductive approach 
maximises diversity especially in the absence of prior research in this area. 
Semantic and latent themes 
The level to which the data are analysed is an important consideration. 
Semantic level analysis is constrained by what is explicitly said, whereas 
latent analysis adds a further dimension which yields additional information 
about underlying meaning of what has been said. Latent analysis was 
expected to yield richer data of patient and practitioner experience in terms 
of unlocking the sentiment of the patient or practitioner’s described 
experience. The interpretive aspect of this accords with the constructivist 
paradigm and produces a report that goes beyond basic description. The 
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data in this study were not deliberately pre-analytically restricted to sematic-
level analysis. Latent analysis was also allowed to be considered. 
Returning to epistemology 
Braun and Clarke (2006) argue that TA can be performed in both 
essesntialist/realist and constructivist paradigms, affecting perspective and 
outcome. This was discussed in the conceptualisation of the study and has 
been revisited here in the discussion on choice of analytical method. 
Although much of the discussion places the approach in the constructivist 
paradigm much of this debate is centred on the researcher’s interpretation of 
constructivism and the extent to which semantic and latent themes play out 
in the data analysis. For example, if latent themes are not readily identified, 
the analysis is based upon language alone. This level of semantic analysis 
would reflect an essentialist/realist approach. If latent themes are identified, 
this would reflect a constructivist approach. Either approach determines how 
meaning is theorised. This was more conclusively demarcated after the 
analysis of the data, allowing epistemological freedom and a more flexible 
approach but acknowledging reflexive influence of this on the reporting 
phase. 
Thematic Analysis Procedure 
Braun and Clarke (2006) describe a six-step guide for TA which is intended 
to be used flexibly, and has procedural similarities to Framework Analysis 
described by Ritchie and Spencer (1994). While Ritchie and Spencer’s 
method could arguably achieve this, they originally developed their method 
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for social policy research and had been regarded as better suited to 
addressing specific research questions or a priori theories (Srivastava and 
Thomson, 2009). As the research question in this study is open-ended and 
there are no a priori theories to address due to paucity of the literature in this 
area, an open and exploratory approach was required to gain understanding 
of the patient’s and practitioner’s experience of accelerated transfusion. In 
this setting Framework Analysis did not present itself as the most appropriate 
choice of analytical method. 
The Braun and Clarke (2006) step-wise approach is summarised and 
adapted for application in this study as described below in table 10.2. 
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Table 10.2: Six-step Thematic Analysis Procedure 
Step Procedure 
1 Data 
Familiarisation 
Professional verbatim transcription of the audio file and quality 
check audio against transcript including punctuation 
Repeated reading of transcripts 
Consider semantic and latent themes and make notes 
2 Initial Codes Codes are identified as basic segments of data (semantic or latent) 
without losing context 
Data-driven (as opposed to theory-driven) 
3 Search for 
Themes 
Focus on broader level of themes across the codes (combine codes 
into themes) 
Identification of any sub-themes  
Produce initial thematic map 
4 Review Themes Identification and refinement of candidate themes 
Review at code-level: do all coded extracts in the theme appear 
coherent. If so, this forms a developed thematic map. If not, do the 
extracts need to be in a different theme or is the theme wrong? 
Review at data set-level: are the themes valid in relation to the data 
set? Do they tell a story about the data? 
5 Define and 
Name Themes 
Each theme will require a detailed analysis which may be structured 
by any sub-themes identified 
Each theme should itself tell a story, and a broader story of the 
whole data set 
Test the theme by being able to describe the scope and content in a 
few sentences 
Give each theme a concise and informative name and produce a 
final thematic map 
6 Report Write an analytic narrative using examples from the data to form an 
argument to address the research question: what is understood 
about the experience of accelerated transfusion 
This should include interpretive questioning such as: What does the 
theme mean?, What are the assumptions?, What are the 
implications – for example on the acceptability/desirability of service 
model change?, What has caused this?, Why is this expressed/said 
in this way? 
 
The patient and practitioner experience enquiries were conducted as two 
separate thematic analyses on each dataset. This decision was based upon 
patients and practitioners having separate contexts and perspectives, and 
the range of potential experience across both types of research participant. A 
combined analysis of the whole data corpus would not allow separate 
understanding and may increase complexity of the analysis potentially 
compromising overall quality. 
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Precis of Thesis Development 
 A qualitative methodological approach was considered appropriate for 
generating understanding of patient and practitioner experience of 
accelerated transfusion and the implications for service change acceptability 
or desirability 
 The method choice is philosophically underpinned by the constructivist 
paradigm, relativist ontology and subjectivist epistemology at the conceptual 
level. However, this was challenged when considering epistemology in the 
context of the analytical process, depending upon whether latent meaning 
could be identified when conducting the analysis. A definite epistemological 
standpoint was not committed to ahead of the analytical phase, but was 
established after coding because of its influence of the following stages of 
TA 
 Lincoln and Guba (1985) criteria for ‘trustworthiness’ in qualitative research 
was used as a framework to evaluate rigour in method choice and data 
analysis 
 Methods based upon subjectivist epistemology are not inherently biased 
because of diametrical opposition to objectivity. Subjectivity can enhance or 
jeopardise the rigour of qualitative research depending on the effectiveness 
of the researcher’s reflexive awareness 
 Semi-structured interviews were favoured over structured interviews as a 
more descriptive and inductive approach, with the intention of controlling a 
priori assumption, potential for researcher bias and enhancing data quality 
 Thematic analysis was used as an inductive method that flexibly aligned with 
the underpinning philosophy of this stand of the study. It was expected to 
yield richer understanding on patient and practitioner experience of 
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accelerated transfusion compared to the more deductive and quantitative 
method of content analysis 
 Pre-analysis considerations, and the six-step analytical procedure were 
based upon Braun and Clarke (2006)  
 The results and finding for this strand of the study are presented in the next 
chapter 
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Chapter Eleven:  
Strand 3 Results 
 Patient and Practitioner Experience 
Enquiry  
 
The aim of this chapter is to firstly introduce and describe the demographic 
characteristics of the research participants who agreed to be interviewed. 
The following sections are structured as described in table 10.2 in chapter 
ten following the six step process of Thematic Analysis (TA) (Braun and 
Clarke, 2006). The chapter will culminate in a synthesis of the data intended 
to inform and support the potential implementation of accelerated transfusion 
as a service development. 
Patient Characteristics 
Five patients agreed to be interviewed about their experience of receiving 
accelerated blood transfusion. All were male with either primary 
myelofibrosis (PMF) or myelodysplastic syndrome (MDS). The age range of 
the participants at the time of the interview was 62 to 78 years (mean 72.2 
years, median 73 years). All were transfusion-dependent and on long-term 
transfusion therapy programmes with a significant history of receiving 
standard rate transfusion, requiring transfusion every 2 to 4 weeks on 
average. The number of month’s experience of receiving standard rate 
transfusion prior to receiving accelerated rate transfusion as part of the study 
was 6 to 51 months (mean 25.2 months, median 27 months). All had 
 
 
164 
 
received transfusions primarily at home or occasionally on the hospital 
oncology unit.  
Practitioner Characteristics 
Six practitioners agreed to be interviewed about their experience of 
delivering accelerated blood transfusion to patients in their homes. Five were 
experienced female community IV therapy nurses and had significant 
experience of delivering both standard rate red cell transfusion outside the 
study and accelerated rate red transfusion as part of the study. One was the 
service manager who had extensive experience of standard rate transfusion. 
She had not performed accelerated transfusion in clinical practice in this role, 
but had experienced the impact on service delivery. 
Step 1: Data Familiarisation  
Interview audio files were professionally transcribed verbatim and transcripts 
were then quality checked for accuracy against the original audio file. 
Member checking was not performed as a commitment relating to the ethics 
application had been made to reduce burden on the research participants. 
Although this could theoretically compromise credibility, this is balanced with 
the benefits of professional transcription and the quality-checking of 
transcripts against the audio file by a professional who was familiar with the 
patient and the service. Amendments were made, including punctuation 
where this would affect intended meaning. Square brackets were added to 
clarify colloquialisms and preserve context. Audio files and transcripts were 
repeatedly listened to and read to increase familiarity and immersion in the 
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data. Informal notes were then made (appendix N), considering semantic 
and latent themes in order to gain a sense of direction and familiarity with the 
data in preparation for further analysis.  
Step 2: Initial Coding 
Dialogue concerning consent, preamble and generic closing comments were 
demarcated in the transcripts to identify these segments as not requiring 
coding. Using a data-driven, open coding approach the remaining data were 
coded by highlighting segments of the electronic transcript using the 
‘comment’ feature in Microsoft WordTM, taking precautions to ensure context 
was intact. Coding was guided by the relevant aspect of the research 
question: understanding the experience of accelerated transfusion i.e. what 
is being said to convey understanding of this experience?, to ensure the 
scope and focus of decision-making was appropriate. It has been suggested 
that the coder should ask themselves about "What is going on?, What are 
people doing?, What is the person saying?, What do these actions and 
statements take for granted?, How do structure and context serve to support, 
maintain, impede or change these actions and statements?" (Charmaz 2003: 
94-95). Lofland et al (2006) suggested that codes should relate to acts, 
activities, meanings, participation, relationships and settings. Lending from 
different research traditions, their different approaches to coding were 
combined in this study to provide useful structure to focus decision-making 
when coding transcripts and assisting the coder to move from purely 
descriptive to more analytical codes. Each coded segment of data were then 
copied and compiled into a Microsoft ExcelTM spreadsheet with each code 
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occupying a separate workbook within the spreadsheet so that text 
associated each code could be grouped and viewed separately. Table 11.1 
below lists the initial codes identified in the patient dataset with a brief 
definition. 
Table 11.1: Initial codes for patient data 
Code Name Definition 
Personal benefit Benefits of accelerated transfusion to the patient on a personal level 
No concerns No concerns or worries about receiving accelerated transfusions 
Feel same Feeling the same after an accelerated transfusion compared to a standard rate 
transfusion 
Future Seeking clarification about the future of accelerated transfusion 
Makes a difference Accelerated transfusion has made a difference to the patient in some way 
Compliance Putting own wishes aside to help the service 
Saving time Identification of time save by accelerated transfusion 
Restriction Restrictions the service places upon the patient 
Ambivalence Would be happy to have either accelerated or standard rate transfusions 
Care received Relationships and interactions with nursing staff delivering blood transfusions 
Mental discomfort Mental difficulties experienced when receiving a blood transfusion 
Active preference Positive personal preference for either accelerated transfusion 
Problems 
(organisational/clinical) 
Experiences creating negative or positive feelings either due to organisational 
factors or clinical factors 
Family responsibilities The effect of receiving blood transfusions on responsibilities toward family 
members 
Delays/waiting Episodes of delay or waiting to receive a blood transfusion 
Social issues The effect of receiving blood transfusions on social issues 
Lifestyle The impact of accelerated transfusion on lifestyle factors 
Resignation Feelings of being resigned to problems and difficulties associated with receiving a 
blood transfusion 
Lengthiness The perception of blood transfusion taking too long 
Convenience Convenience of shorter blood transfusions 
Altruism A point of view about accelerated blood transfusion that identifies benefit for 
others (patients or service) 
Physical comfort/Discomfort Feelings of comfort or discomfort with standard and accelerated rate transfusions 
Service benefit Benefits of accelerated transfusion on a service level 
Flexibility Flexibility offered by shorter duration transfusions 
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Table 11.2 below lists the initial codes identified in the practitioner dataset 
with a brief definition. 
Table 11.2: Initial codes for practitioner data 
Code Name Definition 
Patient benefit Perceived benefit to the patient from accelerated transfusion 
Mutual benefit Accelerated transfusion has both benefit to the patient and the service 
Service benefit Accelerated transfusion benefits the CIVT service 
Service capacity Accelerated transfusion improves CIVT service capacity 
Challenging practice Lack of belief in historic/current practice for duration of transfusion 
Service capacity pressure Factors that increase demands for the CIVT service 
Failing to meet demands Unable to provide CIVT services as demand outstrips capacity 
Efficient use of resources Best use of existing resources (staff time) 
Social/clinical need 
conflict 
Tension between providing care based upon clinical need and social demands of the 
patients 
Patient time impact Factors that compromise the patient’s use of their time 
Patient preference Perceived preference of accelerated transfusion by patients 
Study benefits Benefits to staff being involved in a research study 
Flexibility/scheduling 
 
Impact of accelerated transfusion on scheduling work and ability to provide flexibility 
to patients, or work flexibly 
Saving time Performing accelerated transfusion saves time 
Intruding Sense of the practitioner intruding in the patient’s home or on their time 
Working conditions Impact of long home visits on satisfaction with working conditions 
Clinical knowledge/skills Application of the practitioner’s knowledge and skills 
Safety Practitioners believing accelerated transfusion is safe based upon their experience 
Support Support practitioners have from the hospital clinical haematology team 
Autonomy Practitioner’s feelings toward having clinical decision-making autonomy 
Practitioner preference Practitioner preference for accelerated transfusion 
Guarded expectations Practitioners having moderated expectations about the benefits of accelerated 
transfusion 
Time-consuming Time-consuming nature of the general blood transfusion procedure 
Job satisfaction Effect of accelerated transfusion on job satisfaction 
Selflessness Practitioners putting patient need first (sometimes above their own), having patient 
focus 
Quality Being able to still provide a quality service over a shorter visit time and heightened 
awareness of achieving timescales 
Home transfusion 
preference 
Patient preference for home transfusion (compared to hospital transfusion) 
Hospital benefit Perceived benefit to the hospital oncology unit by performing accelerated transfusion 
Patient continuity Impact of patient transfusion on allowing the same practitioner to re-visit the patient 
again the same day 
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Social impact Impact of accelerated transfusion on wider social issues for the patient 
Further investment Benefit of further investment to maximise the benefits of accelerated transfusion 
 
 
Step 3: Search for Themes 
Table 11.3 below summarises the identification of themes from the initial 
codes in the patient dataset 
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Table 11.3: Identification of themes in patient dataset 
Code Sub-Theme 1 Sub-Theme 2 Main Theme 
Care received Good standard of care  
 
 
 
General experience  
of blood transfusion 
Lengthiness  
 
 
Frustrations 
Restriction 
Delays/waiting 
Resignation 
Problems 
(organisational/clinical) 
Restriction 
Mental discomfort  
Discomfort Physical comfort/Discomfort 
Makes a physical 
difference  
 
 
Personal Benefits 
 
 
 
Benefits of accelerated 
transfusion 
Convenience  
Makes a difference  
to lifestyle 
Flexibility 
Social issues 
Family responsibilities 
Saving time 
Service benefits Service benefits 
Feel same  
Reassurance 
 
 
Accelerated transfusion in 
future practice 
No concerns 
Active preference  
Preference Ambivalence 
Altruism  
Thinking of others Compliance 
Future Future 
Notes on organisation of themes 
Personal benefit Became sub-theme 2 
Makes a difference Became sub-theme 1 and combined with Lifestyle 
Lifestyle Became sub-theme 1 and combined with Makes a Difference 
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Table 11.4 below summarises the identification of themes from the initial 
codes in the practitioner dataset. 
Table 11.4: Identification of themes in practitioner dataset 
Code Name Sub-Theme 
1 
Sub-Theme 
2 
Main Theme 
Guarded expectations Guarded expectations  
Going forward Safety Safety 
Further investment Further investment 
Practitioner preference Practitioner preference Going forward/practitioner benefits 
Study benefits Study benefits  
 
 
Practitioner benefits 
Working conditions Working conditions 
Autonomy Delivery of role 
Clinical knowledge/skills Delivery of role 
Support Delivery of role 
Job satisfaction Delivery of role 
Challenging practice Challenging practice  
 
Problems with current service 
Failing to meet demands Capacity 
Service capacity pressure Capacity 
Time-consuming Time 
Patient time impact Time Problems with current service/perceived 
patient benefit 
Home transfusion 
preference 
Home transfusion preference  
Perceived patient benefit Social impact Social impact 
Patient benefit Patient benefit 
Patient preference Patient preference Feelings about patients/perceived patient 
benefits/ 
going forward 
Selflessness Selflessness  
Feelings about patients Intruding Intruding 
Social/clinical need conflict Social/clinical need conflict Feelings about patients/shared interests 
Patient continuity Patient continuity Shared interests 
Saving time Saving time Shared interests/ service benefits 
Quality Quality  
 Hospital benefit Hospital benefit 
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Service capacity Service capacity Service benefits 
Efficient use of resources Efficient use of resources 
Flexibility/scheduling Flexibility/scheduling Service benefits/shared interests 
Notes on organisation of themes 
Patient benefit Became main theme Perceived Patient Benefit 
Mutual benefit Became main theme Shared Interests 
Service benefit Became main theme Service Benefits 
 
The themes and inter-dependencies shown in table 11.3 identified from the 
patient dataset illustrated as a hand-drawn initial thematic map shown in 
figure 11.1 below. 
 
Figure 11.1: Initial thematic map for patient dataset 
Steps 2 and 3 required an iterative process where codes and themes were 
tested and re-worked. At the end of this process no new codes or themes 
were identified when analysing the final patient and practitioner transcripts. 
 
 
172 
 
This suggested data saturation had been reached for each dataset as 
defined earlier. 
The themes and inter-dependencies shown in table 11.4 identified from the 
practitioner dataset illustrated as a hand-drawn initial thematic map shown 
in figure 11.2 below.  
 
Figure 11.2: Initial thematic map for practitioner dataset 
 
Step 4: Review of Themes 
The themes were firstly reviewed at code-level to evaluate whether the 
codes appeared coherent within their designated theme. The extracts within 
each code were consolidated into a separate ExcelTM spreadsheet workbook 
by theme. The theme was validated by re-reading the coded extracts at 
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dataset level (patients and practitioners) to ensure there was a clear story 
within each theme with respect to understanding the experience of 
accelerated transfusion for each set of participants. Table 11.5 below 
summarises the outcome of this procedure. 
Table 11.5: Review of themes 
Dataset Coherence of code 
within theme 
Validity of theme 
within dataset 
Summary of Changes 
Patient 
 
 
             
              
                 
              
Simplification of initial thematic maps and 
renaming of subthemes without material 
changes to coding.  
 
 
Practitioner               
           
                
             
Main themes Feelings About Patients and 
Perceived Patient Benefits were combined and 
renamed Vicarious Patient Experience.  Shared 
Interests was removed and split between 
Vicarious Patient Experience (Social/Clinical 
Need Tension sub-theme) and Service Benefits 
(Continuity sub-theme was combined into the 
Service Delivery sub-theme ) 
 
The changes made as a result of this review were used to produce 
developed hand-drawn thematic maps as shown below in figures 11.3 and 
11.4. 
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Figure 11.3: Revised thematic map for patient dataset 
 
 
Figure 11.4: Revised thematic map for patient dataset 
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Step 5: Definition and Naming of Themes 
Braun and Clarke (2006) suggest testing each theme by the ability to clearly 
and concisely describe it in a few sentences. The purpose of this is an 
assurance check for theme coherency. Table 11.6 below lists the main 
themes and sub-themes for each dataset with a brief description. 
Table 11.6: Description of themes and sub-themes for each dataset 
Patient Dataset 
Theme Sub-theme Description 
General 
Experience of 
Blood 
Transfusion 
Care Patients both recognise and forgive problems they experience with 
hospital transfusion – the good experience of care outweighs the 
problems experienced 
Problems Patients experience frustration because of the length of time involved in 
receiving a transfusion, with an impact on their level of comfort and this 
is amplified when transfusion is received in the hospital environment. 
Benefits of 
Accelerated 
Transfusion 
Personal Improved comfort and convenience was experienced to varying 
degrees and was patient-dependent. The impact of saved time and 
effect on comfort varied from neutral to highly positive across both 
home and hospital transfusions. 
Service There was patient insight into how accelerated transfusion could benefit 
delivery of the home transfusion service by increasing efficiency. 
Accelerated 
Transfusion in 
Future Practice 
Self The patients did not experience a difference in how they felt after 
accelerated transfusion and this was reassuring to them. Preference for 
accelerated transfusion ranged between ambivalence to enthusiasm 
and was dependent upon the patient’s personal circumstances. 
Others There was a sense of altruism in understanding the potential positive 
effect on service efficiency above their own needs, but also a sense of 
reticence to commit to a preference because of a desire to not take 
advantage. 
Practitioner Dataset 
Theme Sub-theme Description 
Problems with 
Current Service 
Evidence Evidence for standard rate transfusion was doubted because of their 
prior experience, and practitioners indicated that patients shared this 
view 
Time  Practitioners experienced frustration with the time-consuming nature of 
blood transfusion and had concerns about how this impacted on the 
patient’s time. 
Capacity Practitioners had experienced challenges with meeting the growing 
demands of the service due to the volume and diversity of intravenous 
treatments. They felt the service was under pressure and a duty to 
ensure resource was being used as effectively as possible. 
Vicarious Patient 
Experience 
Patient Focus Practitioners showed a great deal of empathy and concern for the 
patient’s quality of life and were committed to patient-focussed care to 
avoid adverse impact on the patient’s social issues, time, freedom and 
comfort. 
Patient Time 
Saved 
The release of time allowed practitioners to more readily shift the focus 
for patients from life-limiting illness and contact with healthcare, to 
‘normal life’. 
Patient 
Preference 
Patients preferred home compared to hospital transfusion in their 
experience and they reported that had received positive feedback about 
accelerated transfusion from patients in terms of preference, 
satisfaction and popularity. 
Social/Clinical 
Need Tension 
Practitioners recognised from past experience that some patients may 
actually prefer longer transfusions because of a desire for company, 
even if this was not clinically necessary, leading to a tension between 
balancing the social and clinical care needs of the patient and 
delivering an efficient service. 
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Practitioner 
Benefits 
Role Accelerated transfusion gave practitioners a sense of increased job 
satisfaction through the application of their knowledge and skills in well 
supported autonomous practice for the benefit of the patient. 
Preference The experience of accelerated transfusion had led to positive feelings 
toward implementing it into routine practice. 
 
Service Benefits Resource Practitioners felt that the releasing time while performing accelerated 
transfusion had increased service capacity for blood transfusion and 
other IV treatments, and avoided hospital admission. Existing resources 
were being used more efficiently without compromising quality. 
 
Delivery There was improved scheduling of work through the benefit of 
enhanced flexibility that accelerated transfusion allows, including better 
patient continuity. Both patients and the service can use time more 
effectively. 
 
Accelerated 
Transfusion in 
Future Practice 
Confidence There was positive practitioner preference for accelerated transfusion 
and perceived patient preference. Experience of performing 
accelerated transfusion had affirmed trust in their safety. 
 
Consolidation There was a mixture of guarded expectations for the longer-term impact 
of accelerated transfusion and the desire to see increased staff 
resource to maximise its benefit, and an eagerness to implement into 
routine practice. 
 
Final theme and sub-theme names were decided by relating the short 
descriptions shown above to the preliminary name to ensure they support a 
clear and coherent final thematic map. Final theme and sub-theme names 
are shown below in table 11.7. 
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Table 11.7: Final theme and sub-theme names 
Patient Dataset 
Theme New Theme Name Sub-theme New Sub-Theme Name 
 
General Experience of 
Blood Transfusion 
Patient General 
Experience of Blood 
Transfusion 
Care Care Received 
 
Problems - 
 
Benefits of Accelerated 
Transfusion 
- Personal Personal Benefits to 
Patient 
 
Service Service Benefits 
 
Accelerated Transfusion 
in Future Practice 
- Self Effect on Self (Patient) 
 
Others Effect on Others (Service) 
 
Practitioner Dataset 
Theme New Theme Name Sub-theme New Sub-Theme Name 
 
Problems with Current 
Service 
Problems with Current 
CIVT Service 
Evidence Doubting the Evidence for 
Safe Infusion Rate 
 
Time  Time-Consuming 
Treatment 
 
Capacity Service Capacity Pressure 
 
Vicarious Patient 
Experience 
Practitioner Perception 
of Patient Experience 
Patient Focus Patient Needs 
 
Patient Time Saved Appropriate Use of Patient 
Time 
 
Patient Preference - 
 
Social/Clinical Need 
Tension 
- 
Practitioner Benefits Practitioner Benefits of 
Accelerated Transfusion 
Role Role Benefits 
 
Preference - 
 
Service Benefits Service Benefits of 
Accelerated Transfusion 
Resource Resource Benefits 
 
Delivery Service Delivery Benefits 
 
Accelerated Transfusion 
in Future Practice 
- Confidence Confidence in Desirability 
and Safety 
 
Consolidation Consolidation into Routine 
Practice 
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The renamed themes and sub-themes were then transposed into the final 
thematic maps shown below in figures 11.5 and 11.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.5: Final thematic map for patient dataset 
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Figure 11.6: Final thematic map for practitioner dataset 
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Step 6: The Report 
 
The following section is an analytic narrative using examples from the data to 
address the research question: what is understood about the patient and 
practitioner’s experience of accelerated transfusion? Through exploration of 
experience, the report addresses the meaning of each theme in the 
respective datasets whilst considering the implications of the acceptability 
and desirability of service-model change. 
Patient Dataset 
The Patient’s General Experience of Blood Transfusion 
The patients who agreed to be interviewed had a long and frequent 
experience of receiving blood transfusion as part of the treatment for their 
haematological condition. All had blood transfusions both on the oncology 
day unit, and at home from the CIVT team. There was a universal account of 
frustration and resignation due to problems associated with blood 
transfusions both inherent to the transfusion process itself and those which 
were service-related. There was a sense of lowered expectations and 
resignation to the transfusion process being intrinsically lengthy and this was 
compounded by infusion problems which sometimes occur unpredictably. It 
was important to recognise this as a general theme because of the 
background level of negative feeling toward blood transfusion per se, 
regardless of the duration of the infusion itself. Morris was the most articulate 
and verbally enthusiastic participant providing the greatest diversity of codes 
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and themes, and this is reflected by the number of quotations included in the 
report. 
Morris: “Before you know it, two hours have gone and you’re just 
starting, type thing, but the best thing I do now is just...it’s a day so 
don’t worry about it.” 
Morris: “I could feel my arm and I knew there was something going 
wrong with it. As it turned out, she’d missed it completely [vein] and it 
was going straight in my muscle, and for about three weeks 
afterwards, I had a totally black arm from there to there. It literally was 
black. It looked like gangrene arm.” 
There was also some questioning of whether the length of transfusion was 
necessary, as the process of receiving blood is much longer than the 
donation process. 
Morris: “As I seem to remember, when I was giving blood, it seemed 
to be about a 20 to 30 minute process when they took one bag out [of 
me]…” 
In addition to this, frustration was expressed with the additional restrictions, 
delays and length of time spent on the hospital oncology unit when home 
transfusion was not possible.  
Morris: “It seemed to go on for an awful long time, but then I realised 
that A, they haven’t got blood on the premises so they have to go out 
every time to get it; even though I’m taking two bags, they can’t pick 
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two bags at a time up; they have to do it one at a time. So quite often, 
because they’re very, very busy; I’ve been in there sometimes in the 
unit [hospital oncology unit] and they’re just parading through. It’s like 
non-stop and you’re lucky if there’s somewhere to sit even. And 
they’re run off their feet I think, quite often, so you could be there an 
hour before anything happens.” 
Richard: “It’s so busy up there [hospital oncology unit] as well, it really 
is, it’s unbelievable” 
Patients were forgiving of this recognising the workload pressures of the 
hospital nursing staff. Frustrations with problems experienced on the hospital 
oncology unit were tempered with expressions of sympathy and gratitude 
toward the nursing staff for the high standard of care they received in what 
they observed as difficult circumstances. 
Morris: “I have struggled sometimes, trying to find somewhere to park 
but once I’m in, everybody’s very helpful. I can’t believe the attention 
I’m getting actually. It’s great.” 
Morris: “I mean, they’re very nice up there, lovely up there, aren’t 
they?  You know, they bring sandwiches round and tea, you know, so 
yes that’s not a problem”. 
Benefits of Accelerated Transfusion 
Patients perceived the benefit of accelerated transfusion on two levels: 
personal benefit, and benefit to the service. Patients were aware that they 
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sometimes had to attend the hospital oncology unit for their regular blood 
transfusions because the CIVT team were unable to offer them a home 
transfusion visit at the time they required their transfusion because of service 
capacity issues. A connection was made as to how this linked with 
accelerated transfusion in future practice and the importance on its potential 
effect on increasing service capacity and is discussed further in the theme on 
future practice. 
Reginald: “And they asked me would I go down to help them rather 
than have it at home because they were a bit short [of staff]…and I 
had experienced the [oncology unit] prior, when [CIVT] has been 
busy” 
For some, home transfusion was important to support their ability to perform 
their carer role.  
Richard: “They decided that it was best to continue it here [transfusion 
at home] because of W [grandson to whom he is sole carer]” 
Patients expressed positive feelings and preference for accelerated 
transfusion, reporting shorter duration transfusions could improve their 
physical and mental comfort whilst receiving treatment.  
Richard: “It’s just so boring, isn’t it [standard rate transfusion]?” 
Reginald: “…because you did get a little bit uncomfortable because 
you’re sat still, in the two hour one, yeah, it [accelerated rate] 
improved that a lot” 
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Jack: “Well, to sit here for er, three hours [for standard rate 
transfusion] is quite a long time really even though I’ve got a 
comfortable settee. So, you know, once I’ve had it done I’m up and 
walking about just, yeah, my legs are going again ’cause I’ve quite a 
bit of problems with my legs so as soon I get exercise a bit, as soon 
as I’ve had it really” 
Jeffrey: “I get my lunch earlier [laughs] [with accelerated] ‘Cause it 
always happens over the sort of lunchtime period ‘cause it doesn’t 
start ‘til about eleven o’clock so it means I get a late lunch if it’s an 
extended one as opposed to an accelerated one” 
Some stated they could use time saved for other things or expressed 
satisfaction in not being engaged in healthcare for as long, as well as the 
freedom and convenience of being able to plan and use their day better. 
Reginald: “That’s how I felt personally because sometimes if you tried 
to arrange things you had to say, because you don’t necessarily know 
what time [the CIVT team] are coming, if they came, say, after half 
past eleven, I knew then there was nothing I could do afterwards, 
because by the time everything was over it was a little bit too late.  
Where on the shorter one [accelerated transfusion] it gave me that 
more freedom where I thought “right I can do something afterwards, I 
can nip in town or whatever” 
Reginald: “I found it then gave you time at the end of the day to 
actually achieve something [accelerated transfusion]” 
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The positive language use when describing accelerated transfusion 
suggested that patients had felt they had been enduring constraints in their 
day-to-day life because of the length of the standard transfusion treatment 
times and this had not only affected them socially but also emotionally. 
Reginald: “but because I was on the shorter one [accelerated 
transfusion] this time found it a lot more convenient, and it didn’t get 
you down.  You know because in hospital it does take a little bit longer 
because they’ve not got both blood bags ready, and I found going to 
the [oncology unit] a lot, lot easier, same at home” 
Some patients also reported benefits of shorter treatment times when having 
transfusions in the oncology unit when they were unable to have home 
transfusions. Although this was not the focus of the study it was an important 
finding in terms of the potential wider application of accelerated transfusion. 
Reginald: “Particularly because I had one done in hospital at the 
[oncology unit] because they [CIVT team] were busy, I found that 
brilliant because it meant you weren’t in the [oncology] unit nowhere 
near as long” 
Many patients were enthusiastic about the benefits they had experienced 
from having accelerated transfusions, while others were ambivalent. The 
degree of benefit experience was variable and largely dependent upon the 
personal circumstances of the patient.  
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Jack: “Er, not really [accelerated transfusion does not make a 
personal difference], no ‘cause I’m retired so I don’t do much. I just…I 
don’t do a lot these days” 
This also linked to the theme relating to future practice (and discussed 
further in the next section). 
Accelerated Transfusion in Future Practice 
The positive feelings and preference expressed for accelerated transfusion 
suggested that patients would be supportive of introducing this into routine 
practice. None of the patients reported medical or wellbeing problems with 
accelerated rate transfusion. Where there was some minor initial concern 
expressed, the experience of participating in the study was reassuring.  
Reginald: “you were a little bit concerned in the beginning wondering 
how it would affect you, for the first one or two, but after that when I 
didn’t feel, me personally, I didn’t feel any different having it in two 
hours than what it was when I was having it in three hours.  So after 
that I was quite comfortable with it. And I had no real concerns.  It’s 
just that feeling beforehand, you know, thinking is it a bit fast?  
[Laughter]…And I’ve had no different feeling than the three hour one” 
 
Some patients said standard rate transfusion would not necessarily 
negatively impact them if they had to have standard rate transfusion at 
home, whereas some were enthusiastic about continuing with accelerated 
transfusion.  
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Jeffrey: “No, I don’t think it makes much difference because it’s only 
… we’re only talking about an hour at the outside”   
Richard: “It’s just, I don’t know… it seems far better, you know.  It’s 
brilliant really [accelerated transfusion]” 
 
This partly related to personal circumstances where shorter duration of 
treatment would not provide any significant personal benefit (and discussed 
in the previous theme on benefits of accelerated transfusion), and partly 
related to the patient’s attitude toward the service itself. There was an explicit 
and implicit sense of altruism in that there was a clear recognition that 
accelerated transfusion could improve home transfusion service-capacity 
(and oncology unit processes), and this was important whether or not it 
benefitted the individual patient.  
Jeffrey: “And, of course, it’s an advantage to you, not you personally, 
but to the community nurses because it means they can treat more 
patients during the day if you’ve got an extra hour spare when they’re 
not dealing with the normal transfusion” 
Jeffrey: “Well, I just think it’s better for everybody really, for all the 
patients as well as the nurses. It means I can think about other people 
who need the same treatment and everybody benefits then” 
 
This was also implicit in that some patients reported a lack of ‘worthiness’ to 
qualify for home transfusion and communicated a sense of gratefully 
accepting whatever the service had to offer (a willingness to compliantly fit 
the service). Despite understanding the potential benefits to home 
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transfusion service capacity by implementing accelerated transfusion, 
patients still expressed a self-sacrificing attitude. This may have moderated 
their willingness in expressing an overt positive preference. 
Morris: “Hmm, but I think, knowing how much they are run off their 
feet, you just feel a little bit unfair that you’re taking advantage having 
it at home. Just go in and join the rest of the group” 
Richard: “I’d choose the hour one [accelerated transfusion] obviously, 
because it’s quicker and, you know, if you had to do the longer one, it 
wouldn’t make any difference” 
 
Practitioner Dataset 
Practitioner Perception of Patient Experience 
The practitioners expressed their perception of the patient’s experience more 
strongly than the patient’s description of their own experience. This vicarious 
account was given without prompting showing that the practitioner’s main 
concern was delivering care in the best interest of the patient, given that the 
premise of the interview was to understand the practitioner’s experience of 
accelerated transfusion. The theme comprised of sub-themes relating to 
preference for accelerated transfusion, patient needs, and appropriate use of 
the patient’s time. The practitioners felt that patients preferred accelerated 
transfusions as it increased their freedom by shortening the home visit time. 
Rose: “I think it’s just how popular that they are…the accelerated 
transfusions really. The patients that I’ve been to see who have 
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experienced both and they are definitely preferring a bit more freedom 
that we’re going to be in for maximum of three hours, rather than four 
or five hours” 
They felt that saving the patient time was important in allowing them to have 
more control over their lives and this was an important aspect of delivering 
holistic care to the patient by recognising their wider, non-clinical needs. 
Rose: “They can schedule things…their own daily schedules as well. 
The fact that they can go shopping afterwards or beforehand and get 
everything ready, it is their freedom and that’s what the team, I think, 
always promote anyway. What we want is their quality of life and their 
treatment because we want them to be empowered” 
Rose: “It is very focused on them. I mean the blood transfusions at 
home service always is very patient focused anyway but we can really 
extend that quality time [due to accelerated transfusion]” 
Appropriate use of patient time was a significant factor. There was a strong 
desire to help the patient improve their quality of life by the ability to mitigate 
the negative effects of prolonged contact with healthcare through shortening 
treatment time with accelerated transfusion. 
Erin: “Yes, you know these people you know they’re not older, they’re 
actively involved in the family and they’re not able to pick the 
grandchildren up from school so actually it’s a knock on effect on the 
whole of the family because we’re transfusing later on in the 
afternoon, they’re not quite sure what time we’re going to finish. So 
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actually they’ve had to make alternative arrangements and then it’s a 
knock on effect for the whole family, yes so it [shorter treatment time] 
fits in with their lifestyle a little bit more” 
Rose: “Obviously when we go and see them it does take up a big part 
of their day. When they know that we’re only going in for that short 
period [accelerated transfusion] we can usually give them… morning 
or afternoon. They can get on with their life, they can prepare. They 
know that we're only going to be there maximum three hours, tops and 
then we’re away. They can get on with their lives and improve their 
quality of life, really” 
The sense of intrusion on the patient’s time and the desire to respect it and 
use it appropriately also translated into intrusion into the personal setting of 
the patient’s home environment. The practitioners were highly aware that 
their presence could be seen as an imposition and the time spent in a 
patient’s home should be as short as possible, and that accelerated 
transfusion supported this. 
Cindy: “Well, you’re not like invading their home environment for like a 
whole day” 
Esther: “I think it gives patients more satisfaction because we’re not in 
the houses as long” 
This sense of intrusion was made acute by patient’s life-limiting conditions, 
anything that mitigated this would be positive for the patient’s experience.  
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Elizabeth: “…at the end of the day some of these patients are very 
unwell and time is a factor for them and they want to fit things in, 
they’ve got grandchildren they want to go visiting friends or whatever.   
So rather than you being there longer they can say well it’s only a 
couple of hours so I can make arrangements to go out in the 
afternoon because time is a factor for them because a lot of patients 
are very unwell and they don’t know how long they’ve got left 
basically… an afternoon to us might mean nothing but to them it 
means a lot” 
A tension between clinical and social needs was also evident. There was a 
conflict between delivering clinical care appropriate to service resources 
whilst providing pastoral aspects of care relating to the social needs of the 
patient. They felt that a lonely patient may prefer a longer treatment time 
because of the social benefits of longer contact with the nurse, and this was 
at odds with comments separately expressed about running the service 
efficiently. 
Elizabeth: “some patients do like you being there and some 
patients…don’t get a lot of visitors and can’t get out so when you go 
they love it because it’s somebody to chat with and discuss.  So from 
that point of view they might feel a little bit, “Oh I wish you was staying 
a little bit longer.” 
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Problems with the Current CIVT Service 
The time-consuming nature of blood transfusion continued into the theme on 
problems with the current service. There were frustrations about how this 
impacted upon service capacity as the service was under increasing 
pressure not only for accepting more home transfusions but also delivering 
and increased volume and diversity of new or additional intravenous 
treatments.  
Olivia: “Just length of treatment really [problems with standard rate 
transfusion] and capacity in the team, ‘cause they could take, kind of, 
six hours with picking up equipment and taking equipment back again” 
Rose: “We’ve got a huge impact with an increased workload with 
different antibiotics that are coming on at the moment” 
The increased pressure to accept more referrals had caused practitioners to 
question evidence for safe rates of transfusion. 
Elizabeth: “Yeah because you’re tied up with that transfusion longer 
[with standard rate transfusion] somebody else is going back in the 
afternoon to do the afternoon dose of antibiotic because you’re still 
with your patient that’s having a transfusion” 
Esther: “Lengthy, very lengthy” 
Olivia: “They were too long for the volume of fluid that was being 
infused [standard rate transfusion]” 
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Olivia: “I think they [patients] couldn’t understand why they took so 
long because there weren’t huge volumes of fluid “ 
Esther: “I mean, it used to be four hours at one time. It was four hours, 
per unit, when I…[inaudible but inferred many years ago]” 
Service Benefits of Accelerated Transfusion 
The experience of delivering accelerated rate transfusions during the study 
(i.e. without formal workload analysis) had shown practitioners resource 
benefits in terms of service capacity in that the time saved could be used to 
provide additional treatment slots and avoid hospital admission. 
Olivia: “it [accelerated transfusion] frees clinical time up for other 
treatments that – being shorter, so we can fit more transfusions in a 
day and more IV other treatments as well.  Just because it’s not as 
time-consuming” 
Erin: “since we’ve been doing the accelerated transfusions we’ve now 
been doing TDS [three times a day] antibiotics so there is, you are 
able to do your first morning’s IV antibiotics at half eight and still get 
back for their afternoon treatment of antibiotics and do a transfusion in 
the middle. So it kind of, it works quite well, yes you have got that 
time” 
Elizabeth: “perhaps because of staff levels we can only fit one 
transfusion in we could perhaps now take two patients on one day 
rather than one which is good for the patients as well because they’re 
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getting their transfusions in a timely manner rather than having to wait 
or to come into hospital when they’ve not need to come into hospital” 
They also reported service delivery benefits as saving time with accelerated 
transfusion had allowed better patient continuity and flexibility in staff 
rostering. 
Elizabeth: “if you’ve got like patients that are on three times a day 
[antibiotics] you can manage your time better knowing that you can 
perhaps do an IV in the morning an IV antibiotic in the morning, your 
transfusion and perhaps go back in the afternoon as well, so you’ve 
got a follow on with your other patients as well with their IV antibiotics” 
Practitioner Benefits of Accelerated Transfusion 
Practitioners expressed an overwhelming preference for accelerated 
transfusion where medically possible. 
Rose: “The accelerated transfusion is fantastic and really, really good 
but like I said we are well aware, as clinicians, that if we need to we 
can reduce and go back to standard [rate transfusion]” 
Practitioners described benefits to their own role in terms of job satisfaction. 
They felt a greater sense of autonomy in that accelerated transfusion allowed 
greater opportunity to exercise clinical skills and judgement while feeling well 
supported by the clinical haematology team in the hospital.  
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Erin: “I do like the aspect that you can deviate as we see fit. So you’re 
going in to do an accelerated transfusion and it’s up to our discretion 
with the patient and we can deviate to a normal transfusion” 
Rose: “I think as well, the freedom has been as well that as we’ve 
gone in and we’ve assessed patients, and usually we know the 
patients really, really well, and we can tell as well whether to 
accelerate or not. There have been incidents where we’ve said we’re 
not accelerating today and we’ve gone back to standard transfusion 
rate. Again, that’s probably our knowledge and skill but the flexibility 
we can have with that as well” 
Erin: “You know knowing that I’ve got the support of the haematology 
team you know I’m their eyes and ears and yes whatever I see is you 
know they will support me 100% and act on what I’ve said…I’ve 
deviated from it a couple of times when I’ve been worried about the 
patients and yes the support that I’ve received from the haematology 
staff has you know been faultless” 
There were additional practical benefits to practitioners if less time is spent in 
the patient’s home and this would improve their working conditions. This was 
expressed discreetly as the connotation was that some patient’s homes, 
although met a basic standard for medical treatment, were not necessarily 
somewhere they would want to spend more time than needed.  
Cindy: “Erm, well, yeah, because it … I have to say, in some cases 
you don’t want to be in a particular environment any longer than you 
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really need to be.  Erm, so that's been a positive for us that we can go 
in, get the job done and be out a lot sooner”  
Esther: “Some environments are very good and some are very poor, 
so with the shorter transfusions, you’re not in the houses as long so 
it’s – it does help us [accelerated transfusion]” 
Accelerated Transfusion In Future Practice 
Practitioner preference for accelerated transfusion extended into views on 
the future of accelerated transfusion in the CIVT service and a desire to see 
it continue for both the service and patient benefit. 
Rose: “I think let’s just carry on and just keep it going really, and keep 
the service” 
Olivia: “I think it would be a definite step back if you went back to the 
regular [standard rate transfusions]…especially for patients that [had] 
accelerated [transfusions], they [patients] wouldn’t understand the 
rationale of going back [to standard rate]” 
Practitioners appeared to be reassured, albeit slightly guarded, about the 
safety of accelerated transfusion and had not experienced any adverse 
events in clinical practice. 
Erin: “And I personally, I have not had any negative or bad 
experiences by doing the accelerated transfusion, touch wood, I've not 
ever had anybody have a, a reaction or a bad effect from it so it’s 
been good” 
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Cindy: “I haven’t had a negative experience whilst doing them.  So no, 
it, it seems to work very well for those that I've done anyway” 
Together with their perception of patient preference and service benefit, this 
contributed to practitioner endorsement of implementing accelerated 
transfusion into future routine practice without affecting any aspect of service 
quality. 
Esther: “They still get a quality of service from us, but on a shorter 
length of time” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
198 
 
Precis of New Knowledge: Implications for the Acceptability and 
Desirability of Service Model Change 
 Both patients and practitioners expressed frustration and 
dissatisfaction with the general blood transfusion process (especially 
where this took place in hospital).  
 Experience of accelerated transfusion had been positive and 
alleviated some of the negative experience of standard rate 
transfusion.  
 Patients felt accelerated transfusion was safe and identified benefits 
to themselves, and/or to others and the wider service, sometimes 
framed in a desire to obligingly take the service on offer as opposed 
actively expressing a preference.  
 Practitioners felt that shorter treatment time was in the interests of the 
patient although acknowledging that some patients may actually 
prefer prolonged visits for social reasons. Interestingly, this was not 
recounted by patients themselves. 
 Practitioners had experienced benefits to the capacity and delivery of 
the service, and felt increased job satisfaction.  
 Practitioners felt their patients gained benefit from accelerated 
transfusion and that the procedure was safe.  
 These findings suggest that both patients and practitioners would 
support the implementation of accelerated transfusion into routine 
practice and that change to the proposed service model would be both 
acceptable and desirable. 
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Chapter Twelve:  
Discussion and Conclusion  
 
This concluding chapter revisits the research problem and reviews how it 
was addressed in the context of the contextual and conceptual framework as 
described in the introductory chapters. The findings are then summarised 
and discussed, while critically evaluating the extent to which the research 
question has been answered and the hypotheses addressed. Specific 
attention is paid to the strengths and limitations of the study and the impact 
of the research on contribution to knowledge and clinical practice, with 
recommendations for clinical practice and further research. 
 
Problem: The Divergence of CIVT Service Capacity and Demand 
Additional pressure of new and diverse intravenous treatments and the 
increased demand for home transfusion outstripped service capacity for this 
relatively small and highly skilled team. Achieving increased capacity within 
current staff resources relied on finding new and efficient ways of delivering 
the service, so that it may continue to benefit patients and avoid in-patient 
admissions. One of the variables in the current service model is treatment 
delivery time per home visit. This posed the question as to whether red cell 
transfusion infusion time could be safely reduced, leading to the concept of 
‘accelerated transfusion’, and whether this would be acceptable and 
desirable to patients and practitioners. 
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Revisiting the Research Question and Hypotheses 
The following research question and hypotheses were developed from the 
conceptual framework. 
General Research Question 
Whether transfusing two units of red cells over 60 minutes per unit 
(accelerated transfusion) is safe and could potentially increase CIVT service 
capacity, while gaining understanding of the patient’s and practitioner’s 
experience. 
Hypotheses 
The following hypotheses were developed for the quantitative aspects of the 
research question: 
 H1: Two units of red cells transfused over 60 minutes each can be 
physiologically tolerated in selected patients (H0 there is no difference 
in the incidence of Transfusion Associated Circulatory Overload 
(TACO) between standard and accelerated rate transfusions). This 
requires ‘proving’ the null hypotheses. 
 H1: Implementation of accelerated transfusion could potentially 
increase CIVT service capacity (H0 Implementation of accelerated 
transfusion would not potentially increase CIVT service capacity). 
The qualitative strand of the study was value-adding, seeking to inductively 
gain understanding of patient and practitioner experience without a priori 
theories and therefore hypotheses were not appropriate. 
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Headline Findings 
The outcome of the study as a whole suggests that accelerated red cell 
transfusion (two units not exceeding 5ml/Kg/Hr) does not appear to cause 
increased harm, could potentially increase the CIVT service capacity, and 
implementing this service change would be acceptable and desirable to both 
patients and practitioners. The research question was answered and 
hypotheses accepted subject to qualification and critique in the following 
sections.  
Summary and Critical Review of Findings in Relation to the Research 
Question and Hypotheses 
Safety/Physiological Enquiry 
This strand of the study was a prospective cohort study based upon a binary 
outcome non-inferiority method which sought to demonstrate that 
accelerated transfusion was no more often associated with TACO than 
standard rate transfusion. The aim of this strand the study was effectively to 
accept the null hypothesis by demonstrating the accelerated transfusion 
procedure is no worse, in terms of patients developing signs of TACO, than 
the current standard rate transfusion procedure. The study was therefore be 
defined as a binary outcome non-inferiority study as there were two possible 
outcomes (TACO, or no TACO). Medical exclusion criteria were developed in 
order to exclude patients from the study with co-morbid conditions and risk 
factors that may predispose circulatory overload. These were developed 
from haemovigilance data where associations had previously been identified 
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in the literature between patient characteristics and the development of 
TACO. Each patient had a standard rate transfusion followed by at least one 
accelerated rate transfusion. A clinical assessment, including vital sign 
observations, were performed pre-transfusion, and at around 24 hours after 
the transfusion to assess the patient for signs of TACO.  
The target number of participants based upon the sample size calculation 
was 39 to power the study to 80%. The number of patients recruited (25) fell 
short of the target but was the maximum achievable in terms of patients 
agreeing to participate in the study in the time available. The sample size 
calculation was highly problematic because of issues with the accuracy and 
representativeness of data used for the calculation.  Firstly, TACO may be 
under-reported to SHOT and/or clinically under-recognised and affects the 
numerator and therefore estimate of incidence. This is further compounded 
by very limited and highly variable data in the literature regarding the 
incidence of TACO and even less in this particular patient group being 
studied. The number of red cell units transfused nationally was a best 
estimate. Red cell wastage had to be estimated based upon average 
wastage data reported by the national Blood Stocks Management Scheme, 
and this was subtracted from the number of units issued. This affects the 
accuracy for the denominator data used to estimate the incidence of TACO 
relating to red cell transfusions where two or fewer units were transfused. 
Sample size and power calculations based upon data relating to the local 
incidence of TACO were considered unreliable due to the potential for a 
relatively rare event skewing fewer denominator data and that the TACO 
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cases did not represent the population being studied. Despite the difficulties 
and limitations in determining sample size, it was important to address this 
as far as was practical with the benefit of all available data and evidence, as 
this was a requirement when applying for ethical approval. However it is 
important to state that failure to meet the number of target participants, 
notwithstanding the limitations of the data used for the calculation, does not 
allow a judgement to be made about non-inferiority. 
Twenty-five patients had standard rate transfusions with a total of 269 
accelerated rate transfusions completed in total. Accelerated transfusion 
(total infusion time for two units is 120 min +/- 10% (108 to 132 minutes) was 
achieved in 87.3% of transfusion episodes (269/308). No cases of TACO 
were detected in the study. Outcome by patient demonstrated no difference 
between standard and accelerated rate transfusion for the development of 
symptoms and signs of TACO (RR = 1.0, OR = 1.0, p =1.0000). Although the 
confidence intervals (CI) crossed 1.0, indicating there was no difference 
between both groups in the study, the CI’s were wide meaning the true RR 
and OR could indicate increased or decreased risk of TACO by accelerated 
transfusion. However logically decreased risk is not a feasible outcome in 
this study. 
Analysing the outcome data by transfusion episodes reduced the RR and OR 
to <1.0 which indicated a reduced risk of TACO in the accelerated 
transfusion group, which again is not logically feasible. It also had the effect 
of narrowing the CI but this still crossed 1.0 indicating that the RR and OR 
analyses are not informative. 
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This type of analysis is difficult to reliably interpret with a small sample size 
and for rare events when the desired and expected positive/bad outcomes 
(TACO) for both interventions are expected to be zero. Computational 
problems will arise in the case of zero events and the statistical method 
made an arbitrary correction for this (Pagano & Gauvreau, 2000; Deeks & 
Higgins, 2010). Such manipulation of the data could have introduced error. 
This is an inherently difficult study to design with the objective of confidently 
demonstrating non-inferiority for accelerated rate transfusion due to the 
unknown true incidence of TACO in this population, and notwithstanding 
TACO is a relatively rare event as this significantly affects the degree of 
confidence in the accuracy of the sample size calculation. The approach was 
theoretically valid but constrained by inherent limitations of the data used for 
the sample size and power calculation. This could be improved by obtaining 
more accurate data on the incidence of TACO in stable adult patients 
receiving red cell transfusion for normovolaemic anaemia. This would need 
to be a large-scale multi-centre audit. At the time of writing, the National 
Comparative Audit of TACO is about to be published, however the scope of 
patients was not limited to stable patients with normovolaemic anaemia or a 
particular infusion rate, though it may be possible to obtain these data with 
permission. Statistical significance could be further improved by increasing 
the size of the study either by continued local data collection on accelerated 
transfusion outcomes, or by expanding as a multi-site study. This would 
allow improved comparison of the incidence of TACO in the ‘standard rate’ 
population compared to the ‘accelerated rate’ population using more 
numerically balanced data. At the time of writing, the surveillance definition 
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for TACO is undergoing review and a consensus is expected in the near 
future. As TACO is the endpoint of the study, universally agreed and 
validated criteria would also improve the quality of the study.  
The conclusion drawn from this study is that accelerated transfusion did not 
cause harm but was unable to confidently demonstrate non-inferiority to 
standard rate transfusion. The study does however add credence to ‘proof of 
concept’ for 5ml/Kg/hr transfusion in this patient group and could therefore 
be regarded as a successful pilot study. 
Although no cases of TACO were reported, its recognition is partly 
established by adverse changes to the patient’s vital sign observations 
according to current criteria. Andrzejewski et al (2013, p. 3042) proposed 
TACO as a “multi-phasic spectrum entity” where the condition may be 
regarded as mild to severe with a commensurate change blood pressure 
among other parameters. Multi-way comparisons were performed to 
demonstrate differences between standard and accelerated rate transfusions 
to explore whether subtle, non-pathological changes occurred which may be 
an early sign of circulatory overload.  There was a statistically significant 
difference between pre and post-transfusion mean arterial pressure (MAP) in 
standard rate transfusion (p = 0.0441) and the first three accelerated 
transfusion (p = 0.0036 to 0.0187), however the increase was not within the 
pathological range. This is in disagreement with Gehrie et al (2015) who 
demonstrated no difference in pre and post transfusion vital sign 
observations in a large data set, and proposed this could be used for 
distinguishing benign and pathological changes. However this study 
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comprised of all types of blood component and was not limited to red cell 
transfusion in patients with normovolaemic anaemia. There was no 
consistent difference in variance of pre and post-transfusion vital sign 
observations when standard and accelerated rate transfusion were 
compared. The mean arterial pressure (MAP) appeared to increase within 24 
hours of transfusion regardless of whether the transfusion was infused at a 
standard or accelerated rate, with the group mean remaining within the 
normal physiological range. If the increase in MAP was related to ‘early 
TACO’ then there is no evidence that accelerated transfusion causes this 
more than standard rate transfusion. It may also be speculated that the non-
pathological increase is a normal physiological response to treated anaemia 
or may have been a chance finding in a relatively small patient sample. 
Service Capacity Enquiry 
This strand of the study was based on workload audit and an evaluation of 
patient eligibility for accelerated transfusion. It was designed to evaluate 
treatment delivery time of the current and the proposed service models 
where in the latter a proportion of transfusions could potentially be at an 
accelerated rate, and how this could potentially affect service capacity. This 
strand of the study aimed to demonstrate the potential impact of accelerated 
transfusion on CIVT service capacity. The analysis showed that 57% (26/46) 
of haematology patients fulfilled the medical inclusion criteria and were 
therefore eligible for accelerated transfusion, demonstrating that accelerated 
transfusion could be offered to a significant proportion of patients being 
transfused at home. 49% (224/459) of home transfusion episodes were 
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eligible to be performed as accelerated rate transfusions. This percentage 
depends upon the medical eligibility and intensity of transfusion in individual 
patients, but nevertheless demonstrates that a significant proportion of the 
home transfusion workload could be performed as accelerated transfusions. 
The analysis showed that if accelerated transfusion was implemented for 
both haematology and medical patients, service capacity could be increased 
by 105 nursing hours per year. This could potentially be utilised for additional 
patient visits whether for transfusion or other IV therapies. 
The calculated increase in service capacity is an indicative estimate based 
upon the potential reduction in treatment time and its impact on the overall 
length of an average visit. This does not illustrate the actual impact of 
nursing-hours released on service activity as this would depend on how the 
nursing-hours could be most profitably utilised. For example, if an hour was 
released by performing an accelerated transfusion in the morning, would this 
be sufficient time for that practitioner to perform an additional IV treatment 
later that working day? The dynamics of planning work for a team are more 
complicated than a simple assessment of treatment time and numbers of 
patients. Other factors include travel time, skill-mix and patient continuity. To 
assess the actual impact on service capacity would require a post-
implementation audit comparing pre-study capacity and post-implementation 
capacity. Adjustment would need to be made for confounding factors such as 
actual total nursing hours available across each of the audit periods, 
accounting for staffing levels and absences. Standardised productivity pre 
and post-implementation could then be evaluated by total IV treatments 
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performed as the numerator) and total nursing hours available as the 
denominator. The study shows the potential for increased capacity based 
upon demonstration of nursing-hours that could be saved. This strand of the 
study focussed entirely on impact on capacity from a time-saving 
perspective. This single-dimension analysis was enriched by the benefit of 
understanding the practitioner’s experience of accelerated transfusion on 
service delivery, which revealed service benefits beyond time-saving. This is 
discussed further in the following section. 
Patient and Practitioner Experience Enquiry 
This strand of the study sought to explore and gain understanding of the 
patient’s and practitioner’s experience of accelerated transfusion by thematic 
analysis of semi-structured interview transcripts. Both patients and 
practitioners expressed frustration and dissatisfaction with the general blood 
transfusion process.  This is in agreement with previous limited research on 
patient’s experience of blood transfusion (Weiss Adams and Tolich, 2011). 
Experience of accelerated transfusion had been positive and alleviated some 
of the negative experience of standard rate transfusion.  Patients felt 
accelerated transfusion was safe and identified benefits to themselves, 
and/or to others and the wider service, sometimes framed in a desire to 
obligingly take the service on offer as opposed to actively expressing a 
preference. Some patients expressed ambivalence toward accelerated 
transfusion and this related to their own personal circumstances where a 
shorter treatment time did not necessarily affect their comfort or use of time. 
Although a positive personal benefit was not expressed by some patients this 
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nevertheless indicates that accelerated transfusion is at least acceptable to 
them in terms of implementing service change. Other patients were highly 
positive about the benefits of a shorter treatment time. Practitioners felt that 
shorter treatment time was in the interests of the patient although suggesting 
that some patients may actually prefer prolonged visits for social reasons. A 
significant proportion of CIVT patients live alone and/or are elderly. An Age 
UK evidence review states that loneliness increased with age and is more 
prevalent among people with long-term health issues (Age UK, 2015), which 
agrees with CIVT practitioner perceptions. This dichotomy was highlighted by 
the clinical/social needs tension identified in the thematic analysis, and the 
problem of how this reconciles with service efficiency. The practitioners were 
very focussed on providing holistic care but were also passionate about 
providing the service to all patients who needed it. Interestingly, the issue of 
extending social contact time with standard rate transfusion was not 
recounted by patients themselves. This may be allied to the self-sacrificing 
and altruistic attitudes identified in the thematic analysis. Patients may have 
felt reticent about exposing non-medical needs knowing other patients or the 
service may be disadvantaged as a result. 
Practitioners had experienced benefits to the capacity (without formal 
analysis) and delivery of the service. They felt increased job satisfaction 
through the opportunity for increased clinical autonomy and the benefit of a 
wider supportive clinical haematology team. Practitioners felt their patients 
gained benefit from accelerated transfusion and that the procedure was safe. 
These findings suggested that both patients and practitioners would support 
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the implementation of accelerated transfusion into routine practice and that 
change to the proposed service model would be both acceptable and 
desirable. 
The analysis has provided insight to judge and make recommendations 
regarding desirability and acceptance if implemented into routine practice. 
The interviews were conducted by the researcher and had the benefit of the 
interviewer’s familiarity with the service, providing shared understanding and 
the ability to accurately interpret the dialogue. The thematic analysis was 
undertaken with demonstrable rigour with a clear audit trail of data and 
decision-making. These were particular strengths of this strand of the study. 
Implications for Practice and Contribution to Knowledge 
A number of publications and awards are cited in this section to demonstrate 
how the study has contributed to practice and knowledge, and are fully listed 
in appendix O. 
Safety/Physiological Tolerability of Accelerated Transfusion  
Although the study was not sufficiently powered to demonstrate non-
inferiority to standard rate transfusion, and constrained by uncertainty of the 
incidence of TACO, it can nevertheless be regarded as a successful pilot 
study. The transfusion of two units of red cells over an hour each (not 
exceeding 5ml/Kg/Hr) did not appear to cause harm in this study. The data 
were reviewed by the research team and a decision was taken to implement 
accelerated transfusion into routine practice, while continuing to collect and 
monitor outcome data. A standard operating procedure for accelerated 
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transfusion is being developed at the time of writing and will append the 
Trust Blood Transfusion policy. It is not anticipated that the transfusion will 
be prescribed as ml/Kg/Hr in order to minimise the potential for rate 
calculation errors. The red cells will continue to be prescribed as unit over 
time (60 minutes) with special attention paid to patients weighing less than 
67Kg where volume-selected units will be obtained to avoid an excessive 
infusion rate (>5ml/Kg/Hr). Accelerated transfusion will be available to 
haematology patients who receive transfusion either at home and/or on the 
oncology day unit if they meet the medical inclusion criteria. The data could 
be generalisable to any stable adult patient with normovolaemic anaemia 
also meeting the medical inclusion criteria. It would not be appropriate to 
extend this to inpatients (whether haematology patients or otherwise) with 
normovolaemic anaemia where there could be acute inter-current illness and 
the administration of other intravenous fluids. This situation could potentially 
add further risks for circulatory overload not accounted for in this study.  
The study will change local practice but also adds to the literature and 
knowledge. The study comprehensively critiques the issues with the current 
understanding of the ‘rate’ of transfusion and how this can be meaningfully 
defined. The deconstruction of the ‘rate’ of transfusion has highlighted the 
significant influence of patient body weight and unit volume on the infusion 
rate. It persuades a change from ‘unit over time’ to ‘ml/Kg/Hr’ when 
describing the rate of transfusion.  This not only offers a standardised 
approach which may be useful to future research in this area, but also 
highlights the benefit of a more personalised approach in the smaller patient 
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who may be at risk of circulatory overload due to their smaller blood volume. 
This aspect of the study inspired a project to develop a red cell dosage 
calculator which predicts the volume of red cells required to meet the target 
haemoglobin (Hb) level based upon pre-transfusion Hb level and the 
patient’s body weight. The validation work for this project showed that using 
the patient’s body weight to calculate the dose significantly increased the 
number of patients meeting their target Hb level (Grey et al, 2016). The 
medical exclusion criteria were developed based upon co-morbidities and 
risk factors that have been previously identified in published haemovigilance 
data and this study will contribute to validating those observations. The 
preliminary data from this study was presented as an oral presentation at the 
International Society of Blood Transfusion Congress in 2015 (Grey, 2015) 
which focussed on how haemovigilance data for TACO had contributed to 
developing a framework for patient-tailored rate and volume of transfusion. 
This original work led to an invitation to join an international working-party for 
the revision of the haemovigilance definition of TACO (ISBT, 2017) with 
further opportunities to collaborate and develop this area of research (Bolton-
Maggs et al, 2017b; Grey et al, 2017b) . The author’s research interest in 
TACO also led to an appointment to the Serious Hazards of Transfusion (UK 
haemovigilance scheme) Working Expert Group, which involves analysing 
TACO reports from the UK and writing the chapter for the annual report. This 
has allowed further opportunity to analyse patient comorbidities and risk 
factors for circulatory overload from TACO reports. Thematic analysis of data 
in the 2015 report was used to develop a TACO risk assessment tool to 
assist practitioners at the bedside to identify patients at risk. The use of this 
 
 
213 
 
tool became a formal recommendation in the annual report (Bolton-Maggs et 
al, 2016). The following year the annual data were used to validate the tool 
and with some minor changes it remained a formal recommendation (Bolton-
Maggs et al, 2017a, Grey et al 2017a). The updated tool has a high degree 
of concordance with the medical exclusion criteria developed for this study 
which is reassuring when planning for implementation into routine practice, 
as these criteria will continue to be applied as a safe practice measure. 
Similar to the SHOT recommendation, medical exclusion criteria for 
accelerated transfusion is essentially a risk assessment for patients at risk of 
TACO. This may actually promote the safety of accelerated transfusion 
above standard rate transfusion because acceptance criteria are a formal 
pre-requisite for accelerated transfusion. This may more robustly exclude 
patients at risk of TACO compared to standard practice where pre-
transfusion risk assessment may not be performed as rigorously.  
Service Capacity 
This aspect of the study provided evidence for the potential for accelerated 
transfusion to increase CIVT service capacity. As discussed previously, the 
‘real world’ effect can only be evaluated by a pre and post-implementation 
audit and the positive results of this preliminary assessment provide the 
impetus for this. The study excluded medical (non-haematology) patients due 
to logistical difficulties in recruiting them as research participants. 
Theoretically, accelerated transfusion could be offered to these patients as 
the findings could be generalisable to this population. In practice some 
issues may make this less desirable in this patient group. Medical patients 
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are not subject to the same level of pre-transfusion assessment or 
consultant-led supervision as haematology patients and the research team 
felt this would make them unsuitable for accelerated transfusion. Although a 
significantly smaller patient group, this would still have an impact on service 
capacity if they could not be included. This could be addressed by the 
Clinical Haematology team offering a referral service for non-haematology 
patients who may benefit from accelerated home transfusion, where pre-
transfusion assessment could be better controlled. From a wider perspective, 
this aspect of the study could contribute to the literature on productivity of 
community services. 
Patient and Practitioner Experience 
The insight obtained from the thematic analysis of the interviews provides 
assurance that implementing this service development would be acceptable 
and desirable to both patients and practitioners. This aspect of the study 
adds to the paucity of studies on the general experience of blood transfusion, 
and specifically to the non-researched area of shorter transfusions in the 
context of home transfusion. This aspect of the research was recognised 
with a national award from the Chief Scientific Officer for Engaging Patients 
and Citizens in Healthcare Science (2017). 
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Summary of Recommendations for Clinical Practice 
Table 12.1 summarises the recommendations for implementation and future 
practice. 
Table 12.1: Summary of recommendations for implementation 
Recommendation Planned Date 
A recommendation for implementation into 
practice has already been made to the Trust 
Clinical Governance and Quality Committee 
following approval by the Hospital Transfusion 
Committee 
Approved in July 2017 
Develop a referral pathway for non-haematology 
patients for home transfusion to allow 
accelerated transfusion in this patient group 
Started November 2017 
Develop a Trust protocol for accelerated 
transfusion to append the Trust Transfusion 
Clinical Process policy and submit for Trust 
ratification 
April 2018 
Include accelerated transfusion protocol in 
Clinical Haematology and CIVT team transfusion 
mandatory training 
April 2018 
Commence accelerated transfusion in practice 
(home transfusion and hospital oncology day 
unit) 
 
May 2018 
Audit patients outcomes of accelerated 
transfusions 
 
From commencement (ongoing) 
Perform a pre and post implementation audit of 
service capacity 
12 months post-implementation 
 
Unanswered Questions and Opportunities for Further Research 
At this juncture, the actual impact on CIVT service capacity is not known and 
as previously discussed this will require a pre-study and post-implementation 
audit to be performed. It would also be of interest to assess the impact of 
accelerated transfusion on capacity and patient flow efficiency in hospital 
oncology units. 
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Similarly, it is not known whether ‘accelerated transfusion’ (not exceeding 
5ml/Kg/Hr) is non-inferior to ‘standard rate’ transfusions in terms of patients 
developing TACO. Post-implementation audit will continue locally but there is 
also scope for a larger multi-centre study. A larger study could have a similar 
design, where the patient acts as their own control. Alternatively a larger 
study would allow randomisation to accelerated or standard rate transfusion. 
Depending on the number of participants, this design however could lead to 
unintentional bias due to variation in patient characteristics across each arm 
of the study. It would also have the disadvantage of fewer accelerated 
transfusions taking place overall. 
The study has also raised the question about the actual contribution of 
infusion rate of blood to the development of TACO, and whether this is 
independent of total volume infused and the presence of comorbid conditions 
and risk factors in the patient. As digital applications become more 
widespread in healthcare organisations there is now more potential for ‘big 
data’ analyses. It may now be possible to perform a multiple linear 
regression on these variables to address this question. 
An interesting an unexpected finding in this study was the post-transfusion 
increase in MAP in both standard rate and accelerated rate transfusion, and 
the reason for this could only be speculated upon. The study was not 
designed to investigate this and the finding was based on relatively small 
numbers. Further contributions to the literature concerning changes to vital 
signs during and after red cell transfusion in normovolaemic patients from a 
larger population would be valuable. Beyond this, evidence as to whether the 
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increase indicates physiological or pathological response would also be 
required. Brain Natriuretic Peptide (BNP) testing is routinely used for 
diagnosing and monitoring heart failure and is also been used to support the 
differential diagnosis of pulmonary complications of transfusion. An increase 
of 1.5 times the baseline is compatible with TACO, and therefore a 
pathological increase (Zhou et al, 2005). This could be studied by performing 
serial BNP tests before, during and after transfusion and would indicate 
stretch of the cardiac muscle in response to volume-loading of the 
circulation. Assuming a statistically significant increase in MAP is present a 
concomitant statistically significant (but less marked) increase in BNP may 
indicate a non-pathological physiological response. 
Dissemination of Findings 
Table 12.2 summarises the previous and planned dissemination of findings. 
Table 12.2: Summary of dissemination plan 
Dissemination Method Planned 
Date 
International Society of Blood Transfusion and International Haemovigilance 
Network Conference (oral presentation on preliminary data) 
June  
2015 
Chief Scientific Officer’s Awards and website 
(Partnering Patient’s and Citizen’s in Healthcare Science) 
March  
2017 
Bolton News  
(newspaper article) 
March  
2017 
Laboratory Medicine News  
(local newsletter to Trust and local GP’s) 
March  
2017 
Trust Clinical Governance & Quality Committee, and Trust Acute Adult Care 
Division Governance Committee 
June  
2017 
Original research paper to be submitted to the British Journal of Haematology 
for publication 
By Dec 
2018 
Abstract for the British Society of Haematology Annual Scientific Meeting  
(oral or poster presentation) 
April  
2018 
Letters to surviving patients to thanks them for their participation as research 
participants and inform them of the outcome of the study 
By April 
2018 
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Concluding Remarks –  
A Practice-Based Problem with a Practice-Based Solution 
This study has opened debate about what constitutes a ‘safe’ rate of 
transfusion and challenged the belief that ‘faster’ rates of transfusion cause 
circulatory overload independently of pre-disposing comorbid conditions and 
risk factors. The process of unpacking this dogma has also exposed the 
inconsistencies and lack of standardisation in the literature and in practice 
when referring to the ‘rate’ of transfusion, and how this is significantly 
influenced by the combined effect of patient body weight and volume of 
blood units. Detailed reassessment and re-articulation of practice has 
provided new evidence for safely shortening blood transfusion infusion-time 
in medically selected patients with normovolaemic anaemia. A real-world 
problem of a resource-limited community-based service, challenged with 
meeting capacity demands impelled the team to question practice in order to 
find efficiencies. Having new evidence to change the way blood transfusion 
is delivered at home has potential to improve CIVT service capacity beyond 
blood transfusion. Patient-centred care is at the heart of the CIVT service 
and its individual team members. Importantly, this service development was 
achieved with the input and endorsement of CIVT practitioners and the 
patients who benefit from their care. 
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Appendix A: 
ACTION: CHIEF INVESTIGATOR & CONSULTANT HAEMATOLOGIST 
 
SAE/SAR REPORT FORM (Document L) version 1: ATS2014/Doc(L) 28.08.14 
 
Participant Identifier  
Date of this transfusion 
(DD-MM-YY) 
 
Date of SAE/SAR 
(DD-MM-YY) 
 
What is being reported? 
(SAE or SAR) 
 
 
 
 
 
 
Describe the SAE/SAR 
 
 
 
 
 
 
 
 
 
 
What 
corrective/preventive 
action has been taken? 
 
 
 
Causality Assessment 
(Consultant 
Haematologist) 
Imputabilit
y 
NA 
Imputabil
ity 
0 
Imputabilit
y  
1 
Imputabilit
y 
 2 
Imputability  
3 
Not 
assessable 
Excluded Possible Likely Certain 
 
Rationale for Imputability 
Score 
 
 
 
 
Is external reporting to 
SHOT/MHRA required? 
YES/NO Describe Rationale 
  
 
 
 
For imputability 1-3:  
Does this SAE/SAR 
require termination of the 
study? 
YES/NO Describe Rationale 
  
 
 
 
Chief Investigator Name (PRINT) SHARRAN GREY Date 
Signature  
Consultant Haematologist Name (PRINT)  
Signature  
 
RETURN THIS FORM TO SHARRAN GREY AFTER TRANSFUSION (Original Copy in Site File) 
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Appendix B: 
Accelerated Transfusion Pre-Prescription Check-List  
(Document E) version 1: ATS2014/Doc(E) 28.08.14 
ACTION: PRESCRIBING MEDICAL OFFICER 
Participant Identifier  
Date Transfusion to be Given  
 
I have checked that the patients still complies with the following medical exclusion criteria for 
accelerated (60 minutes per unit) transfusions: 
 
 
 
 
 
 
HISTORY 
Exclude If 
Patient has had echocardiography with reported heart failure. Reported moderate 
to severe left ventricular dysfunction (ejection fraction <35%). All patients with heart 
failure should have had echocardiography as per NICE guidelines. Check whether 
an echocardiogram has been performed previously with the Cardiology Department 
before accepting a patient into the study. 
Severe aortic stenosis 
Hypoalbuminaemia (<35g/L) 
Low body weight (<50Kg) 
Significant renal failure (eGFR <30ml/min) 
Significant liver failure (bilirubin >µ30mol/L) 
 
 
EXAMINATION* 
Oedema 
Cough, dyspnea and/or respiratory rate >20 breaths per minute 
Tachycardia (heart rate >100 beats per minutes) 
Un-treated or uncontrolled hypertension (diastolic >95 mmHg, systolic >160 
mmHg) 
 
*Tick box if not able to examine at the time of writing the prescription (to be assessed as part of 
pre-transfusion clinical assessment 
 
Name 
 
 
Designation  
Signature  
Date  
 
Place this form with the blood prescription document 
Return this form to Sharran Grey after the Transfusion (Original to be held in Site File) 
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Appendix D: 
PATIENT INVITATION LETTER   
(Document B1) Version: 2  Ref: ATS2014/Doc(B1)   Date 05.05.14 
 
 
Study Title: Accelerated Blood Transfusion 
 
 
Dear Sir/Madam, 
 
 
We would like to invite you to take part in a research study looking at the 
duration of blood transfusions. 
 
 
A doctor from our Clinical Haematology Team has recommended blood 
transfusion as part of the treatment for your condition. 
 
 
If you are agreeable, we would like to offer you blood transfusion(s) 
administered over a shorter length of time. If you agree, we would also like to 
talk to you about your experience of it. 
 
 
Accompanying this letter, you will have received an information sheet which 
describes in more detail what this study is about. Please take time to read 
the leaflet. If you have questions about any aspect of the study your 
consultant would be happy to answer them. Many thanks for taking the time 
to read this letter and information sheet. 
 
 
If we haven’t heard from you within 2 weeks, we will telephone you once. 
 
 
 
 
Yours sincerely, 
 
 
 
 
Haematology Consultant/Specialty Doctor 
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Appendix E: 
(PATIENT) PARTICIPANT INFORMATION SHEET (Document B2) 
Version: 2   Ref: ATS2014/Doc(B2)  Date:05.05.14 
 
 
Study title: Accelerated Blood Transfusion  
 
Introduction 
 
You are invited to take part in a research study looking at the duration of 
blood transfusions. Your doctor has recommended blood transfusion as part 
of the treatment for your condition. 
 
Before you decide, it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following 
information sheet. Do talk to others about the study if you wish. 
 
Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. This 
leaflet describes what the research is about and what it would involve for 
you. 
 
Part 1 tells you about the purpose of the study. 
Part 2 gives you more detailed information about the conduct of the study. 
 
Background 
 
Red blood cells are made in the bone marrow and carry oxygen around the 
body. Certain diseases and medications can stop red blood cells being made 
or destroy them too early. When this happens, anaemia will develop causing 
tiredness, lethargy and breathlessness. A red blood cell transfusion is a 
treatment given to correct anaemia. Two bags of red cells are usually given 
in one treatment over 90 minutes per bag (3 hours in total). 
 
 
Part 1 
 
What is the purpose of the study? 
 
The aim of this study is to see whether the treatment time for red blood cell 
transfusion (2 bags) can be administered over a shorter period of time, and 
to understand patient’s and nurses experience of it. The study will also 
evaluate impacts on organisational economics and service capacity. 
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Why have I been invited? 
 
Your doctor has recommended red blood cell transfusions as part of your 
treatment and thinks you may be medically suitable to receive your blood 
transfusion over a shorter length of time. 
 
 
Do I have to take part? 
 
It is up to you whether you decide to join the study. You have this information 
sheet to help you decide and we can also answer any questions you may 
have. If you agree to take part, we will ask you to sign a consent form. You 
are free to withdraw at any time without giving a reason. This would not 
affect the standard of care you would receive. 
 
 
What will happen to me if I take part? 
 
The number and frequency of your blood transfusions will not be affected by 
participating in the study. You will always receive the same standard of care. 
 
A nurse or member of the haematology team will weigh you so that we can 
select bags of red cells of a volume that is appropriate to your body weight. 
This will be done at home at a time convenient to yourself. 
 
The first blood transfusion administered in the study will be the standard 
length of time (over 90 minutes per bag – a total of 3 hours). Your vital sign 
measurements (blood pressure, heart rate and breathing rate) will be 
recorded before the transfusion. A member of the team will visit you around 
24 hours after the transfusion to check on you, and record your vital signs 
again. 
 
The second and subsequent transfusion(s) administered in the study will 
be the shorter length of time (over 60 minutes per bag – a total of 2 hours). 
Your vital sign measurements (blood pressure, heart rate and breathing rate) 
will be recorded before the transfusion. A member of the team will visit you 
around 24 hours after the transfusion to check on you, and record your vital 
signs again. 
 
After you have had some shorter transfusions, we may ask if we can come 
and talk to you about your experience of it. This will be in the form of a short 
(no longer than 60 minute) interview that will be recorded on a dictaphone. 
This will allow us to transcribe what has been said later. You can stop the 
recording at any time and ask for words to be deleted or rephrased. The 
recording will not identify you i.e. it will be kept anonymous. The interview will 
take place on a time and date convenient to yourself. We do not expect you 
to be asked to do more than one interview, but it is possible that we may ask 
 
 
vii 
 
for a follow-up interview. You can still take part in the blood transfusion part if 
you don’t wish to be interviewed. 
 
What will I have to do? 
 
We will ask you to be at home and available for a check-up around 24 hours 
after your transfusion, and to take part in one interview at a later date (if you 
agree). All other aspects of you blood transfusion treatment will remain the 
same. Participating in this study will not affect any other treatment you may 
be receiving. 
 
 
What are the possible disadvantages of taking part? 
 
You would have to be available for a small number of additional home visits. 
 To be weighed at the beginning of the study 
 To have a short check-up the day after your transfusion 
 To have one short interview  
 
These visits would be arranged in advance with you for a time that is 
convenient to yourself and where possible combined with other planned 
visits. 
 
 
What are the side-effects of the treatment received when taking part? 
 
There are uncommon side-effects of blood transfusion regardless of the 
duration of the transfusion. These will have been explained to you as part of 
your regular blood transfusion treatment. You will also have been given the 
information leaflet “Receiving Blood Transfusion as a Day Case” which tells 
you about the symptoms of blood transfusion reactions and what to do if you 
suspect a reaction and need medical help. You should follow this guidance in 
exactly the same way after receiving a shorter duration blood transfusion. 
 
Any fluid administered into a vein (including blood) could cause ‘fluid 
overload’ if given too quickly or if an excessive volume is given. In 2011 there 
were 33 patients across the UK who were reported to have developed fluid 
overload after receiving 1-2 units of red cells (out of an estimated 2,255,825 
units transfused in the UK). Fluid overload can cause problems with the heart 
and breathing, and in severe cases can be fatal. The chance of fluid overload 
developing is minimised by recognising patients who may be at risk of fluid 
overload and ensuring they receive fluid (and blood) over a length of time 
appropriate to their condition. The eligibility criteria for participating in this 
study have been designed to take account of this. 
 
What are the possible benefits of taking part? 
 
Having a shorter transfusion will not make your treatment more effective in 
any way, but it will reduce the amount of time you spend receiving it. We 
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cannot promise the study will help you, but the information we get from this 
study may help other people needing regular blood transfusions. 
 
 
What happens when the research study stops? 
 
You will still be offered your blood transfusions as normal. Whether you 
receive them over a standard or shorter duration will depend upon the overall 
outcome of the study and your individual response to shorter transfusions. 
 
 
What if there is a problem? 
 
Any complaint about the way in which you have been dealt with in the study 
or any possible harm you might suffer will be addressed (see part 2 for more 
details). 
 
 
Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you 
will be handled in confidence. The details are covered in part 2. 
 
This completes part 1. If you are interested and you are considering 
participation, please read the additional information in part 2 before making a 
decision 
 
 
Part 2 
 
 
What if relevant new information becomes available? 
 
Sometimes we get new information about the administration of blood 
transfusions. If this happens, the clinical haematology team will tell you and 
discuss whether or not you should continue in this study. If you decide not to 
carry on, the team will make arrangements for your usual treatment to 
continue. If you decide to continue, we may ask you to sign an agreement 
outlining the discussion.  
Or 
Your haematology doctor may decide to withdraw you from the study. He/she 
will discuss the reasons for this with you and arrange for your usual 
treatment to continue. 
Or 
If the study is stopped for any other reason, we will tell you and arrange for 
your usual treatment to continue. 
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What will happen if I don’t want to carry on with the study? 
 
If you withdraw from the study we will need to use the data collected on you 
up to the point at which you withdraw. We would advise you not to withdraw 
before you have had your check-up after your blood transfusion (as this is in 
your best interests). We would ask you if we could use the data collected on 
that visit but if you do not want it to be used then it would be destroyed.  
 
 
What if there is a problem? 
 
Complaints 
 
In the first instance we would ask you to report your complaint to any of the 
following people: 
 
Bolton Community IV Team: 01204 462890 
Clinical Haematology Team: 01204 390511 
Sharran Grey (Chief/Principal Investigator): 01204 390254 
 
We would aim to address any complaint at this stage. If you feel you need to 
take the complaint elsewhere or make a more formal complaint, you should 
contact: 
 
The Patient Advice and Liaison Service (PALS) on by telephone on:  
01204 390193. An answer service is available. You can also email PALS: 
PALS@boltonft.nhs.uk  or you can write to them at: 
 
Patient Advice and Liaison Service (PALS) 
Bolton NHS Foundation Trust 
Minerva Road 
Farnworth 
Bolton 
BL4 0JR 
 
 
Harm 
 
In the event that something goes wrong and you are harmed during the 
research and this is due to someone’s negligence, then you have grounds for 
a legal action for compensation against Bolton NHS Foundation Trust, but 
you may have to pay your legal costs. The normal National Health Service 
complaints procedures will still be available to you. 
 
 
Will my taking part in the study be kept confidential? 
 
Yes. The data relating to the actual blood transfusion part of the study will be 
recorded on paper and you will be identified by code (not by name). The data 
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will be: a checklist to say whether you meet certain medical criteria; your vital 
sign observations before and after the transfusions, and consent forms. This 
data (which will not identify you) will be transcribed into a file that will be kept 
on an NHS computer which is password protected. The paper copies will be 
kept securely on NHS premises. The data relating to the interview (if you 
agree to take part) will also identify you by code (not by name) however you 
need to be aware that quotations from the interview may appear in print. This 
data will be a recording of the interview and will be kept on a computer which 
is password protected and will not be identifiable as you. The data will only 
be accessed or viewed by: Bolton Community IV Team, Clinical 
Haematology Team and the Chief Investigator. All data (paper and computer 
records) will be securely destroyed at the end of the study (no later than the 
end of 2018). 
 
 
Involvement of the General Practitioner/Family Doctor 
 
If you agree to participate in this study a letter will be sent to your GP 
informing them of this for your medical records held by your GP. We will 
obtain your consent before doing so. 
 
 
What will happen to the results of the research study? 
 
The results will be written into a doctoral thesis about accelerated blood 
transfusions by the Chief/Principal Investigator. It is likely the results will also 
be published in a number of medical journals. You will not be identified as a 
participant. Depending upon the outcome of the research, the Clinical 
Haematology medical staff may continue to offer and prescribe shorter 
transfusions for patients who meet the medical criteria. We can inform you of 
the outcome of the study if you wish. 
 
Who is organising and funding the research? 
 
The research is being organised and co-ordinated by: 
 
Sharran Grey (Chief/Principal Investigator) 
Consultant Biomedical Scientist (Blood Transfusion Clinical Lead) 
Royal Bolton Hospital 
Bolton NHS Foundation Trust 
BL4 0JR                                                            Tel: 01204 390254 
 
The other members of the research team are: 
 
Dr Clare Barnes (Consultant Haematologist), Royal Bolton Hospital 
Dr Mark Grey (Consultant Haematologist), Blackpool Victoria Hospital 
Dr Yin Thi (Consultant Haematologist), Royal Bolton Hospital 
Dr Karen Lipscomb (Consultant Cardiologist), Royal Bolton Hospital 
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Dr Krystyna Porczynska (Haematology Specialty Doctor), Royal Bolton 
Hospital 
Dr Heyam Hashim (Haematology Specialty Doctor), Royal Bolton Hospital 
Mrs Louise Merrick (Haematology Clinical Nurse Specialist), Royal Bolton 
Hospital 
Mrs Joanne Bowman (Haematology Specialist Nurse), Royal Bolton Hospital 
Mrs Susan Mikolajewski (Bolton Community IV Team Leader) 
 
No funding has been sought for this research. The only additional equipment 
required for the study was a patient weighing scale (costing approximately 
£200) and has been purchased using funds from the Clinical Haematology 
endowment fund. 
 
 
Who has reviewed this study? 
 
All research in the NHS is looked at by an independent group of people 
called a Research Ethics Committee, to protect your interests. This study has 
been reviewed and given favourable opinion by: 
 
Research Ethics Committee North West – Preston (14/NW/0229) 
Manchester Metropolitan University Research Ethics Committee 
 
This study relates to research protocol document number:  
ATS2014/Doc(A)(version 1) 
 
 
Further Information and Contact Details 
 
General Information about the research 
 
Bolton Community IV Team: 01204 462890 
Clinical Haematology Team: 01204 390511 
Sharran Grey (Chief/Principal Investigator): 01204 390254 
 
If you have specific questions (including advice as to whether you should 
participate), you will be directed to the appropriate member of the team 
depending on the nature of your question. 
 
If you wish to speak to an independent person outside the research team 
about participating in this study, you can contact Alison Loftus (Research and 
Development Co-ordinator) at the Royal Bolton Hospital) on 01204 390390. 
 
These numbers can also be used if you have any concerns during the study. 
 
Emergency contacts numbers and advice are listed in your ‘receiving blood 
transfusion as a day case’ booklet. 
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What to do next 
 
If you would like to be a participant in this study, please ring the Clinical 
Haematology Office on 01204 390511, or inform the doctor/nurse at your 
next clinic appointment. We will then make arrangements to take your 
consent to be involved in the study. 
 
 
Thank you for taking time to consider this study. 
Yours Sincerely, 
 
 
 
 
 
 
Sharran Grey  
Consultant Biomedical Scientist/Blood Transfusion Clinical Lead 
(Chief/Principal Investigator) 
Royal Bolton Hospital 
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Appendix F: 
(PATIENT) PARTICIPANT CONSENT FORM  
(Document B3) Version: 1   Ref: ATS2014/Doc(B3)  Date: 12.01.14 
 
Accelerated Transfusion Study 
 
Patient (Participant) Study Number:   
Patient’s Date of Birth: 
Patient’s Initials: 
                                                      
       
1. I wish to participate in this study. I confirm that I have read and understood the information 
sheet (ATS2014/Doc(B2), version number 2). I have had the opportunity to consider the 
information, ask questions (if any) and have had these answered satisfactorily. 
2. I understand that my participation is voluntary and I am free to withdraw at any time without 
giving a reason, without my medical care or legal rights being affected. 
3. I understand that if I withdraw, the data collected from me up to that point will be used in the 
study. 
4. I agree to the storage of my personal information (paper and electronic) for the purposes of 
this study (until the end of 2018). I understand that any information that could identify me will 
be kept strictly confidential and that no personal information will be included in the study 
report or other publication. 
5. I understand that the relevant sections of my medical notes and data collected in this study 
may be looked at my individuals from Bolton NHS Foundation Trust, Research Ethics 
Committees or regulatory authorities, where it is relevant to my taking part in this research. I 
give permission for these individuals to access my records. 
6. I agree for a doctor from the Clinical Haematology Team to assess my medical history to 
check that I am medically suitable to take part in this study, and that he/she may decide in my 
best interests that I am not suitable for shorter transfusions at some point in the study. 
7. I agree to my General Practitioner (GP) being informed by letter of my participation in this 
study   
8. I understand that the nurse administering my blood transfusion will check my willingness to 
continue in the study before every transfusion. 
9. I agree to being invited to be interviewed about my experience of shorter transfusions and 
that I can decline if I decide later that I do not wish to be interviewed. 
 
 
 
(Original copy to be held in Site File                1 Copy in patient’s medical notes) 
 
 
 
 
 
 
 
 
 
 
 
 
Name of Patient Signature of Patient Date form Signed 
   
Name of Investigator Taking 
Consent 
Signature of Investigator 
Taking Consent 
Date form Signed 
   
Patient 
Initials 
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Appendix G: 
Accelerated Transfusion Study  
Document C Version: 1   Ref: ATS2014/Doc(C)   Date: 12.01.14 
 
Dept. Clinical Haematology, 
Royal Bolton Hospital, 
Bolton. BL4 0JR 
Tel: 01204 390511 
Dr [GP Name] 
[Surgery Address]      Date: xx/xx/xx 
 
Dear Dr [GP Name], 
Re: Patient SURNMAME, First name, date of birth, NHS number, Address 
This letter is to inform you that the above named patient has recently agreed to take part in a research 
study. I am contacting you with this information with the patient’s written permission so that you have a 
record of this for their medical records held by your surgery. 
The research is being conducted in the Clinical Haematology Department at the Royal Bolton Hospital 
and will study accelerated transfusion in selected patients (mainly receiving transfusions at home). 
Patients will receive their usual two unit blood transfusions over a standard duration (90 minutes per 
bag), and then over a shorter duration (60 minutes per bag). Some patients will also be invited to take 
part in an interview to talk about their experiences of having a shorter transfusion. 
Patients have been carefully assessed against medical criteria regards predisposition to risk of fluid 
overload due to co-morbidities, and selected for participation accordingly. 
Please contact me, or the Clinical Haematology Team at the Royal Bolton Hospital should you have 
any further questions. 
Yours Sincerely, 
 
Sharran Grey (Chief/Principal Investigator) 
Consultant Biomedical Scientist/Blood Transfusion Clinical Lead 
Royal Bolton Hospital 
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Appendix H: 
ACTION: REGISTERED NURSE PERFORMING TRANSFUSION 
 
CONFIRMATION OF WILLINGNESS TO CONTINUE IN STUDY  
& PRE-TRANSFUSION CLINICAL ASSESSMENT (Document F)  
Version: 2   Ref: ATS2014/Doc(F)   Date: 19.12.14 
 
Participant Identifier  
Date of this transfusion 
(DD-MM-YY) 
 
Confirm that the patient is willing to 
continue in the study 
YES 
(circle) 
NO 
(circle) 
Sign  
Date  
Assessment Criteria Expected Range Actual Value 
Heart rate (beats per minutes) Less than 100/min  
Blood Pressure (systolic mmHg) Less than 160 mmHg  
Blood Pressure (diastolic mmHg) Less than 95 mmHg  
Respiratory rate (breaths per minute) Less than 20/min  
Cough and/or dyspnoea Not present  
Significant Oedema Not present  
Red Cell Unit 1 Start Time  Stop Time  
Red Cell unit 2 Start Time  Stop Time  
 
If any of the above criteria are not met, or the patient does not want to continue in the study, administer 
the transfusion over the standard duration of 90 minutes per unit.  Annotate the prescription 
accordingly. If there are any significant concerns about the patient’s condition, contact the Clinical 
Haematology Team for advice (01204 390511). 
Arrangements for Post-Transfusion Check-Up 
Check-up not required: Patient accepted 
invitation to self-report (there have been 
3 or more previous accelerated 
transfusions without adverse event) 
I have discussed self-
reporting with the 
patient and checked 
they have an 
info/contact booklet 
Tick Initial 
State time agreed with patient for 24 hour 
post-transfusion check-up 
 
State who will be performing the 24 hour 
post-transfusion check-up 
 
Has the person performing the 24 hour 
post-transfusion check-up been notified 
and their availability agreed? 
 
Practitioner performing above assessment Name (PRINT)  
Signature  
 
RETURN THIS FORM TO SHARRAN GREY AFTER TRANSFUSION (Original Copy in Site File) 
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Appendix I: 
24 HOUR POST-TRANSFUSION CLINICAL ASSESSMENT (Document G) Version: 2     Ref: 
ATS2014/Doc(G)  Date: 19.12.14 
 
ACTION: BCIVT NURSE/BCIVT SUPPORT STAFF/CHIEF INVESTIGATOR 
 
Participant Identifier  
Date of Transfusion   Time Transfusion 
Ended 
 
 
If any of the above expected criteria are not met, contact the Clinical Haematology Team for 
advice (01204 390511 or air call consultant haematologist via switchboard 01204 390390). 
State who has been contacted: 
Date and Time of contact:  
State advice received: 
 
If there are any significant concerns about the patient’s condition and/or the patient is acutely unwell, 
arrange for ambulance transfer to hospital. 
RETURN THIS FORM TO SHARRAN GREY (Original to be held in Site File) 
Assessment NOT required 
(3 or more previous accelerated transfusions and patient wishes 
to self-report) 
INITIAL 
Assessment REQUIRED 
(less than 3 previous accelerated transfusions/patient does not 
wish to self-report) 
INITIAL 
Assessment Criteria Expected Range Actual Value 
Heart rate (beats per minutes) Less than 100/min  
Blood Pressure (systolic mmHg) Less than 219 mmHg  
Blood Pressure (diastolic mmHg)   
Respiratory rate (breaths per minute) Less than 20/min  
Cough and/or dyspnoea Not present (NP)  
Significant Oedema Not present (NP)  
Are there any other signs of acute 
illness? 
Not present (NP)  
Has there been ANY adverse event in 
the past 24 hours? 
No  
Date of this assessment 
(DD-MM-YY) 
 
Time of this assessment 
(24 hour clock) 
 
Practitioner performing this 
assessment/completing form 
Name (PRINT)  
Signature  
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Appendix J: 
Interview Schedules (Document K) Version: 1   Ref: ATS2014/Doc(K)   Date: 12.01.14 
Patient Interview 
Introduction 
 Start recording and state consent to record has been obtained [consent form must be signed 
first] 
 Say why recorded interview is needed (accuracy, nothing left out, can go back) 
 State the interview reference (research participant identifier X: on [date]) 
 The recording will be anonymous, but may not be confidential (your words may appear in 
print) and read by others though you won’t be identifiable. 
 Purpose of interview is to gain your views of shorter transfusions. You have been selected 
because you have received both standard rate and shorter transfusions. 
 I will ask you some questions – please feel free to reply as you wish. There are no right or 
wrong answers. I just want your personal opinions and experience. 
 Feel free to interrupt, ask me to repeat/clarify, or criticise a line of enquiry… 
Warm-up 
 Is there anything you’d like to ask me before we move on? 
 I don’t have a long list of questions because I want you to be able to tell freely me what you 
think -think of this more of a ‘chat’ 
Main Body 
Topic Headings/Key Questions Probes and Prompts 
Is there anything particular you want to tell me 
about your experience of receiving standard rate 
and shorter blood transfusions? 
Are there any positives or negatives? 
Do you have a preference? 
Have I asked you the right questions to 
understand your views and experience? 
What is your personal view? 
Can you tell me more about that? 
What makes you say that? 
 
Cool Off 
 Is there anything you would like to add? 
 Do you think we have missed any important areas? 
 Is there anything you wish I’d asked? 
Closing Comments/Closure 
 That brings us to the end of the interview 
 I will now listen to the recording and transcribe it onto the computer 
 Would you like a copy of the transcript? 
 Thanks very much for your time and for agreeing to be interviewed 
 Collect all notes together as a cue the interview is over 
 Ensure no further discussion then switch off the recorder 
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Practitioner Interview 
Introduction 
 Start recording and state consent to record has been obtained [consent form must be signed 
first] 
 Say why recorded interview is needed (accuracy, nothing left out, can go back) 
 State the interview reference (research participant identifier X: on [date]) 
 The recording will be anonymous, but may not be confidential (your words may appear in 
print) and read by others though you won’t be identifiable. 
 Purpose of interview is to gain your views of shorter transfusions. You have been selected 
because you have administered both standard rate and shorter transfusions. 
 I will ask you some questions – please feel free to reply as you wish. There are no right or 
wrong answers. I just want your personal opinions and experience. 
 Feel free to interrupt, ask me to repeat/clarify, or criticise a line of enquiry… 
Warm-up 
 Is there anything you’d like to ask me before we move on? 
 I don’t have a long list of questions because I want you to be able to freely tell me what you 
think – think of this more of a ‘chat’ 
Main Body 
Topic Headings/Key Questions Probes and Prompts 
Is there anything particular you want to tell me 
about your experience of administering standard 
rate and shorter blood transfusions? 
Are there any positives or negatives? 
Do you have a preference? 
Have I asked you the right questions to 
understand your views and experience? 
What is your personal view? 
Can you tell me more about that? 
What makes you say that? 
Cool Off 
 Is there anything you would like to add? 
 Do you think we have missed any important areas? 
 Is there anything you wish I’d asked? 
Closing Comments/Closure 
 That brings us to the end of the interview 
 I will now listen to the recording and transcribe it onto the computer 
 Would you like a copy of the transcript? 
 Thanks very much for your time and for agreeing to be interviewed 
 Collect all notes together as a cue the interview is over 
 Ensure no further discussion then switch off the recorder 
 
 
 
 
 
xix 
 
Appendix K: 
PRACTITIONER INVITATION LETTER  (Document D1)  
Version: 2     Ref: ATS2014/Doc(D1)  Date: 05.05.14 
 
 
Study Title: Accelerated Blood Transfusion 
 
 
Dear Sir/Madam, 
 
 
We would like to invite you to take part in a research study looking at the duration of 
blood transfusions. 
 
 
We are currently recruiting selected patients to this study which involves receiving 
blood transfusion(s) over a shorter length of time. As a practitioner in the Bolton 
Community IV Team you may administer shorter length transfusions to your patients 
during the course of this study. 
 
 
If you agree, we would like to talk to you about your experience of it. 
 
 
Accompanying this letter, you will have received an information sheet which 
describes in more detail what this study is about. Please take time to read the 
leaflet. If you have questions about any aspect of the study I would be happy to 
answer them. Many thanks for taking the time to read this letter and information 
sheet. 
 
 
If I haven’t heard from you within 2 weeks, I will telephone you once. 
 
 
Yours sincerely, 
 
 
 
 
Sharran Grey (Study Chief/Principal Investigator) 
 
Consultant Biomedical Scientist/ Blood Transfusion Clinical Lead 
Royal Bolton Hospital 
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Appendix L: 
 (PRACTITIONER) PARTICIPANT INFORMATION SHEET (Document D2) 
Version: 2     Ref: ATS2014/Doc(D2)  Date: 05.05.14 
 
 
Study title: Accelerated Blood Transfusion 
 
Introduction 
 
You are invited to take part in a research study looking at the duration of 
blood transfusions.  
 
Before you decide, it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following 
information sheet. Do talk to others about the study if you wish. 
 
Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. This 
leaflet describes what the research is about and what it would involve for 
you. 
 
Part 1 tells you about the purpose of the study. 
Part 2 gives you more detailed information about the conduct of the study. 
 
Background 
 
Red cell transfusions are administered to patients who have anaemia due to 
disease and/or medication. For many patients in the study, this will be a long-
term treatment. Two bags of red cells are usually given in one treatment over 
90 minutes per bag (3 hours in total). 
 
 
Part 1 
 
What is the purpose of the study? 
 
The aim of this study is to see whether the treatment time for red blood cell 
transfusion (2 units) can be administered over a shorter period of time (60 
minutes per unit), and to understand patient’s and nurses experience of it. 
The study will also evaluate impacts on organisational economics and 
service capacity. 
 
 
Why have I been invited? 
 
As a practitioner in the Bolton Community IV Team, you may be 
administering shorter duration red cell transfusions to your patients over the 
course of this study. 
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Do I have to take part? 
 
It is up to you whether you decide to join the study. You have this information 
sheet to help you decide and we can also answer any questions you may 
have. If you agree to take part, we will ask you to sign a consent form. You 
are free to withdraw at any time without giving a reason. This would not 
affect you professionally or the standard of care your patients receive 
 
What will happen to me if I take part? 
 
After you have administered some shorter transfusions to your patients, we 
may ask if we can come and talk to you about your experience of it. This will 
be in the form of a short (no longer than 60 minute) interview that will be 
recorded on a dictaphone. This will allow us to transcribe what has been said 
later. You can stop the recoding at any time and ask for words to be deleted 
or rephrased. The recording will not identify you i.e. it will be kept 
anonymous. The interview will take place on a time and date convenient to 
yourself. We do not expect you to be asked to do more than one interview 
(but it is possible that you may be asked for a follow-up interview). Interviews 
will take place during work time. 
 
What will I have to do? 
 
If you agree to take part in an interview and you have some experience of 
administering shorter transfusions, the Chief Investigator will contact you to 
make arrangements to conduct the interview. This will be on a mutually 
convenient date and can be done at your workplace or elsewhere if you 
prefer. 
 
What are the possible disadvantages of taking part? 
 
You will be required to find some time for the interview, but any 
inconvenience should be minimised by arranging this on a convenient date 
and place. The discussion should not involve anything that is sensitive or 
emotionally distressing.  
 
What are the possible benefits of taking part? 
 
We cannot promise the study will help you personally, but the information we 
get from this study may help future patients needing regular blood 
transfusions. 
 
 
What if there is a problem? 
 
Any complaint about the way in which you have been dealt with in the study 
or any possible harm you might suffer will be addressed (see part 2 for more 
details). 
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Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you 
will be handled in confidence. The details are covered in part 2. 
 
This completes part 1. If you are interested and you are considering 
participation, please read the additional information in part 2 before making a 
decision 
 
 
Part 2 
 
 
What will happen if I don’t want to carry on with the study? 
 
If you withdraw from the study we would need to use the data collected from 
you up to the point at which you withdraw.  
 
 
What if there is a problem? 
 
Complaints 
 
In the first instance we would ask you to report your complaint to: 
Sharran Grey (Chief/Principal Investigator): 01204 390254 
 
We would aim to address any complaint at this stage. If you feel you need to 
take the complaint elsewhere or make a more formal complaint, you should 
contact: 
Gilbert Wieringa (Laboratory Medicine Clinical Lead) on 01204 390421 
 
Harm 
 
If you are harmed during the research and this is due to someone’s 
negligence, then you have grounds for a legal action for compensation 
against Bolton NHS Foundation Trust, but you may have to pay your legal 
costs. The normal National Health Service staff complaints procedures will 
still be available to you. 
 
 
Will my taking part in the study be kept confidential? 
 
Yes. The data relating to the interview will identify you by code (not by 
name), however you need to be aware that quotations from your interview 
may appear in print. This data will be a recording of the interview and will be 
kept on an NHS computer which is password protected. The data will only be 
accessed or viewed by the Chief Investigator. All data (paper and computer 
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records) will be securely destroyed at the end of the study (no later than the 
end of 2018). 
 
 
What will happen to the results of the research study? 
 
The results will be written into a doctoral thesis about accelerated blood 
transfusions by the Chief Investigator. It is likely the results will also be 
published in a number of medical journals. You will not be identified as a 
participant. We can inform you of the outcome of the study if you wish. 
 
 
Who is organising and funding the research? 
 
The research is being organised and co-ordinated by: 
 
Sharran Grey (Chief Investigator) 
Consultant Biomedical Scientist (Blood Transfusion Clinical Lead) 
Royal Bolton Hospital 
Bolton NHS Foundation Trust 
BL4 0JR                                                            Tel: 01204 390254 
 
The other members of the research team are: 
 
Dr Clare Barnes (Consultant Haematologist), Royal Bolton Hospital 
Dr Mark Grey (Consultant Haematologist), Blackpool Victoria Hospital 
Dr Yin Thi (Consultant Haematologist), Royal Bolton Hospital 
Dr Karen Lipscomb (Consultant Cardiologist), Royal Bolton Hospital 
Dr Krystyna Porczynska (Haematology Specialty Doctor), Royal Bolton 
Hospital 
Dr Heyam Hashim (Haematology Specialty Doctor), Royal Bolton Hospital 
Mrs Louise Merrick (Haematology Clinical Nurse Specialist), Royal Bolton 
Hospital 
Mrs Joanne Bowman (Haematology Specialist Nurse), Royal Bolton Hospital 
Mrs Susan Mikolajewski (Bolton Community IV Team Leader) 
 
No funding has been sought for this research. The only additional equipment 
required for the study was a patient weighing scale (costing approximately 
£200) and has been purchased using funds from the Clinical Haematology 
endowment fund. 
Who has reviewed this study? 
 
All research in the NHS is looked at by an independent group of people 
called a Research Ethics Committee, to protect your interests. This study has 
been reviewed and given favourable opinion by: 
 
Research Ethics Committee North West - Preston (14/NW/0229) 
Manchester Metropolitan University Research Ethics Committee 
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This study relates to research protocol document number: ATS2014/Doc(A) 
(version 1) 
 
Further Information and Contact Details 
 
General Information about the research 
 
Sharran Grey (Chief/Principal Investigator): 01204 390254 
 
If you wish to speak to an independent person outside the research team 
about participating in this study, you can contact Alison Loftus (Research and 
Development Co-ordinator) at the Royal Bolton Hospital) on 01204 390390. 
 
 
What to do next 
 
Please complete the enclosed form to let us know whether you would like to 
be considered for participation in the study. Please use the pre-paid 
envelope, or hand deliver to the Haematology Department. 
 
Thank you for taking time to consider this study. 
 
 
Yours Sincerely, 
 
 
 
Sharran Grey  
 
Consultant Biomedical Scientist/Blood Transfusion Clinical Lead 
Royal Bolton Hospital 
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Appendix M: 
(PATIENT OR PRACTITIONER) PARTICIPANT INTERVIEW CONSENT 
FORM  
(Document J) Version: 1   Ref: ATS2014/Doc(J)  Date: 12.01.14 
 
Accelerated Transfusion Study 
 
Participant Study Number:   
Participant’s Date of Birth: 
Participant’s Initials: 
                                                      
       
1. I wish to participate in this study. I confirm that I have read and understood the information 
sheet for patients (ATS2014/Doc(B2), version number 2), or information sheet for 
practitioners (ATS2014/Doc(D2), version number 2). I have had the opportunity to consider 
the information, ask questions (if any) and have had these answered satisfactorily. 
2. I understand that my participation is voluntary and I am free to withdraw at any time without 
giving a reason, without my medical care (for patients) or legal rights being affected. 
3. I understand that if I withdraw, the data collected from me up to that point will be used in the 
study. 
4. I agree to the interview being audio recorded using a digital recorder and stored securely on a 
computer, and I understand that I will not be personally identified either in the recording itself 
or files relating to the recording. 
5. I agree to the storage of my personal information (paper and electronic) for the purposes of 
this study (until the end of 2018). I understand that any information that could identify me will 
be kept strictly confidential and that no personal information will be included in the study 
report or other publication. 
6. I understand that anything I say will be anonymous but my words may appear in print. 
 
 
 
Name of Participant Signature of Participant Date form Signed 
   
 
 
 
 
 
 
(Original copy to be held in Site File                1 Copy in patient’s medical notes if patient) 
 
 
 
 
 
 
 
 
 
Name of Investigator Taking 
Consent 
Signature of Investigator Taking 
Consent 
Date form Signed 
   
Participant 
Initials 
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Appendix N: 
Patient interview familiarisation notes  
 Frustrations with the additional restrictions, delays and length of time 
spent on the oncology unit when home transfusion was not possible. 
Patients were forgiving of this recognising the workload pressures of 
the hospital nursing staff [semantic and latent] 
 Importance of home transfusion as a guardian of a child as hospital 
attendance would interfere with carer responsibilities [latent] 
 Accelerated transfusion would improve the physical and mental 
comfort of some patients [semantic] 
 Positive feelings and preference expressed for accelerated 
transfusion [semantic] 
 Some patients said standard rate transfusion would not necessarily 
negatively impact them if they had to have standard rate transfusion at 
home, whereas some were enthusiastic about continuing with 
accelerated transfusion [semantic] 
 No medical or wellbeing problems with accelerated rate transfusion, 
though there was an initial concern expressed [semantic] 
 Using time saved for other things or expressed satisfaction for not 
being engaged in healthcare for as long  [semantic] 
 Frustration with infusion problems (not specific to standard or 
accelerated transfusion) [semantic] 
 Resignation to the transfusion process being lengthy and expectations 
lowered [latent] 
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 Sense of altruism in ensuring best use of services [semantic and 
latent] 
 Awareness of having to attend the hospital oncology units as the 
community IV team was over-capacity [semantic] 
Practitioner interview familiarisation notes 
 Perception that patients preferred accelerated transfusion as it was 
quicker (saving time) and more comfortable, but also a recognition 
that some patients liked the company afforded by longer transfusions 
and this may be a factor for lonely patients with an implication that 
patients may say they are unwell to receive a longer visit. Practitioner 
comment on enjoying giving more time to patients also  [semantic and 
latent] 
 Satisfaction of seeing patient benefit 
 Perception that service capacity and flexibility had increased and 
there was an awareness of the need for best use of resources 
(especially in a small team and increased service demands) with 
some expressions of feelings of selfishness because of the focussing 
on resources [semantic and latent] 
 Importance of avoiding hospital admission [semantic] 
 Historic opinion that standard rate transfusion was too long for the 
volume infused contrary to national guidelines and hospital policy 
especially in the context of very historic transfusion that were over 6 
hours. There was a perception that patients also shared these 
frustrations with the length of transfusion [semantic] 
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 Improvement in scheduling staff rosters and helping patients by being 
able to be more specific about arrival time and helping them organise 
their time better. This had the extra benefit of patient continuity in that 
time saved could be spent by the same nurse being able to do a 
follow up on that patient later the same day [semantic] 
 Positive impact on scheduling of visits from other agencies and 
relatives. Less definite scheduling can impact on others [semantic] 
 Feeling that long treatments were imposing on patients and 
specifically this was a factor for patients with life-limiting conditions. 
Perceived benefit of patients being able to use saved time for leisure 
and family (and family responsibilities) and that patients gained 
freedom and also control over their illness [semantic and latent] 
 Not having to be in undesirable environments for over-long has 
positive effect on practitioner comfort [semantic and latent] 
 Positive feelings and confidence about professional autonomy/job 
satisfaction/use of discretion/application of knowledge and skills and 
the support of clear protocols with clinical back-up. Long-term 
relationships with patients providing confidence in whether they would 
be well enough to meet pre-transfusion criteria [semantic] 
 No adverse effects of accelerated transfusion [semantic] 
 Some uncertainties about how much time could be released as 
needed more confidence in accelerated transfusion and whether extra 
time per visit would need to be factored in in case an accelerated 
transfusion was not possible on the day [semantic] 
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 Accelerated transfusion provided the same patient-focussed quality of 
service, albeit over a shorter visit time with some indication of feelings 
of selfishness for making this point [semantic and latent] 
 Feeling conflicted about placing choice in the patient’s hands about 
preferences over transfusion duration. Clinical 
assessment/practitioner-driven or patient choice (however this would 
only affect patients with experience of longer transfusions) [semantic 
and latent] 
 Sense of promoting quality of life for patients by increasing their 
freedom and empowerment. Perceived improvement in patient 
comfort and the additional benefit of patients being less likely to 
restrict fluid [semantic] 
 Accelerated transfusion increases awareness of the timeframe for 
transfusion, increasing the challenge of meeting the prescribed 
infusion time and allowing use of practical skills to achieve this 
[semantic] 
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